Document:

Exhibit 10.2

PRODUCT DEVELOPMENT AND LICENSE AGREEMENT 

BY AND BETWEEN 

SHIRE LLC 

AND 

DURAMED PHARMACEUTICALS, INC. 

DATED AS OF AUGUST 14, 2006

PRODUCT DEVELOPMENT AND LICENSE AGREEMENT 

     This PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is dated as of August 14, 2006 by and among SHIRE LLC, a Kentucky
limited liability company having a principal place of business at 9200 Brookfield Court, Florence, Kentucky 41042 (together with its Affiliates, “Shire”), SHIRE plc, a British
public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of Section 15.10 of this Agreement, and DURAMED PHARMACEUTICALS,
INC., a Delaware corporation having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”).  Shire and Duramed are sometimes referred to herein
individually as a “Party” and together as the “Parties”. 

RECITALS 

     WHEREAS, Duramed is a pharmaceutical company focused on developing novel pharmaceuticals that are safer and improved versions of widely-prescribed pharmaceutical
products, including cervical ring-based female healthcare products;

     WHEREAS, Shire is a worldwide, specialty pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products;

     WHEREAS, Duramed has made a considerable investment in developing certain cervical and vaginal ring technology;

     WHEREAS, Duramed has been conducting research and development on certain pharmaceutical products that use such ring technology with certain pharmaceutical compounds;
and 

     WHEREAS, pursuant to the terms and conditions of this Agreement, the Parties desire to cooperate on the continued research and development of such pharmaceutical
products, and research and development on other pharmaceutical products that use such ring technology with pharmaceutical compounds, with the results of such cooperation to be commercialized by Shire in the Shire Territory and by Duramed in the
Duramed Territory. 

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows: 

ARTICLE 1

DEFINITIONS 

The following terms shall have the following meanings as used in this Agreement: 

     1.1 “Act” means the United States Federal Food, Drug and
Cosmetics Act, as amended from time to time, and the rules, regulations and guidelines promulgated thereunder. 

     1.2 “Affiliate” means a Person that controls, is controlled
by or is under common control with a Party.  For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means the actual
power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stock of such Person (it being understood that the
direct or indirect ownership of a lesser percentage of such stock shall not necessarily preclude the existence of control), or by contract or otherwise. 

     1.3 “Business Day” means any day other than (a) Saturday or
Sunday or (b) any other U.S. Federal holiday. 

     1.4 “cGCP” means the current Good Clinical Practice
standards for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials, including the requirements in 21 C.F.R. Parts 11, 50, 54, 56, 312, and 314, that provide assurance that the data and
reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. 

     1.5 “cGLP” means current Good Laboratory Practices (i) as
promulgated under the Act at 21 C.F.R. Part 58, as the same may be amended or re-enacted from time to time and (ii) as required by Law in countries other than the United States where non-clinical laboratory studies are conducted. 

     1.6 “cGMP” means all applicable standards relating to
manufacturing practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical products, including (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts
210 and 211 and The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products as each may be amended from time to time, (b) the principles detailed in the ICH Q7A guidelines, (c) Laws
promulgated by any Governmental Authority in any country having jurisdiction over Manufacturing or (d) guidance documents promulgated by any Governmental Authority in any country having jurisdiction over Manufacturing (including but not limited to
advisory opinions, compliance policy guides and guidelines).

     1.7 “Clinical Trial Costs” means the [*] incurred by a Party
or its Affiliates that is specifically attributable or reasonably allocable to the conduct of clinical trials, and which is payable (a) in the case of such clinical trials conducted by a clinical research organization (“CRO”) or other
Third Party on behalf of a Party or its Affiliates, as an out-of-pocket expense to such a CRO, or (b) in the case of such clinical trials conducted by a Party or its Affiliates, at such Party’s or its Affiliate’s actual cost including
internal costs and direct expenses.

     1.8 “Collaboration Intellectual Property” means any
Inventions, Improvements, Patents, Know-How, or other intellectual property (whether patentable or not) (i) conceived, developed or reduced to practice by either Party or its Affiliates, alone or jointly with each other or a Third Party, during the
Reimbursement Period in connection with any Development Plan or the Development of Collaboration Products hereunder, or (ii) existing as of the date of this 

2 

Agreement and Controlled by Duramed and its Affiliates and related to Collaboration Products or the Development, use or Commercialization of a Collaboration Product. 

     1.9 “Collaboration Patents” means any and all Patents
included in the Collaboration Intellectual Property. 

     1.10 “Collaboration Product” means: 

	 	 	(a)	  (i)
        a pharmaceutical product formulated as a cervical or vaginal ring product
        that contains or comprises any Compound(s) initially identified on Exhibit
        A hereto, (ii) any [*], and (iii)
        any and all Improvements to the foregoing, in each case made during the
        Reimbursement Period and for which Shire has reimbursed Development Expenses
    during the Reimbursement Period; and
	 	 	 	 
	 	 	(b)	 the levonorgestrel/ethinyl
        estradiol tablets 0-15 mg/0.03 mg and ethinyl estradiol tablets 0.01
        mg extended-cycle oral contraceptive product of Duramed approved by the
    FDA on May 25, 2006 under New Drug Application number [*] (“Seasonique”). 

     1.11 “Commercialization” means
    any and all activities directed to the commercial Manufacturing, marketing,
    offering for sale and selling of a pharmaceutical product. In addition, “Commercialize” means
to engage in any of the foregoing activities. 

     1.12 “Compound” means any of the compounds set forth on Exhibit A.

     1.13 “Control” means with respect to any intellectual
property right or other intangible property, that a Party or one of its Affiliates owns or has a license or sublicense to such item or right, and has the ability to grant access, license or sublicense in or to such right without violating the terms
of any agreement or other arrangement with any Third Party.

     1.14 “Development” means all activities relating to the
research, development of, and obtaining Regulatory Approval for, a pharmaceutical product, including all test method development, stability testing, toxicology, formulation, process development, cGMP audits (excluding any audits for commercial
Manufacture), cGLP audits, cGCP audits, validation, quality assurance/quality control development, preclinical and clinical testing and studies, regulatory affairs and outside counsel regulatory legal services relating to any of the foregoing, and
any activities relating to the Manufacture of pharmaceutical products other than commercial quantities thereof. 

     1.15 “Development Expenses” means the expenses incurred by
Duramed or its Affiliates from and after the Effective Date in carrying out a Development Plan and specifically attributable or reasonably allocable to the Development of a Collaboration Product, including [*] incurred in connection with (i) a
Global Development Plan pursuant to Section 3.2.2(c), and/or (ii) seeking Regulatory Approval of a Collaboration Product in [*]. Development Expenses shall include, but are not limited to expenses arising from: [*] for the [*] a Governmental
Authority to obtain Regulatory Approval of a Collaboration Product in the United States; and [*] and[*] Collaboration Products[*].  Development Expenses shall exclude (i) [*], (ii) [*] incurred in 

3 

connection with seeking Regulatory Approval outside [*] other than in connection with a Global Development Plan pursuant to 3.2.2(c), (iii) [*], and (iv) [*].

     1.16 “Diligent Efforts” means, with respect to a Party, the
efforts and resources that would be used by such Party consistent with prevailing pharmaceutical industry standards for a company of similar size and scope to such Party with respect to a product or potential product at a similar stage in its
development or product life and of similar market potential taking into account safety, efficacy and the competitiveness of alternative products in the market or under development. 

     1.17 “Drug Approval Application” means an application for
Regulatory Approval required before commercial sale or use of a pharmaceutical product as a drug in a regulatory jurisdiction, including a new drug application (“NDA”) or
supplemental new drug application or any amendments thereto submitted to the FDA. 

     1.18 “Duramed Territory” means the United States, Canada,
Albania, Austria, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Liechtenstein, Moldova, Poland, Romania, Russia, Slovakia, Slovenia, Switzerland, Ukraine, Kazakhstan, Macedonia, Lithuania, Latvia, Azerbaijan, Armenia
and Georgia, and their respective territories and possessions; provided, however, that in the event that Pliva, dd does not become an Affiliate of Duramed within twelve (12) months of the
Effective Date, the Duramed Territory shall thereafter mean only the United States and Canada. 

     1.19 “Effective Date” means the effective date as set forth
in that certain Settlement Agreement, dated as of August 14, 2006, by and between the Parties (the “Settlement Agreement”).

     1.20 “EMEA” means the European Medicines Agency or any
successor agency thereto. 

     1.21 “FDA” means the United States Food and Drug
Administration or any successor federal agency thereto. 

     1.22 “First Commercial Sale” means, with respect to a
pharmaceutical product and on a country-by-country basis, the first commercial sale after receipt of Regulatory Approval of such product in such country.  Sales for clinical studies, compassionate use, named patient programs, sales under a treatment
IND, test marketing, any nonregistrational studies, or any similar instance where the product is supplied with or without charge shall not constitute a First Commercial Sale.

     1.23 “GAAP” means generally accepted accounting principles
in the U.S., consistently applied. 

     1.24 “Governmental Authority” means any court, tribunal,
arbitrator, agency, legislative body, commission, official or other instrumentality of (a) any government of any country, (b) a federal, state, province, county, city or other political subdivision thereof or (c) any supranational body, including
without limitation the FDA and the EMEA. 

4 

     1.25 “Improvement” means any enhancement or modification of
(a) a Collaboration Product’s or Ring Product’s dosage, dosage form or indication, (b) the cervical or vaginal ring, for Ring Products and Collaboration Products based on a cervical or vaginal ring, (c) a [*] that is not a cervical or
vaginal ring product, or (d) the process or method for the Manufacture of a Collaboration Product or Ring Product, in each case whether or not patentable, that is developed by or for, invented or acquired by, or comes under the Control of, Duramed
or Shire or their respective Affiliates during the Term; provided, however, that (x) with respect to a Ring Product, or a Collaboration Product based on a cervical or vaginal ring, an Improvement shall not include any modification or improvement not
used for a cervical or vaginal ring product, and for modifications or improvements used for a cervical or vaginal ring products, only to the extent used for such products, (y) with respect to a [*] that is not a cervical or vaginal ring product, an
Improvement shall not include any other delivery system or formulation involving the same compound; provided, however, that if Duramed ceases development of such [*] or an NDA for such [*] was not approved, and Duramed commences development of
another delivery system or formulation involving the same compound for such [*] during the Reimbursement Term, such delivery system or formulation involving such compound shall be included as an Improvement, and (z) with respect to a Collaboration
Product, Improvements shall not include any active pharmaceutical ingredient other than the applicable Compound, and with respect to a Ring Product, Improvements shall not include any compounds other than [*]. 

     1.26 “IND” means an Investigational New Drug Application
filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA) or a clinical trial exemption (CTX). 

     1.27 “Invention” means any discovery (whether patentable or
not) conceived during the Term and potentially useful for the Manufacture, use, Development or Commercialization of a product. 

     1.28 “Know-How” means any non-public information, results
and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, ideas, discoveries, inventions, improvements, trade secrets, practices, methods, tests, assays, techniques, specifications,
processes, formulations, formulae, knowledge, know-how, skill, experience, materials, including pharmaceutical, chemical and biological materials, products and compositions, scientific, technical or test data (including pharmacological, biological,
chemical, biochemical, toxicological and clinical test data), clinical study protocols, analytical and quality control data, stability data, studies and procedures, drawings, plans, designs, diagrams, sketches, technology, documentation, and
patent-related and other legal information or descriptions. 

     1.29 “Law” or “Laws” means all laws, statutes, rules, codes, regulations, orders, judgments and/or ordinances of any Governmental Authority. 

     1.30 “Losses” means any and all liabilities, damages, fines,
penalties, deficiencies, losses and expenses (including interest, court costs, amounts paid in settlement, reasonable fees of attorneys, accountants and other experts or other reasonable expenses of litigation or other proceedings or of any claim,
default or assessment); provided, however, that the term “Losses” 

5 

shall not include any special, consequential, indirect, punitive or similar damages, except to the extent actually paid by a Party pursuant to any Third Party Claim. 

     1.31 “Manufacture” means all activities related to the
manufacturing of a pharmaceutical product, or any ingredient thereof, for Development or for commercial sale, packaging, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities
related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing. 

     1.32 “Patent” means (a) patents, re-examinations, reissues,
renewals, extensions, supplementary protection certificates and term restorations, any confirmation patent or registration patent or patent of addition based on any such patent, (b) pending applications for patents, including without limitation
continuations, continuations-in-part, divisional, provisional and substitute applications, and inventors’ certificates, (c) all foreign counterparts of any of the foregoing, and (d) all priority applications of any of the foregoing. 

     1.33 “Patent Expenses” means the fees and expenses of
outside counsel and payments to Third Parties incurred after the Effective Date in connection with the preparation, filing, prosecution and maintenance of the Collaboration Patents, including the costs of patent interference and opposition
proceedings, net of any reimbursement of such expenses by Third Parties. 

     1.34 “Person” means any natural person, corporation, firm,
business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof. 

     1.35 “Regulatory Approval” means all approvals (including,
without limitation, where applicable, pricing and reimbursement approval and schedule classifications), product and/or establishment licenses, registrations or authorizations of any regional, federal, state or local regulatory agency, department,
bureau or other governmental entity, necessary for the manufacture, use, storage, import, export, transport, offer for sale, or sale of a pharmaceutical product in a regulatory jurisdiction.

     1.36 “Ring Intellectual Property” means (i) Collaboration
Intellectual Property and (ii) any Patents and Know-How (whether patentable or not) existing as of the date of this Agreement and Controlled by Duramed and its Affiliates and related to pharmaceutical products formulated as a cervical or vaginal
ring. 

     1.37 “Ring Product” means a cervical or vaginal ring product
containing the pharmaceutical product known as [*], and any Improvements thereto created by Shire pursuant to the license granted under Section 10.1. 

     1.38 “Shire Territory” means all countries in the world,
together with their territories and possessions, other than the countries, territories and possessions that are part of the Duramed Territory. 

     1.39 “Shire Territory Global Development Expenses”
means those Development Expenses of Duramed approved under the Global Development Plan solely with respect to 

6 

obtaining Regulatory Approval of Collaboration Products in the Shire Territory.  For the avoidance of doubt, any other Development Expenses of Duramed approved under the Global Development Plan, including for obtaining Regulatory
Approval of Collaboration Products in the United States shall not be considered Shire Territory Global Development Expenses. 

     1.40 “Supply Agreement” means the supply agreement between
Duramed and Shire for the supply of finished Collaboration Products attached hereto as Exhibit B. 

     1.41 “Third Party” means any entity other than Duramed or
Shire or their respective Affiliates. 

     1.42 “Valid Claim” means (a) any claim of an issued and
unexpired patent within a Patent which has not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction in an unappealed or unappealable decision, and which has not been disclaimed or admitted to be
invalid or unenforceable through reissue or otherwise, or (b) a pending claim in a pending patent application within a Patent. Notwithstanding subsection (b) above, in the event that a pending claim in a pending patent application does not issue as
a valid and enforceable claim in an issued patent within seven (7) years after the earliest date from which such patent application claims priority, such a pending claim shall not be a Valid Claim, unless and until such pending claim subsequently
issues as a claim in an issued patent meeting the criteria set forth in clause (a) above, in which case such claim shall be reinstated and be deemed to be a Valid Claim as of the date of issuance of such patent. 

Interpretation.  Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or
singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and other similar words refer to this entire Agreement; (d) “including” shall be deemed followed by “without limitation”,
“but not limited to” or words of similar meaning; and (e) the terms “Article” and “Section” refer to the specified Article and Section of this Agreement. Whenever this Agreement refers to a number of days, unless
otherwise specified, such number shall refer to calendar days. 

Additional Definitions.  Each of the following definitions is set forth in the Section of this Agreement indicated below: 

  	
    Agreement
      	
    Preamble
      
	
    Breaching Party
      	
    Section 14.2
      
	
    Carryover Expenses
      	
    Section 7.2.1
      
	
    Ceased Collaboration Product
      	
    Section
    14.3.1     
	
    Collaboration Manager
      	
    Section
    2.4        
	
    Collaboration Product INDs
      	
    Section
    13.3(b)   
	
    Confidential Information
      	
    Section
    11.1.1     
	
    Development Plan
      	
    Section
    3.2.1      
	
    Disclosing Party
      	
    Section
    11.1.1     
	
    Dollars
      	
    Section
    17.7       
	
    Duramed
      	
    Preamble
      
	
    Duramed Marks
      	
    Section
    12.7.3     

  

7 

  

  	
    Global Development Plan
      	
    Section
    3.2.2(c) 
      
	
    Indemnification Claim Notice
      	
    Section
    15.2       
	
    Indemnified Party
      	
    Section
    15.2       
	
    Indemnifying Party
      	
    Section
    15.2       
	
    Indemnitee
      	
    Section
    15.2       
	
    Indemnitees
      	
    Section
    15.2       
	
    Maximum Annual Reimbursement Amount
      	
    Section
    7.2.1      
	
    Maximum Quarterly Reimbursement Amount
      	
    Section
    7.2.1      
	
    Maximum Reimbursement Amount
      	
    Section
    7.2.1      
	
    Milestone Payments
      	
    Section
    7.2.1      
	
    NDA
      	
    Section
    1.17       
	
    Notifying Party
      	
    Section
    14.2       
	
    Parties
      	
    Preamble
      
	
    Party
      	
    Preamble
      
	
    Receiving Party
      	
    Section
    11.1.1     
	
    Recovery
      	
    Section
    12.4.2(c) (iv)    
	
    Reimbursement Period
      	
    Section
    7.2.1      
	
    Reimbursable Expenses
      	
    Section
    7.2.1      
	
    [*]
      	
    Section
    3.4        
	
    [*]
      	
    Section
    3.4        
	
    [*]
      	
    Section
    3.4        
	
    [*]
      	
    Section
    3.4        
	
    [*]
      	
    Section
    3.4        
	
    Representatives
      	
    Section
    16.1       
	
    Seasonique
      	
    Section
    1.10       
	
    Settlement Agreement
      	
    Section
    1.19       
	
    Shire
      	
    Preamble
      
	
    Shire Marks
      	
    Section
    12.7.3     
	
    Steering Committee
      	
    Section
    2.4        
	
    Term
      	
    Section
    14.1       
	
    Third Party Claim
      	
    Section
    15.1.1     
	
    $
      	
    Section
    17.7       

  

     ARTICLE 2

PRODUCT DEVELOPMENT 

     2.1 General.  The general purpose of this Agreement is the Development and Commercialization of
Collaboration Products.

     2.2 Exclusive Development of Certain Ring Products. Duramed acknowledges and agrees that during
the Reimbursement Period, all Development of pharmaceutical products comprising a cervical or vaginal ring that contains or comprises any of the Compound(s) identified on Exhibit A hereto by
Duramed or its Affiliates, shall be undertaken exclusively with Shire pursuant to the terms of this Agreement. 

8 

     2.3 Collaboration Managers.  Each Party shall appoint a senior representative having a general
understanding of development, regulatory, manufacturing and marketing issues to act as its Collaboration Manager (a “Collaboration Manager”). Each Collaboration Manager shall be
primarily responsible for facilitating the flow of information and otherwise promoting communications and collaboration between the Parties and also internally within the respective Parties. Each Collaboration Manager shall also be responsible for:

               (a) facilitating coordination among the various functions representatives of Duramed or Shire, as appropriate; and 

               (b) providing single-point communication for seeking consensus both internally within the respective Party’s organization
and together regarding strategy, planning, development, regulatory and manufacturing issues. 

     2.4 Steering Committee. As soon as practicable after the Effective Date, the Parties shall form
a Steering Committee (the “Steering Committee”), which shall function in accordance with the Steering Committee charter attached hereto as Exhibit
C. The members of the Steering Committee shall cooperate in good faith to effectively implement this Agreement and to amicably resolve any disputes or disagreements related to the implementation hereof. 

ARTICLE 3

DEVELOPMENT
OF COLLABORATION PRODUCTS 

     3.1 Overview. Subject to the terms and conditions of this Agreement, (a) Duramed shall be
responsible for the Development of Collaboration Products for Commercialization in the Duramed Territory, and (b) Shire shall be responsible for the Development of Collaboration Products for Commercialization in the Shire Territory. 

     3.2 Development Plans. 

          3.2.1 Scope.  The Development of each Collaboration Product under this Agreement shall be
governed by a development plan (each, a “Development Plan”).  Each Development Plan shall be developed by the responsible Party for review and comment by the Steering Committee,
with the overall objective of achieving the commercial potential of the Collaboration Product. Each Development Plan shall describe the proposed overall program of Development for the Collaboration Product for each indication in the Duramed
Territory and Shire Territory, as applicable, including [*] and [*] and [*] Regulatory Approval, as well as [*] Drug Approval Applications and Regulatory Approvals. Each of Duramed’s Development Plans shall include a budget for Development
Expenses, including separately [*] during the Reimbursement Period. 

          3.2.2 Preparation and Review of Development Plans.

               (a) The Development Plan for the Development by Duramed of Collaboration Products for Commercialization in the Duramed Territory
shall be prepared by Duramed and shall be delivered to the Steering Committee.  Duramed shall consider in good faith any comments from the Steering Committee. The current Development Plans for existing Collaboration Products are attached as
Exhibit D hereto. 

9 

               (b) The Development Plan for the Development by Shire of Collaboration Products for Commercialization in the Shire Territory
shall be prepared by Shire and shall be delivered to the Steering Committee.  Shire shall consider in good faith any comments from the Steering Committee.

               (c) In the event the Steering Committee unanimously agrees that a Collaboration Product (or any aspect of its Development) should
be Developed under a global Development program, the Steering Committee shall prepare a global Development Plan (each, a “Global Development Plan”). Once a Global Development Plan
is agreed to, [*] under such Global Development Plan.  The Development Expenses incurred in the conduct of Development under a Global Development Plan shall be subject to reimbursement pursuant to Section 7.2. 

          3.2.3 Updates to Development Plans. As early as necessary in [*] beginning with the [*] after
the Effective Date, or otherwise as may be required during any [*], Duramed, Shire or the Steering Committee, as applicable, shall update and prepare the Development Plan for any Collaboration Products for the following [*] to take into account
completion, commencement or cessation of Development activities not contemplated by the then-current Development Plan, and submit such proposed, updated Development Plan to the Steering Committee for its review and comment no later than [*].

          3.2.4 Diligence.  Each Party shall use Diligent Efforts to carry out the Development of each
Collaboration Product for Commercialization.  Notwithstanding the foregoing, each Party acknowledges that the other Party makes no representations and/or warranties that any Development Plan will be successful or that the activities hereunder will
result in any Collaboration Products suitable for Commercialization. 

     3.3 [*] of Collaboration Products. Duramed shall have the right, [*] Development of a
then-existing Collaboration Product. Duramed shall not directly or indirectly, alone or with or through a Third Party, [*] Development [*] Collaboration Product[*] provided, however, that in the event [*], Duramed shall have the right [*]
Development of such [*]Collaboration Product [*] hereunder to the [*] Development. If Duramed [*] Collaboration Product [*] Development [*] in the [*] in respect of which [*], Shire may [*] Development and Commercialization of such Collaboration
Product [*]; provided, however, [*]Development. 

     3.4 [*]. In the event that Duramed [*] Development of a [*] Collaboration Product, Duramed may, [*] such Collaboration Product
[*].  Duramed shall deliver to Shire a [*] Development of the Collaboration Product [*]. Shire shall have [*] in which to [*] Duramed that it [*] for failing [*] set forth in this Section 3.4. In delivering any [*], Shire shall specify what [*] to
complete its [*] of the [*]. Duramed shall use its reasonable best efforts to provide Shire any [*] within [*]of receipt of the [*]. Shire may not [*] so long as (i) such [*] is in the [*]; (ii) such [*] and [*] reasonably demonstrate that such [*]
has [*] of at least [*] in [*], provided that any [*] having the [*] to achieve at least [*] in [*] in the United States, as [*], shall be deemed to satisfy this requirement; and (iii) Duramed has
the [*] in the Shire Territory. 

10 

ARTICLE 4

REGULATORY ACTIVITIES 

     4.1 General Obligations. Duramed shall be responsible for, and use Diligent Efforts in,
preparing and filing Drug Approval Applications and seeking Regulatory Approvals for Collaboration Products in the Duramed Territory.  Shire shall be responsible for, and use Diligent Efforts in, preparing and filing Drug Approval Applications and
seeking Regulatory Approvals for Collaboration Products in the Shire Territory.  In furtherance of the foregoing, Shire shall have sole discretion with respect to preparing and filing Drug Approval Applications and seeking Regulatory Approvals for
Collaboration Products from the EMEA in all European Union member states, regardless of whether any countries within the Duramed Territory are members of the European Union, provided that, [*] seeking Regulatory Approvals for a Collaboration Product
[*] of the First Commercial Sale of such Collaboration Product (and the [*] includes any [*]), Duramed shall [*] Regulatory Approval for such Collaboration Product [*]. 

     4.2 Transfer of Data to Shire. Within [*] after the Effective Date, Duramed shall provide to
Shire copies of all substantive or material Manufacturing, pre-clinical and clinical data compiled as of the Effective Date with respect to the existing Collaboration Products, including any study reports in draft or final form. Thereafter on [*],
Duramed shall provide to Shire copies of all such data (including any data compiled in support of a Drug Approval Application) as soon as reasonably practicable after such data becomes available or compiled, including any drafts and final versions
of any study reports. All disclosures under this Section 4.2 shall be delivered in electronic format. During the Reimbursement Period, on [*], Shire shall provide to Duramed [*] Inventions and Improvements [*] Shire or its Affiliates, [*], during
the previous [*]. 

     4.3 Transfer of Data to Duramed. On [*], Shire shall provide to Duramed copies of all
substantive or material Manufacturing, pre-clinical and clinical data compiled by or on behalf of Shire with respect to the Collaboration Products (including any data compiled in support of a Drug Approval Application) as soon as reasonably
practicable after such data becomes available or compiled, including any drafts and final versions of any study reports. All disclosures under this Section 4.3 shall be delivered in electronic format.  During the Reimbursement Period, on [*], Shire
shall provide to Duramed [*] Inventions and Improvements [*] Shire or its Affiliates [*], during the previous [*].

     4.4 Right of Reference.

          4.4.1 Duramed shall permit Shire access to and grant Shire the right to reference and use, for purposes of the Collaboration
Products, all data, regulatory filings and regulatory communications associated with any submissions for Regulatory Approval or other issues associated with any Collaboration Product, that is or would be relevant to Shire’s Development or
Commercialization of a Collaboration Product in the Shire Territory, or in connection with any Regulatory Approval process within the European Union, including without limitation with the EMEA.  To the extent that any such data, regulatory filings
or regulatory communications are held by a Third Party, then Duramed shall arrange direct access to the portions of such data, regulatory filings or regulatory communications that are relevant to the activities of Shire that are contemplated by this
Agreement. 

11 

          4.4.2 Shire shall permit Duramed access to and grant Duramed the right to reference and use, for purposes of the Collaboration
Products, all data, regulatory filings and regulatory communications associated with any submissions for Regulatory Approval or other issues associated with any Collaboration Product, that is or would be relevant to Duramed’s Development or
Commercialization of a Collaboration Product in the Duramed Territory. To the extent that any such data, regulatory filings or regulatory communications are held by a Third Party, then Shire shall arrange direct access to the portions of such data,
regulatory filings or regulatory communications that are relevant to the activities of Duramed that are contemplated by this Agreement. 

     4.5 Meetings.

          4.5.1 In the event that Shire desires Duramed to participate in any meeting, discussion or substantive telephone conference call
with any Governmental Authority relating to any Drug Approval Application or Regulatory Approval for Collaboration Products in the Shire Territory or such meetings, discussions or substantive telephone conferences pertaining to member states of the
European Union outside the Shire Territory, Shire shall provide Duramed with reasonable advance notice of any such meeting, discussion or conference call and Duramed shall participate with Shire. Shire shall reimburse Duramed for its reasonable
out-of-pocket expenses incurred in connection with such participation, and any such reimbursement shall not be credited against the reimbursement provided for in Section 7.2. 

          4.5.2 In the event that Duramed desires Shire to participate in any meeting, discussion or substantive telephone conference call
with any Governmental Authority relating to any Drug Approval Application or Regulatory Approval for Collaboration Products in the Duramed Territory other than, subject to Section 4.1, those member states in the European Union in the Duramed
Territory for which Shire is responsible, Duramed shall provide Shire with reasonable advance notice of any such meeting, discussion or conference call and Shire shall participate with Duramed. Duramed shall reimburse Shire for its reasonable
out-of-pocket expenses incurred in connection with such participation. 

     4.6 Assistance. Subject to the terms of this ARTICLE 4, each Party agrees to provide the other
with all reasonable assistance and take all actions reasonably requested by the other Party that are necessary or desirable to enable the other Party to comply with any Law applicable to the Collaboration Products, including, but not limited to,
meeting, reporting and other obligations to maintain and update any Regulatory Approvals for the Collaboration Products. 

     4.7 Compliance with Laws. Each Party and its Affiliates and permitted Third Party contractors
shall perform its responsibilities under this ARTICLE 4 in accordance with all applicable Laws, including without limitation cGLPs, cGCPs and cGMPs. 

ARTICLE 5

COMMERCIALIZATION
OF COLLABORATION PRODUCTS 

     5.1 Principles of Commercialization.  Subject to the terms and conditions of this Agreement,
Duramed shall have the sole right and responsibility with respect to Commercializing Collaboration Products in the Duramed Territory.  Subject to the terms and 

12 

conditions of this Agreement, Shire shall have the sole right and responsibility with respect to Commercializing Collaboration Products in the Shire Territory. 

     5.2 Shire Territory.

          5.2.1 For each Collaboration Product, Shire shall be solely responsible for handling all returns, recalls, order processing,
invoicing and collection, distribution, and inventory and receivables arising from sales to Third Parties within the Shire Territory. Duramed may not accept orders from a Third Party for a Collaboration Product or make sales for its own account
(except to Shire) or for Shire’s account in the Shire Territory.  If Duramed receives any order for a Collaboration Product in the Shire Territory, it shall refer such orders to Shire for acceptance or rejection. Shire shall have the right and
responsibility for establishing and modifying the terms and conditions with respect to the sale of all Collaboration Products in the Shire Territory, including any terms and conditions relating to or affecting the price at which the Collaboration
Products shall be sold, discounts available to managed care providers, any discount attributable to payments on receivables, distribution of the Collaboration Products, and credits, price adjustments, or other discounts and allowances to be granted
or refused. 

          5.2.2 In the event that Duramed desires to Commercialize a Collaboration Product in any country of the Shire Territory, Duramed
may so notify Shire in writing and the Parties shall meet in person or by teleconference within [*] thereafter to discuss whether Shire desires to relinquish its rights to Commercialize such Collaboration Product in such country and, if so, the
Parties shall discuss in good faith commercially reasonable terms to effectuate such transfer of rights.  Nothing in this Section 5.2.2 shall be deemed to limit any other rights of the Parties under this Agreement. 

     5.3 Duramed Territory.

          5.3.1 For each Collaboration Product, Duramed shall be solely responsible for handling all returns, recalls, order processing,
invoicing and collection, distribution, and inventory and receivables arising from sales to Third Parties within the Duramed Territory. Shire may not accept orders from a Third Party for a Collaboration Product or make sales for its own account
(except to Duramed) or for Duramed’s account in the Duramed Territory. If Shire receives any order for a Collaboration Product in the Duramed Territory, it shall refer such orders to Duramed for acceptance or rejection. Duramed shall have the
right and responsibility for establishing and modifying the terms and conditions with respect to the sale of all Collaboration Products in the Duramed Territory, including any terms and conditions relating to or affecting the price at which the
Collaboration Products shall be sold, discounts available to managed care providers, any discount attributable to payments on receivables, distribution of the Collaboration Products, and credits, price adjustments, or other discounts and allowances
to be granted or refused. 

          5.3.2 In the event that Shire desires to Commercialize a Collaboration Product in any country of the Duramed Territory, Shire may
so notify Duramed in writing and the Parties shall meet in person or by teleconference within [*] thereafter to discuss whether Duramed desires to relinquish its rights to Commercialize such Collaboration Product in such country and, if so, the
Parties shall discuss in good faith commercially reasonable terms to 

13 

effectuate such transfer of rights.  Nothing in this Section 5.3.2 shall be deemed to limit any other rights of the Parties under this Agreement. 

     5.4 Shire Regulatory Responsibilities. With respect to the Shire Territory, Shire shall use
Diligent Efforts to obtain and maintain all regulatory filings and Regulatory Approvals in the Shire Territory for each Collaboration Product Developed pursuant to this Agreement, including all INDs and Drug Approval Applications. Except as provided
in Section 4.1, as between the Parties, Shire shall be solely responsible for all activities in connection with obtaining and maintaining Regulatory Approvals required for the Commercialization of Collaboration Product in the Shire Territory,
including all Drug Approval Applications with the EMEA, regardless of whether any countries within the Duramed Territory are member states of the European Union, including in all cases communicating and preparing and filing all reports (including
adverse drug experience reports) with the applicable Governmental Authorities. 

     5.5 Duramed Regulatory Responsibilities.  With respect to the Duramed Territory, and except as
provided in Section 5.4, Duramed shall use Diligent Efforts to obtain and maintain all regulatory filings and Regulatory Approvals in the Duramed Territory for each Collaboration Product Developed pursuant to this Agreement, including all INDs and
Drug Approval Applications. Except as otherwise provided herein, as between the Parties, Duramed shall be solely responsible for all activities in connection with obtaining and maintaining Regulatory Approvals required for the Commercialization of
Collaboration Product in the Duramed Territory, including communicating and preparing and filing all reports (including adverse drug experience reports) with the applicable Governmental Authorities. 

     5.6 Pharmacovigilance.  As soon as reasonably practicable following the Effective Date, the
pharmacovigilance departments of each of Duramed and Shire shall meet and determine the approach to be taken for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Collaboration
Products, consistent with the provisions of this Section 5.6.  Such approach shall be documented in a separate and appropriate written pharmacovigilance agreement between Duramed and Shire.  Each Party agrees to share relevant information it
receives (either directly or indirectly) with the other Party in a timely manner so as to allow such other Party to comply with its responsibility to report pharmacovigilance information under this Section 5.6. 

     5.7 Diligence in Commercialization. Duramed shall use Diligent Efforts to Commercialize the
Collaboration Products in the Duramed Territory; provided that Duramed shall have no specific obligation to Commercialize the Collaboration Products in any particular country or countries.  Shire shall use Diligent Efforts to Commercialize the
Collaboration Products in the Shire Territory; provided that Shire shall have no specific obligation to Commercialize the Collaboration Products in any particular country or countries.. 

     5.8 Commercialization Expenses. Duramed shall bear all costs in connection with the
Commercialization of Collaboration Products in the Duramed Territory. Shire shall bear all costs in connection with the Commercialization of Collaboration Products in the Shire Territory.

     5.9 Compliance with Laws. Each Party or its permitted Third Party contractors shall perform its
responsibilities under this ARTICLE 4 in accordance with all applicable Laws. 

14 

ARTICLE 6

MANUFACTURE
AND EXPORTATION OF COLLABORATION PRODUCTS 

     6.1 Manufacture and Supply. 

          6.1.1 Manufacturing Process. Duramed shall use Diligent Efforts to develop a process for the
Manufacture of Collaboration Products and to scale up such process to a level sufficient to Manufacture and supply clinical and commercial supplies of Collaboration Products for the Shire Territory, including the preparation of filings necessary to
obtain Regulatory Approval for the Manufacture of Collaboration Products for sale in the Shire Territory and the selection of any Third Party(ies) to engage in the Manufacture and supply of Collaboration Products and components thereof. In the event
that Duramed includes the filings referred to in this Section 6.1.1 in Drug Master Files in the Duramed Territory, Shire may reference such Drug Master Files for countries in the Shire Territory in which Shire seeks Regulatory Approval of
Collaboration Products.  Once such filings are made, no changes to the process for the Manufacture of Collaboration Products for sale in the Shire Territory shall be made without the written consent of Shire, such consent not to be unreasonably
withheld, unless such changes are required by Law.

          6.1.2 Supply of Collaboration Product.  At the completion of each Development Plan, the Parties
shall establish a final finished dosage form for each Collaboration Product. Shire shall purchase from Duramed, and Duramed shall supply to Shire, Collaboration Product in accordance with the terms and conditions of the Supply Agreement. 

     6.2 Specifications and Terms of Supply. Duramed shall establish the specifications, including
any necessary documentation, certificates of analysis and test results, for the Collaboration Products to be Manufactured under this ARTICLE 6, in each case subject to the prior written approval of Shire, such approval not be unreasonably withheld.
The Parties shall endeavor to maintain compatible specifications for Collaboration Products on a worldwide basis, and to minimize the number of distinct specifications in different countries. 

     6.3 Exportation of Collaboration Products by Duramed.  Duramed shall not actively sell any
Collaboration Product outside the countries of the Duramed Territory, and shall not sell Collaboration Product to any Person, inside the Duramed Territory knowing or having reason to believe that the Collaboration Products are likely to be sold in
the Shire Territory. Duramed shall not market or promote the Collaboration Products in the Shire Territory.

     6.4 Exportation of Collaboration Products by Shire. Shire shall not actively sell any
Collaboration Product outside the countries of the Shire Territory, and shall not sell Collaboration Product to any Person, inside the Shire Territory knowing or having reason to believe that the Collaboration Products are likely to be sold in the
Duramed Territory.  Shire shall not market or promote the Collaboration Products in the Duramed Territory.

ARTICLE 7

FINANCIAL TERMS 

     7.1 Initial Reimbursement for Development Expenses. Shire shall pay to Duramed a one-time fee
equal to $25,000,000 within five (5) Business Days after the Effective Date. It is 

15 

intended that such payment serve as reimbursement to Duramed for Development Expenses that Duramed has incurred up to the Effective Date.  This fee shall be non-creditable and non-refundable against any future obligations of Shire
under this Agreement. 

     7.2 Reimbursement of Development Expenses. 

          7.2.1 Reimbursement.  Subject to the terms and conditions contained herein, Shire shall pay to
Duramed, on a calendar quarterly basis, (i) reimbursements of amounts equal to Development Expenses that are incurred by Duramed, and (ii) milestone payments for meeting the milestones set forth in Schedule 7.2.1A and Schedule 7.2.1B
(“Milestone Payments”). Shire shall pay such reimbursement to Duramed for an eight (8) year period commencing on the Effective Date (the “Reimbursement Period”), up to an aggregate amount of $140,000,000, provided, however, that such aggregate amount shall be subject to reduction in connection with (a) Milestone Payments paid in
respect of Seasonique, as set forth on Schedule 7.2.1A, and (b) Milestone Payments paid in respect of the Ring Product, as set forth on Schedule 7.2.1B (all such Milestone Payments, together with the Development Expenses being referred to
collectively as the “Reimbursable Expenses”).  Milestone Payments shall be paid at any time during the Term that the applicable milestone is met. Notwithstanding the foregoing, and
subject to Section 3.2.2(c), in no event shall the aggregate Reimbursable Expenses (including, for the avoidance of doubt, all Milestone Payments and all Development Expenses) to be paid by Shire hereunder exceed $140,000,000 (the
“Maximum Reimbursement Amount”). In no event shall Shire be required to pay Reimbursable Expenses in excess of [*] during any calendar year (the “Maximum Annual Reimbursement Amount”).  In addition, any Development Expenses in excess of [*] (the “Maximum Quarterly Reimbursement Amount”) during any calendar quarter (irrespective of Milestone Payments), that Duramed incurs shall never become a Reimbursable Expense, and shall not be counted toward Reimbursable Expenses or the Maximum Reimbursement Amount.  For
purposes of determining the Maximum Annual Reimbursement Amount or the Maximum Quarterly Reimbursement Amount, amounts for any partial years or quarters will be prorated based on the number of days in such partial calendar year or quarter. Subject
to the foregoing, the amount of Reimbursable Expenses in any calendar year in excess of [*], if any (“Carryover Expenses”), including any unreimbursed Carryover Expenses from
previous years, shall carry over to the first calendar quarter of the immediately following calendar year during the Reimbursement Period and be reimbursed by Shire as part of the Reimbursable Expenses for such calendar quarter until all Carryover
Expenses have been recovered.  Carryover Expenses shall be subject to, and count toward, the Maximum Reimbursement Amount and the Maximum Annual Reimbursement Amount, but shall not be subject to, or count toward, the Maximum Quarterly Reimbursement
Amount. In the event the Reimbursement Period expires prior to Duramed having incurred Reimbursable Expenses equal to the Maximum Reimbursement Amount, Duramed shall have no right to receive any further payment from Shire. During the Term of this
Agreement, no cessation or suspension by Shire of Development of Collaboration Product for the Shire Territory shall affect Shire’s reimbursement obligations under this Section 7.2.1.  Shire Territory Global Development Expenses shall be
reimbursable hereunder as Development Expenses but shall not be subject to or count toward the Maximum Reimbursement Amount, the Maximum Annual Reimbursement Amount or the Maximum Quarterly Reimbursement Amount.

16 

     7.2.2 Quarterly Forecasting. By February 28, May 31, August 31, and November 30 each year, Duramed shall provide Shire with a forecast for the current calendar quarter,
each calendar quarter remaining in that calendar year and each quarter of the following calendar year, setting forth Duramed's reasonable projected Reimbursable Expense for each Collaboration Product together with any forecast Carryover Expenses at
the end of each of the current calendar year and the following calendar year. Such forecasts shall be provided by Duramed to Shire in good faith. 

     7.2.3 Quarterly Reporting.  Within thirty (30) days after the end of each calendar quarter during the Reimbursement Period, Duramed shall deliver to Shire a reasonably detailed report setting forth
the Reimbursable Expenses for each Collaboration Product that Duramed has incurred during such calendar quarter. Shire shall pay such amount to Duramed within forty-five (45) days after the end of each calendar quarter during the Reimbursement
Period, or in any event within fifteen (15) days after Shire’s receipt of the aforementioned report if it is not timely delivered by Duramed after the end of the applicable calendar quarter. 

     7.2.4 No Other Payments. Shire shall have no obligation to pay royalties or any other amounts to
Duramed in connection with the transactions contemplated under this Agreement other than as expressly set forth in this ARTICLE 7 and as contemplated by the Supply Agreement. Duramed shall be solely responsible for all Development Expenses (other
than Shire Territory Global Expenses) which are not Reimbursable Expenses, and all Development Expenses which are Reimbursable Expenses in excess of the Maximum Reimbursement Amount. 

     7.2.5 Shire Development Fees.  Shire shall be solely responsible for all Development Expenses it
incurs with respect the Collaboration Products in the Shire Territory.

ARTICLE 8

 PAYMENT TERMS 

     8.1 Payment Method.  All amounts due to either Party hereunder shall be paid in United States
Dollars by wire transfer in immediately available funds to an account designated by such Party. Any payments or portions thereof due hereunder that are not paid by the date such payments are due under this Agreement shall bear interest [*] at the
lower of (a) the [*], on the due date (or, if the due date is not a business day, on the last business day prior to such due date), or (b) the [*] on the[*] such [*]. 

     8.2 Payment Schedules; Reports. The payments due pursuant to Sections 7.1 and 7.2 are due and
payable on the dates described therein.  The Parties acknowledge that any expenses or costs reported under this Agreement may be based upon estimates, which estimates shall be made in compliance with GAAP consistently applied by such Party in
accordance with past practice; provided that when the actual results become known relative to any estimated amount, any difference between the actual results and the estimate is reported and the next payment due hereunder related to such estimated
item is appropriately adjusted for such difference. The Parties acknowledge and agree that any reports and payments relating to any cost, expense, or other financial amount shared pursuant to this Agreement for the [*] of any [*] shall reflect [*]
reconciliations and adjustments, if any, applicable to the previous [*] reported results.

17 

     8.3 Taxes. Duramed shall be responsible for any and all income or other taxes owed by Duramed
and required by applicable Law to be withheld or deducted from any of the payments made by or on behalf of Shire to Duramed hereunder, and Shire may deduct from any amounts that Shire is required to pay hereunder an amount equal to such taxes. The
Parties shall reasonably cooperate in connection with the other’s efforts to minimize liability for taxes, to the extent legally permissible, and shall reasonably support each other in the event of an audit by any taxing authority.  Shire shall
not be responsible for payment of any income, franchise, gross receipts or personal property taxes paid by Duramed on Duramed’s income, capital, assets or gross sales as a result of this Agreement.

     8.4 Records Retention; Audit. 

          8.4.1 Record Retention.  Each Party shall maintain complete and accurate books, records and
accounts used for the determination of expenses incurred in connection with the performance of Development or Commercialization activities (including, in the case of Duramed, the calculation of Development Expenses), in sufficient detail to confirm
the accuracy of any payments required under this Agreement, which books, records and accounts shall be retained by such Party for [*] after the end of the period to which such books, records and accounts pertain, or longer as is required by
applicable Law. 

          8.4.2 Audit. Shire shall have the right to have an independent certified public accounting firm
of internationally recognized standing, reasonably acceptable to Duramed, to have access during normal business hours, and upon reasonable prior written notice, to such of the records of Duramed as may be reasonably necessary to verify the accuracy
of reimbursement amounts paid by Shire under this Agreement for any calendar year ending not more than three (3) years prior to the date of such request; provided, however, that, Shire shall not have the right to conduct more than [*] in any [*] and
that Shire shall not be permitted to audit the same period of time more than [*].  The accounting firm shall disclose to Shire only whether the various expenses subject to reimbursement under this Agreement are correct or incorrect and the specific
details concerning any discrepancies. [*] of such [*], in which case [*]. If Duramed disputes the findings pursuant to this Section 8.4.2, the Parties shall meet and discuss such dispute. If such dispute is not resolved within [*], then it shall be
subject to ARTICLE 16. 

          8.4.3 Payment of Additional Amounts. If, based on the results of any audit, (a) additional
payments are owed by Shire to Duramed under this Agreement, then Shire shall make such additional payments, or (b) the payments previously made by Shire to Duramed under this Agreement are in excess of the amounts that were actually required to be
made, then Duramed shall return such excess payments, in each case within [*] after the accounting firm’s written report is delivered to the Parties.  The provisions of Section 8.1 shall apply to such payment. 

ARTICLE 9

DURAMED
LICENSE AND TECHNOLOGY TRANSFER 

     9.1 Development License Grant.  During the Term of the Agreement, Duramed hereby grants to Shire
a nonexclusive, worldwide, fully paid-up license under the Collaboration Intellectual Property to Develop and use Collaboration Products for the purpose of 

18 

Commercializing Collaboration Products in the Shire Territory. Notwithstanding the foregoing nonexclusive license grant, Duramed shall not undertake clinical trials of a Collaboration Product in any European Union country in the
Shire Territory without first obtaining the prior written consent of Shire. 

     9.2 Commercialization License Grant.  During the Term of the Agreement, Duramed hereby grants to
Shire an exclusive (even as to Duramed and its Affiliates), worldwide, fully paid-up license under the Collaboration Intellectual Property to Commercialize Collaboration Products in the Shire Territory. Following the Reimbursement Period, the
license granted under the previous sentence shall remain exclusive as to the Commercialization of then-existing Collaboration Products but shall not restrict Duramed from using the Collaboration Intellectual Property for any other purpose, including
to Commercialize improved or alternative variants of such Collaboration Products, or products that compete with such Collaboration Products. 

     9.3 Technology Transfer in Event of Failure to Supply.  In the event Duramed ceases Development
or Commercialization of any Collaboration Product and Shire desires to continue such Development or Commercialization in the Shire Territory, then, pursuant to the Supply Agreement, Duramed shall, at its option, either supply the applicable
Collaboration Product to Shire or facilitate the transfer of the manufacture of the applicable Collaboration Product to Shire or Shire’s designee in accordance with Article VIII of the Supply Agreement.

ARTICLE 10

LICENSE
RELATING TO RING PRODUCT 

     10.1 License Relating to Ring Intellectual Property.  Duramed hereby grants to Shire an
exclusive (even as to Duramed and its Affiliates), worldwide, fully paid-up, irrevocable and perpetual license, with the right to grant sublicenses, under the Ring Intellectual Property, solely to research, Develop, Manufacture, use, and
Commercialize the Ring Product throughout the world. 

     10.2 Ring Technology Transfer.  As soon as practicable following the Effective Date, the Parties
shall meet to discuss and identify the Know-How included in the Ring Intellectual Property that Shire believes is most promising to successfully develop the Ring Product. Duramed shall in good faith provide all reasonable information requested by
Shire to assist Shire in identifying such Know-How. Upon identifying such Know-How, Duramed shall, and shall cause its Affiliates to disclose to Shire or an Affiliate designated by Shire, such KnowHow to enable Shire to engage in Development
activities related to Ring Product in accordance with the licenses granted in Section 10.1. Notwithstanding the foregoing, Duramed makes no representations and/or warranties that the Ring Product can be successfully Developed or Commercialized or
that the Know-How disclosed hereunder will be sufficient for such Development or Commercialization. 

19 

ARTICLE 11

CONFIDENTIALITY

     11.1 Confidential Information. 

          11.1.1 Confidential Information.  As used in this Agreement, the term “Confidential Information” means all secret, confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer, electronic or other form, provided pursuant to
this Agreement or generated pursuant to this Agreement by one Party or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”), including but not limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products, and
any other materials that have not been made available by the Disclosing Party to the general public. Confidential Information of Duramed shall include all Collaboration Intellectual Property. Confidential Information shall not include any
information or materials that: 

               (a) were already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by
the Disclosing Party, to the extent such Receiving Party has documentary evidence to that effect; 

               (b) were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the
Receiving Party; 

               (c) became generally available to the public or otherwise part of the public domain after disclosure or development thereof, as
the case may be, other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement; 

               (d) were disclosed to a Party, other than under an obligation of confidentiality, by a third party who had no obligation to the
Disclosing Party not to disclose such information to others; or 

               (e) were independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential
Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect. 

          11.1.2 Confidentiality Obligations.  Each of Duramed and Shire shall keep confidential all
Confidential Information of the other Party with the same degree of care it maintains the confidentiality of its own Confidential Information but in no event less than a reasonable degree of care. Neither Party shall use such Confidential
Information for any purpose other than in performance of this Agreement or disclose the same to any other Person other than to such of its and its Affiliates’ directors, managers, employees, independent contractors, agents or consultants who
are bound to confidentiality restrictions consistent with terms herein and who have a need to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this Agreement.  Upon termination of this
Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the possession of the Receiving Party and its Affiliates or their directors,
managers, employees, independent contractors, agents or 

20 

consultants, except that the Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall continue to be subject to
the provisions of this ARTICLE 11. 

          11.1.3 Permitted Disclosure and Use. Notwithstanding Section 11.1.2, a Party may disclose
Confidential Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) obtain Regulatory Approval to the extent such disclosure is made to a Governmental Authority; (b) comply with or enforce any of
the provisions of this Agreement; (c) comply with Laws; or (d) comply with applicable stock exchange regulations. If a Party deems it necessary to disclose Confidential Information of the other Party pursuant to this Section 11.1.3, such Party shall
give reasonable advance notice of such disclosure to the other Party to permit such other Party sufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such information.  In addition,
notwithstanding Section 11.1.2, the Parties shall cooperate to prepare standardized public responses to anticipated inquiries from the public, press, stockholders, investors and/or analysts with respect to the activities hereunder. Despite the
foregoing, each Party agrees that the other Party is free to disclose this Agreement in its entirety to the United States Federal Trade Commission and the United States Department of Justice, or to any court with jurisdiction over the litigations
settled under the Settlement Agreement between Shire Laboratories Inc. and Barr Laboratories Inc. dated August 14, 2006. 

          11.1.4 Unauthorized Disclosure. The Receiving Party acknowledges and agrees that the
Confidential Information of the Disclosing Party constitutes proprietary information and trade secrets valuable to the Disclosing Party, and that the unauthorized use, loss or outside disclosure of such Confidential Information shall be presumed to
cause irreparable injury to the Disclosing Party. 

          11.1.5 Notification.  The Receiving Party shall notify the Disclosing Party promptly upon
discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information, and shall cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of such
Confidential Information and to prevent its further unauthorized use or disclosure.  The Receiving Party acknowledges that monetary damages may not be a sufficient remedy for unauthorized disclosure of Confidential Information and that the
Disclosing Party may be entitled, without waiving other rights or remedies, to such injunctive or equitable relief as may be deemed proper by a court of competent jurisdiction in the event of such unauthorized disclosure. 

     11.2 Confidentiality of this Agreement.  The terms of this Agreement shall be Confidential
Information of each Party and, as such, shall be subject to the provisions of this ARTICLE 11. 

ARTICLE 12

OWNERSHIP
OF INTELLECTUAL PROPERTY 

     12.1 Ownership. Duramed shall be the exclusive owner of all right, title and interest in and to
all Collaboration Intellectual Property, and Shire hereby assigns to Duramed all right, title and interest therein. Nothing herein shall be construed as granting Shire any rights in any of 

21 

the foregoing except as expressly provided herein.  Shire shall, at the request of Duramed, perform any acts that Duramed may reasonably deem necessary or desirable to evidence or confirm Duramed’s ownership interest in the
Collaboration Intellectual Property, including but not limited to making further written assignments in a form determined by Duramed. 

     12.2 Patent Filings. Duramed shall have the sole right to prepare, file, prosecute and maintain
all Collaboration Intellectual Property throughout the world.  In furtherance of the foregoing, Duramed shall be responsible for the conduct of any interference proceedings related to any Collaboration Patent.  Except as provided below, Duramed
shall be responsible for all Patent Expenses incurred throughout the world.  Subject to the following sentence, should Duramed elect not to prepare and/or file any such Collaboration Patent in the Shire Territory, it shall (a) provide Shire with
written notice as soon as reasonably possible after making such election but in any event no later than [*] before Shire would be faced with a possible loss of rights, (b) give Shire the right, at Shire’s discretion and expense, to prepare,
file, prosecute or maintain the Collaboration Patent in Duramed’s name, and (c) offer reasonable assistance in connection with such preparation, filing, prosecution or maintenance.  In the event Duramed determines in its sole discretion, acting
in good faith, to maintain certain Collaboration Intellectual Property as a trade secret, Duramed shall have no obligation under the previous sentence. 

     12.3 Cooperation.  The Parties agree to cooperate in the preparation, filing, prosecution and
maintenance of all Patents under this ARTICLE 12, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the filing Party concerning the Invention disclosed in
such Patent, obtaining execution of such other documents which shall be needed in the filing and prosecution of such Patent, and, as requested, updating each other regarding the status of such Patent, and shall cooperate with the other Party so far
as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such Patents.

     12.4 Enforcement and Defense of Patents. 

          12.4.1 Infringement of Third Party Patents. 

               (a) Third Party Claims; Third Party Royalties.  In the event of a Third Party Claim against
Shire, Duramed or their respective Affiliates alleging that the making, using, importing, selling or offering to sell a Collaboration Product infringes or shall infringe claims in any patents of a Third Party, the Party first obtaining knowledge of
such Third Party Claim shall immediately provide the other Party notice of such Third Party Claim with the related facts in reasonable detail. Shire shall have the sole right to control such defense with respect to any Collaboration Product with an
attorney of Shire’s choice if the alleged infringing activity relates solely to the Shire Territory. In such case, Duramed shall have the right to be represented by independent counsel at Duramed’s own expense. Duramed shall have the sole
right to control such defense with respect to any Collaboration Product with an attorney of Duramed’s choice if the alleged infringing activity relates solely to the Duramed Territory. In such case, Shire shall have the right to be represented
by independent counsel at Shire’s own expense. If the alleged infringing activity relates to both the Duramed Territory and the Shire Territory, then the Parties shall have the joint right, but not the obligation, to control such 

22 

defense with respect to Collaboration Product with an attorney of their mutual agreement. If the Parties are unable to agree on such joint defense, then the Parties shall use good faith efforts to determine the Party to assume
control of such defense and choice of counsel. In such case, the other Party shall have the right to be represented by independent counsel at its own expense. If, as a result of a judgment in any litigation or settlement with a Third Party, either
Party or its Affiliates is required to pay royalties to any Third Party, such Party shall bear all cost of such royalties. 

               (b) Cooperation. If a Party shall become engaged in or participate in any suit described in this
Section 12.4.1, the other Party shall cooperate, and shall cause its and its Affiliates’ employees to cooperate, with such Party in all reasonable respects in connection therewith, including giving testimony and producing documents lawfully
requested, and using its reasonable and diligent efforts to make available to the other, at no cost to the other (other than reimbursement of actually incurred, reasonable out-of-pocket travel and lodging expenses), such employees who may be helpful
with respect to such suit, investigation, claim, interference or other proceeding. 

          12.4.2 Prosecution of Infringers. 

               (a) Notice.  If either Party learns that a Third Party is infringing or allegedly infringing any
Collaboration Intellectual Property, or if any Third Party claims that any Collaboration Intellectual Property is invalid or unenforceable, it shall promptly notify the other Party thereof including available evidence of infringement or the claim of
invalidity or unenforceability.  The Parties shall cooperate and use reasonable efforts to stop such alleged infringement or to address such claim without litigation. 

               (b) Enforcement and Defense. 

                  (i) [*] to take the appropriate steps to enforce or defend any Collaboration Intellectual Property [*], and will have the [*] to
    take the appropriate steps to enforce or defend any Collaboration Intellectual Property [*]. [*] may take steps including the initiation, prosecution and control any suit, proceeding or other legal action by counsel of its own choice. [*] for the
    costs of such enforcement or defense. Notwithstanding the foregoing, [*], to be[*]. 

                  (ii) If, pursuant to Section 12.4.2(b)(i), [*] take the appropriate steps to enforce or defend any Collaboration Patent [*] of
    the date one Party has provided notice to the other Party pursuant to Section 12.4.2(a) of such infringement or claim, then [*], to bring any such suit, action or proceeding by counsel of its own choice and [*], to be [*]. 

               (c) Cooperation; Damages. 

                  (i) If one Party brings any suit, action or proceeding under this Section 12.4.2, the other Party agrees to be joined as party
    plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or proceeding; provided, however, that neither Party shall be required to transfer any right,
    title 

23 

  
    or interest in or to any property to the other Party or any other party to confer standing on a Party hereunder. 

                  (ii) The Party not pursuing the suit, action or proceeding hereunder shall provide reasonable assistance to the other Party,
    including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any out-of-pocket expenses incurred by the non-enforcing or defending Party in providing
    such assistance. 

                  (iii) Neither Party shall settle or otherwise compromise any such suit, action or proceeding in a way that adversely affects the
  other Party’s intellectual property rights or its rights or interests with respect to the Collaboration Product without such Party’s prior written consent. 

                  (iv) Any settlements, damages or other monetary awards (the “Recovery”) recovered pursuant to a suit, action or proceeding brought pursuant to Section 12.4.2 shall be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the
  other Party, with any remaining amounts (if any) with respect to a country in the Duramed Territory or the Shire Territory to be allocated to Duramed or Shire, respectively. 

     12.5 Notice of Certification. Duramed and Shire each shall immediately give notice to the other
of any certification filed under the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (or its foreign equivalent) claiming that a Collaboration Patent, is invalid or that infringement of a Collaboration Patent, shall not arise
from the manufacture, use, offer for sale, sale or importation product by a Third Party. Nothing in this Section 12.5 shall prevent or otherwise limit Duramed’s right to take any and all such actions with regard to the matters described in this
Section 12.5 as required by applicable Law.

     12.6 Patent Term Extensions.  Duramed and Shire shall cooperate in good faith in gaining patent
term extensions due to delay(s) in Regulatory Approval wherever applicable to the Collaboration Patents.  However, [*] in determining which Collaboration Patent(s) to [*] compound, composition, article, product, process, or use. Should [*] that a
[*] for a Collaboration Patent and [*] of such Collaboration Patent, it shall (a) provide [*] as soon as reasonably possible [*] but in [*], (b) give [*] Collaboration Patent in [*], and (c) offer reasonable assistance in connection with such
extension.

     12.7 Trademarks and Copyrights. 

          12.7.1 Product Trademarks. All Collaboration Products shall be marketed and sold worldwide under
and in connection with trademarks, trade dress, logos and slogans selected in accordance with this Section 12.7. 

          12.7.2 Trademark Selection. Duramed shall have the right and responsibility to select and
register trademarks, trade dress, logos and slogans for each Collaboration Product for use in the Duramed Territory. Shire shall have the right and responsibility to select and register 

24

  

trademarks, trade dress, logos and slogans for each Collaboration Product for use in the Shire Territory; provided, that Shire may determine to use a Duramed Mark (as defined below) in connection therewith as further set below in
Section 12.7.3. 

          12.7.3 Ownership of Trademarks. Duramed shall own, throughout the world, any trademarks, trade
dress, logos and/or slogans, and all registrations therefor, used or intended to be used for a Collaboration Product which Duramed owns as of the Effective Date or that is otherwise selected and/or registered by Duramed for use in connection with
Collaboration Products (collectively, the “Duramed Marks”).  Shire shall own, throughout the world, any trademark, trade dress, logo and/or slogans, and all registrations therefor,
selected and/or registered by Shire for use in connection with Collaboration Products (collectively, the “Shire Marks”). All goodwill attributable to a Duramed Mark generated by
the Commercialization of a Collaboration Product bearing a Duramed Mark shall inure to the benefit of Duramed.  All goodwill attributable to a Shire Mark generated by the Commercialization of a Collaboration Product bearing a Shire Mark shall inure
to the benefit of Shire.  Shire shall not use and/or register any Duramed Marks in the Shire Territory without the prior consent of Duramed. Duramed shall not use and/or register any Shire Marks in the Duramed Territory without the prior consent of
Shire, provided, however, that if Shire determines to use a Duramed Mark for the Commercialization of a Collaboration Product in the Shire Territory, Duramed shall grant to Shire, a non-exclusive, royalty-free license, with the right to grant
sublicenses, to use such Duramed Mark in the Shire Territory, solely in conjunction with the Commercialization of the Collaboration Products.  Shire shall comply with Duramed’s then-current guidelines for trademark usage, a copy of which shall
be provided to Shire from time to time, in connection with Shire’s use of such Duramed Mark. Duramed shall solely bear all costs of prosecution of applications to register and to record licenses (if applicable) for, and maintenance of, each
Duramed Mark for each Collaboration Product. Shire shall solely bear all costs of prosecution of applications to register and to record licenses (if applicable) for, and maintenance of, each Shire Mark for each Collaboration Product, and any Duramed
Marks that Shire elects to use in accordance with the provisions of this Section 12.7.3 within the Shire Territory. Duramed shall cooperate with Shire as reasonably requested by Shire in order to register (in Duramed’s name) any Duramed Marks
licensed to Shire under this Section 12.7.3 in the Shire Territory.

     12.8 Enforcements of Trademarks.

               (a) Notice.  If either Party learns that a Third Party is infringing or allegedly infringing any
Duramed Marks of Shire Marks, or if any Third Party claims that any Duramed Marks of Shire Marks is invalid or unenforceable, it will promptly notify the other Party thereof including available evidence of infringement or the claim of invalidity or
unenforceability.  The Parties will cooperate and use reasonable efforts to stop such alleged infringement or to address such claim without litigation. 

               (b) Enforcement and Defense. Duramed will have the first right (but not the obligation) to take
the appropriate steps to enforce or defend any Duramed Marks throughout the world, and will have the exclusive right (but not the obligation) to take the appropriate steps to enforce or defend any Duramed Marks in the Duramed Territory. Duramed may
take steps including the initiation, prosecution and control any suit, proceeding or other legal action by counsel of its own choice. Duramed will be solely responsible for the costs of 

25 

such enforcement or defense.  Notwithstanding the foregoing, Shire will have the right, at its own expense, to be represented in any such action by counsel of its own choice. Shire will have the exclusive right (but not the
obligation) to take the appropriate steps to enforce or defend any Shire Marks in the Shire Territory.

               (c) If, pursuant to Section 12.8(a), Duramed fails to take the appropriate steps to enforce or defend any Duramed Marks within
the Shire Territory within [*] of the date one Party has provided notice to the other Party pursuant to Section 12.8(a) of such infringement or claim, then Shire will have the right (but not the obligation), at its own expense, to bring any such
suit, action or proceeding by counsel of its own choice and Duramed will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

               (d) Cooperation; Damages. 

                  (i) If one Party brings any suit, action or proceeding under this Section 12.8, the other Party agrees to be joined as party
    plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or proceeding; provided, however, that neither Party will be required to transfer any right,
    title or interest in or to any property to the other Party or any other party to confer standing on a Party hereunder. 

                  (ii) The Party not pursuing the suit, action or proceeding hereunder will provide reasonable assistance to the other Party,
    including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any out-of-pocket expenses incurred by the non-enforcing or defending Party in providing
    such assistance. 

                  (iii) Neither Party will settle or otherwise compromise any such suit, action or proceeding in a way that adversely affects the
    other Party’s intellectual property rights or its rights or interests with respect to the Duramed Marks of Shire Marks without such Party’s prior written consent. 

                  (iv) Any Recovery recovered pursuant to a suit, action or proceeding brought pursuant to this Section 12.8 will be allocated
    first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) with respect to a country in the Duramed Territory or the Shire Territory to be
    allocated to Duramed or Shire, respectively. 

     12.9 Costs of Defense. All of the unrecovered costs, expenses and legal fees (including internal
costs, expenses and legal fees) incurred by the Parties in bringing, maintaining and prosecuting any action to maintain, protect or defend the Duramed Marks or Shire Marks shall be borne by the Party bringing, maintaining or prosecuting the relevant
action. 

26 

ARTICLE 13

REPRESENTATIONS
AND WARRANTIES; EXCLUSIVITY 

     13.1 Mutual Representations and Warranties. Each of the Parties hereby represents and warrants
to the other Party that, as of the date hereof:

               (a) Such Party has full corporate right, power and authority to enter into this Agreement and to perform its respective
obligations under this Agreement and that it has the right to grant the rights and licenses granted pursuant to this Agreement. 

               (b) This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The
execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is bound, nor violate any Law of any Governmental Authority
having jurisdiction over it. 

               (c) Such Party has not granted any right to any Third Party that would conflict with the rights granted to the other Party
hereunder. 

               (d) Such Party has obtained all necessary consents, approvals and authorizations of all Government Authorities and other Persons
required to be obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement. 

     13.2 Mutual Covenants. Each Party hereby covenants to the other Party that, during the Term:

               (a) Such Party shall not grant any right to any Third Party that would conflict with the rights granted to the other Party
hereunder; 

               (b) In the course of Development hereunder, such Party shall not use any employee or consultant that, to such Party’s
knowledge, is debarred by the FDA (or any foreign equivalent) or is the subject of debarment proceedings by the FDA (or any foreign equivalent). 

     13.3 Duramed Representations and Warranties. Duramed hereby represents and warrants to Shire
that, as of the date hereof: 

               (a) There is no action or proceeding pending or, to Duramed’s knowledge, threatened, with respect to any existing
Collaboration Product and/or the Ring Intellectual Property (excluding ordinary course patent prosecution activities before the U.S. Patent and Trademark Office and equivalent foreign counterparts and Regulatory Authorities). There are no material
unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or by an arbitrator) against Duramed or its Affiliates with respect to existing Collaboration Products
and/or the Ring Product.

27 

               (b) Attached hereto as Schedule 13.3(b) is a true, correct and
complete list of all INDs (including the INDs referenced in the preceding sentence) and Drug Approval Applications filed with a Governmental Authority relating to Collaboration Products (together, the “Collaboration
Product INDs”) and all Collaboration Product INDs are and remain in effect. 

               (c) Intellectual Property. 

                  (i) The Collaboration Intellectual Property includes the Patents set forth in Schedule 13.3(c) .  Such schedules contain, where
    relevant for the Shire Territory, all application numbers and filing dates, registration numbers and dates and jurisdiction. 

                  (ii) Duramed has a good faith belief that the Collaboration Intellectual Property may be configured into a commercial vaginal or
    cervical ring product, either directly or through Development, that does not infringe the intellectual property rights of any Third Party. 

                  (iii) Duramed has the right to grant to Shire the licenses set forth in this Agreement, free of any rights, encumbrances or
    claims of any Third Party and without payment by Shire of any royalties, license fees or other amounts to any Third Party. 

                  (iv) All Patents included in the Ring Intellectual Property are subsisting and, to Duramed’s knowledge, valid, enforceable
    and inventorship thereof is properly identified therein. None of such Patents is currently involved in any interference, reissue, reexamination, or opposition proceeding, and neither Duramed nor any of its Affiliates has received any written notice
    from any person, or has knowledge, of such actual or threatened proceeding.

                  (v) To Duramed’s knowledge, there is no unauthorized infringement by a Third Party of Patents included in the Ring
    Intellectual Property. 

               (d) Compliance with Law. 

                  (i) To Duramed’s knowledge, Duramed, its Affiliates and any Third Party to which Duramed or its Affiliates have
    subcontracted activities in connection with Compound and existing Collaboration Products, and the Ring Product have, complied with all applicable Laws, permits, governmental licenses, registrations, approvals, concessions, franchises,
    authorizations, orders, injunctions and decrees, including the Act, in the research, Development, Manufacture and use thereof, and have not received any written notice from any Governmental Authority claiming that any such activities as conducted by
    them are not in such compliance. 

                  (ii) No Governmental Authority has commenced or, to Duramed’s knowledge, threatened to initiate any action to reject or
    withdraw the 

28 

  

  

  

  
    Collaboration Product INDs, or commenced or, to Duramed’s knowledge, threatened to initiate any action to enjoin production of Collaboration Products at any facility, nor has Duramed or any of its Affiliates or, to the
    knowledge of Duramed, any of its Contractors, received any notice to such effect. 

                  (iii) Duramed has delivered or otherwise made available to Shire copies of all substantive or material (A) reports of FDA Form
    483 inspection observations, (B) establishment inspection reports, (C) warning letters, and (D) other documents that assert ongoing lack of compliance in any material respect with any applicable Laws (including those of the FDA), in each case to the
    extent received by Duramed or any of its Affiliates or, to the knowledge of Duramed, any of its contractors from the FDA relating to a Collaboration Product and/or Compound, or the Ring Product. Neither Duramed nor any of its Affiliates has received
    any such reports, letters or other documents from any other Governmental Authority relating to a Collaboration Product and/or the Ring Product. 

                  (iv) To Duramed’s knowledge, in the course of the Development of the Collaboration Products or the Ring Intellectual
    Property, Duramed has not used any employee or consultant that is debarred by the FDA or is the subject of debarment proceedings by the FDA. 

     13.4 Performance by Affiliates/Third Parties.  Either Party may retain Affiliates and/or Third
Parties to perform Development and Commercialization activities under this Agreement. Each Party shall remain responsible for and be guarantor of the performance by its Affiliates and Third Parties and shall cause its Affiliates and Third Parties to
comply with the provisions of this Agreement in connection with such performance. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate or Third Party, for any
obligation or performance hereunder prior to proceeding directly against such Party.  Wherever in this Agreement the Parties delegate responsibility to Affiliates, Third Parties or local operating entities, the Parties agree that such entities may
not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 

     13.5 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE 13,
DURAMED AND SHIRE MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND DURAMED AND SHIRE EACH SPECIFICALLY DISCLAIMS ANY OTHER REPRESENTATIONS AND WARRANTIES,
WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE. 

     13.6 Limitation of Liability. EXCEPT FOR ANY BREACHES OF SECTIONS 6.3 AND 6.4, IN NO EVENT SHALL
EITHER PARTY BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY 

29 

  

HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS SHALL NOT LIMIT EITHER PARTY’S OBLIGATIONS TO THE OTHER PARTY FOR
INDEMNIFICATION OF THIRD PARTY CLAIMS UNDER ARTICLE 15. 

ARTICLE

14 TERM AND TERMINATION 

     14.1 Term.  This Agreement shall commence as of the Effective Date and, unless sooner terminated
as provided herein, shall expire on the later of (i) the last Valid Claim contained in any Collaboration Patent or (ii) the date when Shire and its Affiliates cease selling the last of its Collaboration Products, but in any event not before eight
(8) years after the Effective Date (the “Term”). 

     14.2 Termination for Material Breach.  Either Party (the “Notifying Party”) may terminate this Agreement on a Collaboration Product-by-Collaboration Product basis at any time in the event the other Party (the “Breaching
Party”) has materially breached this Agreement with respect to such Collaboration Product and, if the material breach is capable of cure, such material breach continues uncured for a period of ninety (90) days
after written notice thereof by the Notifying Party; provided, however, in the event that the Breaching Party has in good faith commenced cure within such ninety (90) day period, but cannot practically complete such cure within such ninety (90) day
period, the Breaching Party shall have an additional ninety (90) day cure period. In the event a material breach is incapable of cure, without limiting any other rights of the Notifying Party, including the right to seek injunctive relief, the
non-Breaching Party shall not have the right to terminate this Agreement on a Collaboration Product-by-Collaboration Product basis if (i) the Breaching Party is providing full cooperation to mitigate the breach, and (ii) the breach was not caused by
willful misconduct by the Breaching Party. 

     14.3 Termination of Commercialization by Shire. 

          14.3.1 [*]. Shire may elect to cease Development or Commercialization of any Collaboration Product for the Shire Territory at any
time in the Shire Territory (such Collaboration Product, to the extent of the ceased Development activities, the “Ceased Collaboration Product”). In such event Shire shall promptly
notify Duramed thereof, and offer Duramed the right to repurchase the Ceased Collaboration Product on terms to be mutually agreed.  Without limiting the previous sentence, if at any time [*] under this Agreement [*] Ceased Collaboration Product [*]
Collaboration Product, [*] that are the subject [*] upon the [*], including the [*], to be [*]. If [*], or [*] after receipt of [*], whichever occurs first, then [*] on such terms and conditions that, [*].

          14.4 Upon Termination.  Termination of this Agreement shall not affect the obligation of any
Party to pay the other Party any amounts due hereunder accrued prior to the termination date hereof. The right to terminate this Agreement shall not prejudice any other right or remedy in equity or at Law of a Party in respect of any breaches of
this Agreement. Upon termination of this Agreement by Duramed, all worldwide rights to Commercialize the Collaboration Products shall revert to Duramed.  Upon termination by Duramed with the 

30 

exception of one copy which Shire shall keep for its internal business purposes, Shire shall promptly transfer any materials, information, books and records, and data in its possession relating to Development, Commercialization or
to Regulatory Approvals of the Collaboration Products, together with any other books and records of Duramed made available to Shire in furtherance of the transactions contemplated hereby. 

     14.5 Survival. The provisions of Sections 8.4, 12.1, 13.6, 14.4, and 14.5, and Articles X, XI,
XV, XVI and XVII shall survive [*] this Agreement.

ARTICLE 15

INDEMNIFICATION; INSURANCE 

     15.1 Indemnification. 

          15.1.1 Indemnification by Shire.  Shire hereby agrees to hold Duramed, its Affiliates, and their
respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees,
stipulations or injunctions by a Third Party (each a “Third Party Claim”) resulting directly from (a) any breach by Shire of any of its representations, warranties, covenants or
obligations pursuant to this Agreement, (b) the negligence or willful misconduct by Shire or its Affiliates or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement, (c) use,
handling, storage, sale or other disposition of Collaboration Products (including, without limitation, those Third Party Claims that involve death or bodily injury (or allegations thereof) to any individual or any property other than intellectual
property) arising out of activities conducted by or on behalf of Shire or related to the Shire Territory, or (d) the conduct of clinical testing of the Collaboration Products by or on behalf of Shire, except for such matters as Duramed is obligated
to indemnify Shire under Section 15.1.2; in each case except to the extent that such Losses result from the negligence or willful misconduct of Duramed. 

          15.1.2 Indemnification by Duramed. Duramed hereby agrees to hold Shire, its Affiliates, and
their respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Third Party Claims resulting directly from (a) any breach by Duramed of any of its representations, warranties,
covenants or obligations pursuant to this Agreement, (b) the negligence or willful misconduct by Duramed or its Affiliates or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement,
(c) manufacture, use, handling, storage, sale or other disposition of Collaboration Products (including, without limitation, those Third Party Claims that involve death or bodily injury (or allegations thereof) to any individual or any property
other than intellectual property) arising out of activities conducted by or on behalf of Duramed or related to the Duramed Territory, (d) the conduct of clinical testing of the Collaboration Products by or on behalf of Duramed, or (e) Duramed’s
(or its agent’s, contractor’s or other designee’s, other than Shire) failure to comply with cGMP, applicable product specifications or applicable Law in connection with the Manufacture of Collaboration Product supplied to Shire
hereunder; in each case except to the extent that such Losses result from the negligence or willful misconduct of Shire. 

31 

          15.1.3 The rights of indemnification under this Section 15.1 shall be subject to the provisions of Sections 15.2 through 15.8.

     15.2 Notice of Claim.  All indemnification claims in respect of any indemnitee seeking indemnity
under Section 15.1 (collectively, the “Indemnitees” and each an “Indemnitee”) shall be made solely by the
corresponding Party (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon which such Indemnified Party intends to base a
request for indemnification under Section 15.1, but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such Third Party Claim. Each
Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim Notice, the
Indemnified Party shall furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. The Indemnifying Party shall not be obligated to
indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party materially prejudices the defense of such Third Party Claim. 

     15.3 Control of Defense.  At its option, the Indemnifying Party may assume the defense of any
Third Party Claim subject to indemnification as provided for in Sections 15.1.1 and 15.1.2 by giving written notice to the Indemnified Party within [*] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the
defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party
shall not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim.

     15.4 Right to Participate in Defense. Without limiting Section 15.3, any Indemnitee shall be
entitled to participate in, but not control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the
Indemnitee’s own expense unless (a) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 15.3
(in which case the Indemnified Party shall control the defense). 

     15.5 Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that shall not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the Indemnifying Party
shall have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such
terms as the Indemnifying Party, in its reasonable discretion, shall deem appropriate (provided, however that such terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto), and shall
transfer to the Indemnified Party all amounts which said Indemnified Party shall be liable to pay prior to the 

32 

time of the entry of judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 15.3, the Indemnifying
Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent shall be at the Indemnified
Party’s reasonable discretion).  The Indemnifying Party that has assumed the defense of the Third Party Claim in accordance with Section 15.3 shall not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached
without the written consent of such Indemnifying Party.  Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee shall admit any liability with respect to, or settle, compromise or discharge,
any Third Party Claim without first offering to the Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with Section 15.3. 

     15.6 Cooperation.  If the Indemnifying Party chooses to defend or prosecute any Third Party
Claim, the Indemnified Party shall, and shall cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by
the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 

     15.7 Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable
costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

     15.8 Treatment of Certain Losses.  Duramed shall be solely responsible for all Losses from Third
Party Claims resulting directly from the use or administration of the Compounds, Collaboration Products prior to the Effective Date. 

     15.9 Insurance. Each Party shall obtain and keep in force, through self insurance or otherwise,
in a form reasonably acceptable to the other Party hereto, insurance in scope and amount as required by Law applicable to a Party’s activities hereunder and such additional amounts as may be reasonably necessary to cover such Party’s
indemnity obligations under this Agreement with scope and coverage as is normal and customary in the biotechnology/pharmaceutical industry generally for parties similarly situated. It is understood that such insurance shall not be construed to limit
a Party’s liability with respect to its indemnification obligations under this ARTICLE 15. Each Party shall, except to the extent self 

33 

insured, provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain and keep in force under this ARTICLE 15.

     15.10 Guaranty. In
consideration of [*] under this Agreement, and to induce [*] to enter into this
Agreement, [*] under this Agreement, in accordance with the terms and conditions
of this Agreement, [*] under this Agreement in accordance with its terms.

ARTICLE 16

DISPUTE RESOLUTION 

     16.1 Disputes. The Parties hereby agree that all disputes arising under this Agreement shall be
referred to a senior executive of Duramed and a senior executive of Shire (the “Representatives”). If any such matter has not been resolved within [*] of such referral to the
Representatives either Party may invoke the provisions of Section 16.2 for such dispute.  No dispute resolution procedure set forth in this Agreement shall be construed as an agreement to arbitrate under any federal or state arbitration Law,
including but not limited to the Federal Arbitration Act, and shall not deprive a court of competent jurisdiction from resolving any dispute arising under, or related to, this Agreement. 

     16.2 Litigation.  Any dispute that is not resolved as provided in the preceding Section 16.1,
whether before or after termination of this Agreement, may be submitted by either Party only to any court of competent jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of New York. The
Parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in New York, NY and waive any objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby and further agree not to commence any such action, suit or proceeding except in any such court.

     16.3 Injunctive Relief. Notwithstanding anything to the contrary in this Agreement, either Party
shall have the right to seek temporary injunctive relief in any court of competent jurisdiction as may be available to such Party under the Laws and rules applicable in such jurisdiction with respect to any matters arising out of the other
Party’s performance of its obligations under this Agreement. 

ARTICLE 17

MISCELLANEOUS 

     17.1 Entire Agreement; Amendment.  This Agreement, including the exhibits attached hereto and
thereto (each of which is hereby and thereby incorporated herein and therein by reference), sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties, which shall continue to govern the obligations of the Parties with respect to 

34 

information disclosed thereunder with respect to periods prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the
Parties other than as are set forth herein.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance
of doubt, the Parties agree that all covenants, promises, agreements, warranties, representations, conditions, and understandings set forth herein are made and deemed effective as of the Effective Date, and that the execution of this Agreement shall
not constitute a waiver of any right or claim of either Party as of the Effective Date. 

     17.2 Force Majeure.  Each Party shall be excused from the performance of its obligations under
this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse shall be continued so long as the condition constituting force
majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including without limitation, an act of God,
voluntary or involuntary compliance with any regulation, Law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe; provided, however, the payment of invoices due and owing hereunder shall not be delayed by the payer because of a force majeure affecting the payer, unless such force majeure specifically
precludes the payment process. 

     17.3 Notices. All notices or other communications that are required or permitted under this
Agreement shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses
below. Any such communication shall be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal delivery or overnight courier as provided in this
Agreement), and (b) on the second Business Day after dispatch, if sent by internationally-recognized overnight courier.  Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

	For Duramed: 	 	Duramed Pharmaceuticals,
        Inc. 

400 Chestnut Ridge Road 

Woodcliff Lake, NJ 07677 

Phone: 201-930-3300 

Fax: 201-930-3330 

Attention: President 
	 	 	 
	 with a copy to: 	 	Barr Pharmaceuticals,
        Inc. 

400 Chestnut Ridge Road 

Woodcliff Lake, NJ 07677 

Phone: 201-930-3300 

Fax: 888-843-0563 

Attention: General Counsel 

 

35 

	For Shire: 	 	Shire LLC 

    725 Chesterbrook Boulevard 

Wayne, Pennsylvania 19087-5637 

Fax: (484) 595-8163 

Attention: General Counsel 
	 	 	 
	 with a copy to: 	 	Morgan, Lewis & Bockius
        LLP 

502 Carnegie Center 

Princeton, NJ 08540 

Fax: (609) 919-6701 

Attention: Randall B. Sunberg 

     17.4 Independent Contractors. In making and performing this Agreement, Shire and Duramed shall
act at all times as independent contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an agency, partnership, limited partnership, joint venture or employer and employee relationship between
Shire and Duramed and this Agreement shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. Except as otherwise provided in this Agreement,
each Party shall be solely responsible for its own costs and expenses associated with this Agreement. 

     17.5 Non-Solicitation.  From and after the Effective Date until the one (1) year anniversary of
the termination or expiration of this Agreement, neither Party shall, and shall cause each of its Affiliates not to, directly or indirectly, without the other Party’s prior written consent, solicit the employment of any employee (or former
employee bound by a non-competition obligation) of the other Party or its Affiliates with whom it has come in contact in conducting activities under this Agreement; provided, however, that the foregoing provisions shall not apply to (a) a general
advertisement or solicitation program that is not specifically targeted at such persons or (b) the solicitation of any employee after such time as such employee’s employment has been terminated by the other Party or its Affiliate. 

     17.6 Maintenance of Records.  Each Party shall keep and maintain all records required by Law
with respect to Collaboration Products and shall make copies of such records available to the other Party upon reasonable request. 

     17.7 United States Dollars. References in this Agreement to “Dollars” or
“$” shall mean the legal tender of the United States. 

     17.8 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against either Party. 

     17.9 Assignment.  Neither Party shall sell, transfer, assign, delegate, pledge or otherwise
dispose of, whether voluntarily, involuntarily, by operation of Law or otherwise, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other Party (which consent may be granted, withheld or
conditioned at such other Party’s sole and absolute discretion); provided, however, that either Party may assign or transfer 

36 

this Agreement or any of its rights or obligations under this Agreement without the consent of the other Party to any Affiliate of such Party, or to any Third Party (a) with which it merges or consolidates, or to which it
transfers all or substantially all of its assets to which this Agreement pertains or (b) subject to Section 14.3.1, in part, in connection with the sale or transfer of such Party’s business relating to Commercialization of any Collaboration
Product within a particular country.  The assigning Party (unless it is not the surviving entity) shall remain jointly and severally liable with, and shall guarantee the performance of, the relevant Affiliate or Third Party assignee under this
Agreement, and the relevant Affiliate assignee, Third Party assignee or surviving entity shall assume in writing all of the assigning Party’s obligations under this Agreement.  Notwithstanding the foregoing, in the event Duramed sells,
transfers, assigns, delegates, pledges, licenses or otherwise disposes of a Collaboration Product(s) to a Third Party (whether pursuant to a joint venture, collaboration or otherwise), Shire shall have no obligation to reimburse such Third Party for
any development expenses such Third Party may incur with respect to such Collaboration Product(s); provided, however, that Duramed shall remain entitled to reimbursement pursuant to Section 7.2 for any remaining Collaboration Products up to the
Maximum Reimbursement Amount. Any purported assignment or transfer in violation of this Section 17.9 shall be void ab initio and of no force or effect. Notwithstanding anything to the contrary herein, in the event any assignment by Shire hereunder
gives rise to any obligation to withhold any amounts payable to Duramed, Shire, or its assignee, shall be entitled to deduct from all payments due under this Agreement the amount of all applicable withholding taxes to the extent Shire, or its
assignee, pays such taxes to the appropriate governmental authority on behalf of Duramed. Shire shall properly furnish Duramed with copies of tax receipts evidencing the payment of all such taxes, levies and assessments. Duramed and Shire shall
cooperate with each other in obtaining any exemption from, a refund for, or reduced rate of tax available under any applicable law or tax treaty.  Notwithstanding the foregoing, Shire shall be liable for, and indemnify Duramed against, any non-U.S.
taxes, any value-added or sales taxes, any duties or levies and assessments, howsoever designated or computed that are required to be paid or withheld by Shire on such payments. Shire shall so indemnify Duramed within [*] of Shire’s receipt of
notification from Duramed (in accordance with Section 17.3 hereof) that either (i) based upon current facts and circumstances, Duramed does not have or will not have during the applicable tax year any or sufficient foreign tax credits available to
utilize to offset such tax liability; or (ii) Duramed has applied for a refund from the taxing authority at issue (such notice to include a copy of such refund application). Notwithstanding anything in this Agreement to the contrary, in the event
that withholding taxes are paid on behalf of Duramed by Shire, if Duramed uses a foreign tax credit received as a result of the payment of withholding taxes by Shire and thereby reduces the amount of U.S. income tax that Duramed otherwise would have
paid, or otherwise receives a refund, Duramed shall refund to Shire the amount of such reduction with respect to such foreign tax credit or such refund. 

     17.10 Counterparts.  This Agreement may be executed in two counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument.  Signatures provided by facsimile transmission shall be deemed to be original signatures. 

     17.11 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

37 

     17.12 Severability. If any one or more of the provisions of this Agreement is held to be invalid
or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make
a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

     17.13 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

     17.14 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter
for a particular period of time. 

[Signature Page Follows.] 

38 

      IN WITNESS WHEREOF, the Parties have executed this Collaboration and License Agreement in duplicate originals by their proper officers as of the date first written above. 

	 	 DURAMED PHARMACEUTICALS, INC.  
	 	 	 
	 	 	 
	 	By: 	 
	 	 	

	 	 	Name 
	 	 	Title
	 	 	 
	 	 SHIRE LLC  
	 	 	 
	 	 	 
	 	By: 	 
	 	 	

	 	 	Name 
	 	 	Title

 

	 	 SHIRE PLC (solely for purposes
    of Section 15.10)  
	 	 	 	 
	 	 	 	 
	 	By: 	 	 
	 	 	
	 
	 	 	Name 	 
	 	 	Title	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	[Signature Page to Product Development
    and License Agreement]

 

 

EXHIBIT A

INITIAL
COLLABORATION PRODUCTS 

 

	Compound
	 [*] 
	 [*] 
	 [*] 
	 [*] 
	 [*] 

 

  EXHIBIT B

SUPPLY AGREEMENT 

 BETWEEN 

 SHIRE LLC 

 AND 

 DURAMED LABORATORIES, INC. 

 DATED AS OF 

 AUGUST 14, 2006 

 

 SUPPLY AGREEMENT 

      This
    SUPPLY AGREEMENT (this “Agreement”),
    dated as of August 14, 2006, by and among Shire LLC, a Kentucky limited liability
    company having a place of business at 725 Chesterbrook Boulevard, Wayne,
    Pennsylvania 19087 (“Shire”),
    and Duramed Pharmaceuticals, Inc., a Delaware corporation having a place
    of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”)
    (each a “Party” and
    collectively, the “Parties”). 

 RECITALS 

      WHEREAS,
    the Parties have entered into that certain Product Development and License
    Agreement (the “Product Development
    Agreement”), dated as of the date
    hereof, pursuant to which the Parties are developing Collaboration Products
    (as defined therein), with such Collaboration Products to be commercialized
    by Duramed in certain geographic regions, and by Shire in the rest of the
    world (capitalized terms used herein but not defined herein shall have the
    meanings set forth in the Product Development Agreement); 

      WHEREAS,
    the Product Development Agreement contemplates the Parties entering into
    this Agreement to govern the supply of Collaboration Products by Duramed
    to Shire; and 

      WHEREAS,
    Duramed desires to manufacture and/or supply the Collaboration Products to
    Shire upon the terms and subject to the conditions of this Agreement. 

      NOW,
      THEREFORE, in consideration of the
      foregoing premises and the mutual covenants contained herein, and for other
      good and valuable consideration, the receipt and sufficiency of which are
      hereby acknowledged, the Parties agree as follows: 

ARTICLE I

DEFINITIONS 

      “Affiliate” means,
    with respect to a Party, any entity that directly or indirectly controls,
    is control led by, or is under common control with, such Party, but only
    for so long as such control continues. For purposes of this definition, “control” means
    the power to direct the management and affairs of an entity, directly or
    indirectly, whether through the ownership of voting securities, by contract
    or otherwise. In the case of a corporation, the direct or indirect ownership
    of fifty percent (50%) or more of its outstanding voting shares shall in
    any case be deemed to confer control, provided that, the direct or indirect
    ownership of a lower percentage of such securities shall not necessarily
    preclude the existence of control. 

      “API
      Cost” for a Shire Product means
      the actual cost paid by Duramed on a pass-through basis for the active
      pharmaceutical ingredient in such Shire Product. For the avoidance of doubt,
      all raw material and manufacturing costs of cervical and vaginal rings
      in a Shire Product shall not be included in the API Cost. 

      “Changeover
      Plan” has the meaning set forth
      in Section 8.2. 

 

       “Effective
      Date” means the date on which
      the Parties have attached mutually agreed Exhibits to this Agreement for
      the supply of a particular Collaboration Product in accordance with Section
      2.1. 

      “Force
      Majeure Event” has the meaning
      set forth in Section 9.1. 

      “Fully
      Allocated Manufacturing Cost” means
      the actual cost incurred by Duramed for Manufacturing Shire Product, calculated
      in accordance with GAAP and using normal standard cost accounting and allocation
      methods and procedures of Duramed consistently applied and maintained,
      including, but not limited to, API Cost, all raw material and manufacturing
      costs of cervical and vaginal rings, and all costs of active and inactive
      ingredients therein; provided that, for purposes of this Agreement, Fully
      Allocated Manufacturing Cost shall not include overhead absorption related
      to significant idle or excess capacity in connection with (i) expansion
      of an existing facility; or (ii) the construction or validation of any
      new manufacturing facility of Duramed or any of its Affiliates that may
      be constructed after the date of this Agreement first written above.

      “Losses” means
    any and all liabilities, damages, fines, penalties, deficiencies, losses
    and expenses (including interest, court costs, amounts paid in settlement,
    reasonable fees of attorneys, accountants and other experts or other reasonable
    expenses of litigation or other proceedings or of any claim, default or assessment);
    provided, however, that the term “Losses” shall not include any
    special, consequential, indirect, punitive or similar damages, except to
    the extent actually paid by a Party pursuant to any Third Party Claim. 

      “Manufacturing” shall
    mean all activities related to the manufacturing of a Shire Product or any
    component or ingredient thereof, including packaging, in-process and finished
    product testing, release of product or any component or ingredient thereof,
    quality assurance activities related to manufacturing and release of product,
    ongoing stability tests and regulatory activities related to any of the foregoing. 

      “Net
      Sales Price” shall mean, [*] 

      “Packaging
      Specifications” means the packaging
      and labeling specifications for Shire Product set forth on Exhibit
      B, as amended or supplemented from
      time-to-time in accordance with Section 3.13.

      “Product
      Specifications” means the specifications
      for Shire Product set forth on Exhibit
      A, as amended or supplemented from
      time-to-time on mutual agreement of the Parties. 

      “Purchase
      Order” has the meaning set forth
      in Section 3.2. 

      “Rolling
      Forecast” has the meaning set
      forth in Section 3.1. 

      “Shire
      Product” means a Collaboration
      Product to be manufactured hereunder as set forth in Section 2.1. 

      “Term” has
    the meaning set forth in Section 7.1. 

  2 

 

      “Termination
      Assistance Services” has the
      meaning set forth in Section 8.1. 

 ARTICLE II

  SUPPLY OF PRODUCTS 

      Section
    2.1. Collaboration
    Products. Pursuant to the terms and
    conditions of this Agreement, Shire shall exclusively purchase from Duramed,
    and Duramed shall supply to Shire, Shire’s requirements for Collaboration
    Products, including for Development activities under the Product Development
    Agreement, in placebo and active forms. Upon Development of a Collaboration
    Product under the Product Development Agreement, the Parties shall attach
    hereto mutually agreed Exhibits applicable to the supply of such Collaboration
    Product. This Agreement, together with such Exhibits, shall be considered
    a separate agreement for each Collaboration Product. Duramed shall have no
    obligation to supply any Collaboration Product that has not been reduced
    to final finished dosage form under the applicable Development Plan, and
    all Exhibits hereto shall be consistent with such final finished dosage form. 

      Section
    2.2. Cooperation
    on Manufacturing Plan. The Parties acknowledge
    that Duramed will require certain minimum lead times and may have various
    options for manufacturing Shire Product hereunder, which options may include
    (i) building a dedicated manufacturing plant, which plant may or may not
    include excess capacity, (ii) utilizing excess capacity at existing manufacturing
    plants, (iii) expanding capacity at existing manufacturing plants, or (iv)
    combinations of the foregoing. Within [*] following the Effective Date (with
    respect to each Collaboration Product), the Parties shall meet to develop
    non-binding forecasts for capacity planning purposes of Shire’s anticipated
    needs for each Shire Product for clinical and commercial purposes over the
    clinical testing period and (i) the twelve (12) month period following first
    commercial launch of each Shire Product; and (ii) the 36 month period following
    the first commercial launch of each Shire Product. Thereafter, the Parties
    shall meet on an as-required basis, but no less than once each calendar quarter,
    to update such capacity planning forecast. The Parties shall also reasonably
    cooperate to develop non-infringing manufacturing techniques for Collaboration
    Products. 

      Section
    2.3. Initial
    Forecast and Purchase Order. At least
    [*] prior to the first anticipated clinical use or commercial launch for
    a Shire Product, Shire shall submit to Duramed an initial forecast (the “Initial
    Forecast”), which Initial Forecast
    shall be updated thereafter in accordance with Section 3.1. Notwithstanding
    any other provision of this Agreement, in no event shall Shire submit a Purchase
    Order for any initial order of a Shire Product [*] prior to the required
    delivery date for such initial order.

      Section
    2.4. Initial
    Implementation Meeting. No later than
    thirty (30) days after the receipt of an initial Purchase Order, Duramed
    and Shire shall hold an initial implementation meeting (at such time and
    place or by such means as are mutually agreed by the Parties) to develop
    specific implementation requirements for the supply of Shire Product to Shire.
    Thereafter, Duramed and Shire shall conduct implementation-planning meetings
    as reasonably required by the Parties in order to update and discuss (i)
    the current status of Duramed’s implementation activities, and (iii)
    the status of any actual and anticipated problem areas, their impact on the
    work efforts of Duramed, and actions being taken and/or needed to be taken
    by the Parties in order to reduce the potential impact of such problems. 

  3 

 

 ARTICLE III

  FORECASTS, ORDERS AND SHIPMENT 

      Section
    3.1. Forecasted
    Quantities. [*] 

      Section
    3.2. Purchase
    Order Form. Shire shall submit all orders
    for the purchase of Shire Products using the form of purchase order attached
    hereto as Schedule 1 (each
    a “Purchase Order”).
    Each Purchase Order will be delivered to such location as Duramed designates
    in writing to Shire from time to time. After Duramed receives a Purchase
    Order, Duramed shall acknowledge receipt thereof in writing within five (5)
    business days, either (i) accepting the Purchase Order, or (ii) seeking clarification
    of the Purchase Order, if necessary. Duramed shall have no obligation to
    accept any Purchase Order that does not include all information required
    on Schedule 1 or
    that is inconsistent with the terms and conditions of this Agreement. In
    the event that an order is rejected, Duramed and Shire will cooperate in
    good faith to resolve any supply issues raised by such order. The minimum
    size of any order placed by Shire will be a full batch in accordance with Exhibit
    A hereto.

      Section
    3.3. Delivery
    of Shire Product. Upon acceptance of
    a Purchase Order, Duramed shall deliver all Shire Product by the delivery
    date covered by such Purchase Order in accordance with the terms of this
    Agreement and such Purchase Order, including the quantities accepted in each
    Purchase Order. At the time of delivery to Shire, all Shire Product manufactured
    hereunder shall meet the Product Specification applicable thereto in all
    material respects, and shall be finished, packaged, labeled and/or ready
    for commercial sale by Shire as required in accordance with the Packaging
    Specifications. 

      Section
    3.4. Expedited
    Delivery. Upon the request of Shire
    to supply the quantities of Shire Product under a Purchase Order on an expedited
    basis, Duramed shall notify Shire of any expected increased costs that Duramed
    anticipates it will incur. Subject to prior written approval by Shire of
    these increased costs, Duramed shall use reasonable efforts to supply the
    quantities of Shire Product on an expedited basis. Duramed shall not have
    any liability for any failure to meet any such requested expedited delivery
    schedule. 

      Section
    3.5. Excess
    Purchase Orders. Duramed shall use commercially
    reasonable efforts to, but shall not be obligated to supply quantities of
    any Shire Product in excess of 120% of the quantities set forth in the most
    recent forecast for such quarter. If Duramed believes it will be unable to
    deliver any additional volume on the date specified by Shire in the applicable
    Purchase Order, Duramed shall notify Shire in writing as promptly as practicable,
    and shall provide a proposed alternative delivery schedule. Any agreement
    on the delivery schedule for such additional volume shall be documented in
    writing and shall become effective only upon mutual written agreement of
    both Parties to the terms and conditions thereof.

      Section
    3.6. Cancellation
    of Orders. Shire may not cancel an order
    without payment to Duramed in full for the order. Duramed shall, in good
    faith, use commercially reasonable efforts to mitigate the costs of cancellation
    of any Purchase Order. 

      Section
    3.7. Conflict.
    The terms of this Agreement shall prevail over any conflicting, inconsistent
    or additional terms set forth in any Purchase Order. 

  4 

 

      Section
    3.8. Delivery
    and Risk of Loss. All Shire Products
    shipped under this Agreement will be shipped Ex-Works (Incoterms 2000) Duramed’s
    manufacturing facility to such location designated by Shire in the applicable
    accepted Purchase Order. Shire will pay all freight, insurance charges, taxes,
    import and export duties, inspection fees and other charges applicable to
    the sale and transport of Shire Products. Risk of loss to Shire Products
    shall pass to Shire upon delivery to Shire’s designated carrier. Title
    to all Shire Products manufactured hereunder shall pass to Shire on payment
    by Shire for the applicable Shire Product or pro-rata portion thereof.

      Section
    3.9. Certificate
    of Analysis. A Certificate of Analysis
    (“COA”)
    will accompany each shipment of Shire Products in the form attached hereto
    as Schedule 2. 

      Section
    3.10. Location
    of Manufacturing. All Shire Products
    Shire shall be manufactured in a facility that has been designated as an
    approved manufacturing facility by the applicable Regulatory Approval for
    such Shire Product. Should Duramed desire to change any of the manufacturing
    site for a Shire Product, or any component thereof, to a site other than
    those designated in the applicable Regulatory Approval, Duramed shall notify
    Shire in writing and the Parties shall thereafter meet to discuss the potential
    consequences of such a change. Duramed shall not change manufacturing sites
    for any Shire Product, or any component thereof, except in accordance with
    the authorization of the applicable Governmental Authority, and the procedures
    and requirements set forth in this Agreement. 

      Section
    3.11. Shortage
    of Materials. In the event that the
    materials and/or resources required to manufacture and deliver Shire Products
    to Shire in accordance with this Agreement are, or are reasonably anticipated
    to become, in short supply such that Duramed may be unable to provide Shire
    with the quantities of Shire Products set forth in a Purchase Order, Duramed
    shall notify Shire of such shortage as promptly as practicable. If Duramed
    so notifies Shire, Duramed and Shire shall promptly meet to discuss how to
    address the potential shortage. In the event that Duramed, at any time, has
    any information indicating that it may not be able to supply Shire with all
    Shire Products in accordance with a confirmed Purchase Order, Duramed shall
    as soon as practicable provide Shire a written notice to that effect. To
    the extent that there is any such shortage, Duramed shall allocate on a pro-rata
    basis the supply of Shire Products and similar Duramed products based on
    the prior 12 months’ sales for each of Shire and Duramed for such products.
    Any failure by Duramed to meet its obligations under this Agreement as a
    result of a general shortage of raw materials (i.e., a shortage that not
    only affects Duramed, but also affects the general market for such raw materials)
    shall not be considered a breach of this Agreement provided that Duramed
    is meeting its obligations under Article IX. To the extent (other than as
    a result of a Force Majeure Event) that Duramed fails to supply at least
    80% of the quantities of Shire Product in the aggregate ordered for a particular
    calendar quarter for two consecutive calendar quarters, Shire may request
    and Duramed shall, at its cost and expense, qualify a second source of supply.
    Such second source shall be qualified and ready to manufacture Shire Product
    within 12 months following such Shire request. If Duramed fails to qualify
    and have ready such second source, then Shire shall have the right to qualify
    and make ready such second source and Duramed shall promptly reimburse Shire
    for costs and expenses incurred by it in so doing. Such second source shall
    be used by Duramed to supply Shire Product to Shire under this Agreement
    at least to the extent required to maintain the second source as a qualified
    manufacturer of Shire Product. 

  5 

 

      Section
    3.12. Product
    Specifications. Duramed shall manufacture
    all Shire Product so that, at the time of delivery to Shire, the Shire Product
    conforms, in all material respects, to the Product Specifications, cGMP and
    any reasonable requests communicated by Shire to Duramed in order for Shire
    to comply with any legal or regulatory obligations applicable to Shire. At
    the time of shipment of Shire Products, the Shire Products shall have a minimum
    remaining shelf life of not less than that agreed upon by the Parties with
    respect to the Shire Product at issue as set forth in Exhibit
    A. On mutual agreement of the Parties,
    the Parties may modify the Product Specifications of the Shire Product by
    amendment to Exhibit A, unless such changes are required by any regulatory
    authority, in which case Shire may unilaterally modify the Product Specifications
    of the Shire Product. Upon modification of such Product Specifications, Duramed
    shall use commercially reasonable efforts to alter its manufacturing processes
    to meet such Product Specifications and shall not be liable for any failure
    to meet its obligations hereunder while acting in good faith to meet the
    new Product Specifications. 

      Section
    3.13. Packaging
    Specifications. Duramed shall package
    the Shire Product in accordance with the Packaging Specifications. Changes
    in the Packaging Specifications shall be subject to the mutual agreement
    of the Parties on a schedule to be agreed by the Parties, taking into account
    the time and cost required for Duramed to implement any necessary manufacturing
    or packaging modifications. Shire shall compensate Duramed for the cost of
    any inventory of old packaging that cannot be used as a result of any modification
    by Shire to the Packaging Specifications, and for any other costs incurred
    as a result of the implementation of the modifications to the Packaging Specifications
    requested by Shire. Shire will be responsible for ensuring the accuracy of
    all information contained on all labels for Shire Products and for the compliance
    of all such labels with applicable Laws and Regulatory Approvals. 

      Section
    3.14. Facility
    Maintenance; Inspection; Reports. Duramed
    shall, at all times, maintain and operate all facilities where Shire Products
    are manufactured, packaged or tested, and implement required quality control
    procedures to perform its obligations under this Agreement. Not more than
    once every twelve (12) months (or more often in the case of a deficiency),
    Duramed shall permit, or cause its contractors to permit, quality assurance
    representatives of Shire or designated third parties and representatives
    of the applicable Government Authority to inspect such facilities upon reasonable
    advance notice, during normal business hours and on a confidential basis.
    Duramed shall promptly provide, or cause its contractor to provide, Shire
    with a copy of any notice from the applicable Government Authority received
    at the conclusion of an inspection relating to any Shire Product. 

      Section
    3.15. Subcontracting.
    Duramed shall have the right to subcontract manufacture and supply under
    this Agreement to any Affiliate of Duramed or to a Third Party, provided
    that, (i) Duramed shall procure that
    such Affiliates and Third Parties comply with the terms and conditions of
    this Agreement, (ii) Duramed shall be liable for any non-performance or breach
    by such Affiliate or Third Party, and (iii) any subcontracting to a Third
    Party shall be subject to Shire’s approval, which approval shall not
    be unreasonably withheld.

      Section
    3.16. Competing
    Products. Subject to the Product Development
    Agreement, Shire recognizes and acknowledges that Duramed and its Affiliates
    have been, and 

  6 

 

 will continue to be, actively involved
    in the field in which the Shire Products may be sold. Shire acknowledges
    that Duramed and its Affiliates currently, or may in the future, market,
    sell and distribute products that compete directly with any Shire Product,
    and may continue to market, sell and distribute these and other competing
    products throughout the Term of this Agreement. 

 ARTICLE IV

  REPRESENTATIONS AND WARRANTIES 

      Section
    4.1. Mutual
    Representations. Each Party hereby represents
    and warrants to the other Party, as of the date hereof, as follows: 

      (a) Due
      Authorization. Such Party is a corporation
      duly incorporated and in good standing (where such concept applies) as
      of the Effective Date, and the execution, delivery and performance of this
      Agreement by such Party have been duly authorized by all necessary action
      on the part of such Party. 

      (b) Due
      Execution. This Agreement has been
      duly executed and delivered by such Party and constitutes a legal, valid
      and binding obligation of such Party, enforceable against such Party in
      accordance with its terms. 

      (c) No
      Conflict. Such Party’s execution,
      delivery and performance of this Agreement do not: (i) violate, conflict
      with or result in the breach of any provision of the charter or by-laws
      (or similar organizational documents) of such Party; (ii) conflict with
      or violate any law, rule, regulation or governmental order applicable to
      such Party or any of its assets, properties or businesses; or (iii) conflict
      with, result in any breach of, constitute a default (or event which with
      the giving of notice or lapse of time, or both, would become a default)
      under, require any consent under, or give to others any rights of termination,
      amendment, acceleration, suspension, revocation or cancellation of any
      agreement to which it is a party. 

      (d) Duly
      Licensed. Such Party is duly licensed,
      authorized or qualified to do business and is in good standing (where such
      concept applies) in every jurisdiction in which a license, authorization
      or qualification is required for the ownership or leasing of its assets
      or the transaction of business of the character transacted by it, except
      where the failure to be so licensed, authorized or qualified would not
      have a material adverse effect on such Party’s ability to fulfill
      its obligations hereunder. 

ARTICLE V

QUALITY ASSURANCE 

      Section
    5.1. Duramed
    Compliance. Duramed shall manufacture,
    fill, package, handle and warehouse the Shire Products in conformity with
    all applicable laws, cGMP requirements and the Product Specifications. Shire  shall
    maintain all Regulatory Approvals and all permits and licenses issued by
    any Governmental Authority that are necessary to permit Duramed to manufacture
    and supply the Shire Products. Duramed shall advise Shire of any information
    of which it becomes aware arising out of Duramed’s activities hereunder
    that have adverse regulatory compliance and/or reporting consequences affecting
    the Shire Products. 

  7 

 

      Section
    5.2. Inspections.
    Duramed shall advise Shire of any requests by any Governmental Authority
    for inspections of the premises used to manufacture Shire Products. In the
    event the portion of Duramed’s facilities at which Shire Product are
    manufactured is inspected by any Governmental Authority, Duramed shall use
    commercially reasonable efforts to ensure that Shire shall have the right
    to be present during such inspection. To the extent relating directly to
    a Shire Product, Duramed shall notify Shire of any alleged violations or
    deficiencies relating to a facility at which any Shire Products are manufactured,
    packaged or stored, and, to the extent relating directly to a Shire Product,
    shall disclose to Shire all relevant portions of any notice of observations
    or potential violations as well as a copy of its response thereto. 

      Section
    5.3. Shire
    Compliance. Shire shall hold, store,
    handle, ship, deliver, distribute and/or sell the Shire Products (i) in accordance
    with applicable cGMP requirements, laws and Regulatory Approvals; and (ii)
    in compliance with the Product Specifications. Shire shall enter into all
    necessary compliance agreements as may be reasonably required or designated
    by Duramed, including but not limited to the quality agreement attached hereto
    as Exhibit C (the “Quality Agreement”)
    and any other agreements to cover quality assurance and adverse incident
    reporting, including the safety agreement attached hereto as Exhibit D (the “Safety
    Agreement”). 

      Section
    5.4. Quality
    Control. Upon delivery of Shire Products
    to Shire, Shire shall be solely responsible for compliance with all Laws
    and Regulatory Approvals with respect to the Shire Products. 

      Section
    5.5. Rejection
    of Delivered Products. Within [*] of
    receipt of any Shire Product, Shire shall inspect the Shire Product and advise
    Duramed of any defect whereby the Shire Product does not conform to the Product
    Specifications. Any Shire Product not refused within [*] shall be deemed
    accepted subject to Section 5.6 below; provided, however,
    that such acceptance or deemed acceptance shall not adversely affect any
    claim for indemnification provided in Article XI. If Shire desires to refuse
    acceptance, Shire shall, within such thirty (30) day period, inform Duramed
    of its refusal to accept the defective Shire Product and the reason(s) therefor.
    In the event that Shire refuses acceptance, Duramed, upon confirmation of
    the reasons for refusal of the Shire Product, will replace the defective
    Shire Product or refund the purchase price thereof, at Shire’s option.
    If Duramed and Shire do not agree on the refusal or rejection of Shire Product,
    then any Party may refer the matter for final analysis to a specialized laboratory
    of national reputation acceptable to both Parties for the purpose of determining
    the results. Any determination by such laboratory shall be final and binding
    upon the Parties. The cost of any such review by a laboratory shall be borne
    by Shire if it is determined that the Shire Product conforms to the Product
    Specifications, and by Duramed if determined that it does not. 

      Section
    5.6. Latent
    Defects. Shire shall have the right
    to refuse and reject any Collaboration Product within [*] from the date Shire
    becomes aware of a defect in a Shire Product delivered hereunder, in the
    case of defects that are not evident upon a reasonable initial inspection
    but which subsequently become evident. 

      Section
    5.7. Non-Conforming
    Products. Notwithstanding any other
    provisions of this Agreement, Shire shall return to Duramed or its designee
    any Shire Products that do not conform with the Product Specifications at
    the time of shipment to Shire, or if Shire and 

  8 

 

 Duramed mutually agree, to dispose
    of such Shire Products as Duramed may direct. Duramed shall be responsible
    for the costs associated with the proper disposal of all such Shire Products
    not in conformance with the Product Specifications at the time of shipment
    and shall promptly replace or credit, at the option of Duramed, such non-conforming
    Shire Products.

      Section
    5.8. Cost
    of Recall. In the event that any Shire
    Product is quarantined or recalled, or is subject to a stop-sale action,
    whether voluntary or by the action of any Governmental Authority, or as a
    result of the revocation or expiration of any Regulatory Approval, any expenses,
    including any out-of-pocket administrative costs and reasonable fees of any
    experts or attorneys that may be utilized by either Party, government fines
    or penalties, related to such recall, quarantine or stop-sale, shall be borne
    by Shire unless it is determined that the reason for the quarantine, recall
    or stop-sale action is the result of the breach by Duramed of its obligations
    under this Agreement, and in such case such expenses shall be shared according
    to the relative responsibility of each Party. Such determination may be made
    by the Governmental Authority involved, or by mutual agreement of the Parties
    following examination and review of all records pertinent to the manufacture
    of the Shire Product subject to such recall. 

      Section
    5.9. Regulatory
    Actions. If any regulatory authority
    in the Shire Territory takes any action with respect to a Shire Product that
    requires a response or action by Duramed, Duramed shall use commercially
    reasonable efforts, at the expense of Shire, to carry out the response or
    action, at all times in consultation with Shire, and promptly thereafter
    Duramed shall meet with Shire and agree a suitable plan of action in order
    to try and rectify and/or address any problem(s) identified by the Regulatory
    Authority within a reasonable period of time at the expense of Shire. Notwithstanding
    the foregoing, if any of the above expenses result from Duramed’s breach,
    negligence or willful misconduct hereunder, then any expenses incurred under
    this Section 5.9 shall be Duramed’s responsibility. 

ARTICLE VI

PRICE AND PAYMENTS 

      Section
    6.1. Clinical Non-Seasonique Supply Prices. [*]

 [*]

      Section
    6.2. Commercial
    Non-Seasonique Supply Prices. [*] 

[*]

     Section
    6.3. Clinical
    Seasonique Prices. [*] 

[*]

     Section
    6.4. Commercial
    Seasonique Supply Prices. [*] 

[*] 

     Section 6.5.Unit
Price Negotiation. [*].
  9 

 

      Section
    6.6. Records.
    Duramed shall keep complete and accurate records, consistent with GAAP, of
    the Fully Allocated Manufacturing Costs and API Costs.

      Section
    6.7. Invoices.
    Duramed may invoice for Shire Product at any time following tender thereof
    to Shire’s carrier. All invoices shall be sent to a single address specified
    in writing by Shire. Payment for Shire Product shall be due within [*] after
    the date of the invoice by check or electronic funds transmission in United
    States dollars without any offset or deduction of any nature whatsoever.
    All electronic payments shall be made to such account as Duramed shall have
    specified in writing to Shire with written confirmation of payment sent by
    facsimile to such address as Duramed shall have specified in writing to Shire.
    If Shire fails to pay any undisputed invoiced amount when due, a service
    charge will be imposed by Duramed equal to the [*] per month or the highest
    rate permitted by law of the outstanding amount for each month or portion
    thereof that such amount is overdue. 

      Section
    6.8. Taxes.
    The purchase price of Shire Products as determined in accordance with Section
    6.1 shall be exclusive of any applicable value added tax and any other taxes,
    duties and impositions that, if applicable, shall be paid by Shire to Duramed
    at the same time as the purchase price for such Shire Product. Shire shall
    bear the cost of any such taxes, duties or impositions of any kind, nature
    or description applicable to the sale and transportation of Shire Product,
    and Shire will forthwith pay to Duramed all such amounts upon demand.

      Section
    6.9. Separate
    Sale. Each shipment of Shire Product
    shall constitute a separate sale, obligating Shire to pay therefor, whether
    such shipment is in whole or only partial fulfillment of any Purchase Order. 

      Section
    6.10. Deductions.
    Shire shall not to make any deductions of any kind from any payments due
    to Duramed hereunder unless Shire will have received prior written authorization
    from Duramed authorizing such deduction. 

      Section
    6.11. Audit. 

      (a) Audit.
    Shire shall have the right to have an independent certified public accounting
    firm of internationally recognized standing, reasonably acceptable to Duramed,
    to have access during normal business hours, and upon reasonable prior written
    notice, to such of the records of Duramed as may be reasonably necessary
    to verify the accuracy of amounts paid by Shire under this Agreement for
    any calendar year ending not more than three (3) years prior to the date
    of such request; provided, however, that, Shire shall not have the right
    to conduct more than one such audit in any twelve (12) month period and that
    Shire shall not be permitted to audit the same period of time more than once.
    The accounting firm shall disclose to Shire only whether the various expenses
    subject to reimbursement under this Agreement are correct or incorrect and
    the specific details concerning any discrepancies. Shire shall bear all costs
    of such audit, unless the audit reveals a discrepancy in Shire’s favor
    of more than five percent (5%), in which case Duramed shall bear the cost
    of the audit. If Duramed disputes the findings pursuant to this Section 6.11,
    the Parties shall meet and discuss such dispute.

      (b) Payment
      of Additional Amounts. If, based on
      the results of any audit, (a) additional payments are owed by Shire to
      Duramed under this Agreement, then Shire shall make 

  10 

 

 such additional payments, or (b) the
    payments previously made by Shire to Duramed under this Agreement are in
    excess of the amounts that were actually required to be made, then Duramed
    shall return such excess payments, in each case within fifteen (15) Business
    Days after the accounting firm’s written report is delivered to the
    Parties.

 ARTICLE VII

  TERM AND TERMINATION 

      Section
    7.1. Term.
    The term of this Agreement shall commence on the Effective Date and shall
    continue until terminated in accordance with this Article VII (the “Term”).
    Shire may terminate this Agreement as to the supply of particular Shire Product
    at any time on one (1) years written notice to Duramed. Subject to Article
    VIII, Duramed may terminate this Agreement as to the supply of particular
    Shire Product at any time on eighteen (18) months written notice to Shire,
    provided that Duramed may not terminate this Agreement under this sentence
    until ten (10) years following the Effective Date. Termination of this Agreement
    with respect to one or more Shire Products shall not relieve the Parties
    of any obligations with respect to any other Shire Products, and this Agreement
    shall remain in effect as to such other Shire Products. 

      Section
    7.2. Termination
    of Exclusivity. Notwithstanding the
    provisions of Section 7.1, the obligations of the Parties under Section 2.1
    shall be effective as of the date of execution of this Agreement and may
    not be terminated except on mutual agreement of the Parties. Termination
    of this Agreement as to the supply of any particular Shire Product under
    Section 7.1 shall not affect the rights and obligations of the Parties with
    respect to the other Shire Products under Section 2.1. 

      Section
    7.3. Termination
    for Cause. Either Party may terminate
    this Agreement as to the supply of a particular Shire Product at any time
    in the event that the other Party materially breaches this Agreement as to
    such Shire Product and such material breach continues uncured for a period
    of ninety (90) days after written notice thereof; provided, however,
    in the event that the breaching Party has in good faith commenced cure within
    such ninety (90) day period, but cannot practically complete such cure within
    such ninety (90) day period, the breaching Party shall have an additional
    ninety (90) day cure period. In the event a material breach of this Agreement
    is incapable of cure or cannot be cured in the time periods set forth in
    the previous sentence acting using commercially reasonable efforts, without
    limiting any other rights of the non-breaching Party, including the right
    to seek injunctive relief, the non-breaching Party shall not have the right
    to terminate this Agreement if (i) the breaching Party is providing full
    cooperation to resolve and/or mitigate the breach, and (ii) the breach was
    not caused by willful misconduct by the breaching Party. 

      Section
    7.4. Survival.
    The provisions of Sections 5.8 and 7.4, and Articles VIII, X, XI and XII
    shall survive termination or expiration of this Agreement. Termination of
    this Agreement shall not affect the obligation of any Party to pay the other
    Party any amounts due hereunder accrued prior to the termination date hereof.
    Except in the event of termination by Duramed under Section 7.3, upon termination
    of this Agreement Duramed shall deliver to Shire on an ex-works basis all
    manufactured and work-in progress quantities of Shire Product in its possession
    that have been manufactured in respect of a specific Purchase Order(s) accepted
    by 

  11 

 

 Duramed hereunder subject to payment
    in advance therefor by Shire. The right to terminate this Agreement shall
    not prejudice any other right or remedy in equity or at law of a Party in
    respect of any breaches of this Agreement. 

 ARTICLE VIII

TERMINATION ASSISTANCE SERVICES 

      Section
    8.1. Termination
    Assistance Services. If (i) Duramed
    terminates this Agreement as to the supply of particular Shire Product under
    Section 7.1 (and Shire intends to continue Commercializing the applicable
    Shire Product), or (ii) Shire terminates this Agreement under Section 7.3
    (and Shire intends to continue Commercializing the applicable Shire Product),
    Duramed shall for a period of one (1) year thereafter, upon Shire’s
    request, provide any cooperation reasonably requested by Shire that may be
    required to facilitate the transfer of the manufacture of the applicable
    Shire Product to Shire or Shire’s designee (“Termination Assistance
    Services”). Shire shall reimburse
    Duramed for the reasonable costs of Duramed in providing Termination Assistance
    Services. The rights of Shire under this Section 8.1 shall be without prejudice
    to the Parties’ rights to pursue legal remedies for breach of this Agreement,
    either for breaches prior to termination or during the period this Agreement
    is continued in force post termination. 

      Section
    8.2. Development
    of Changeover Plan. If and to the extent
    requested by Shire, whether prior to, upon, or following termination of this
    Agreement by Shire, Duramed shall use commercially reasonable efforts to
    assist Shire in developing a plan that shall specify the tasks to be performed
    by the Parties in connection with the Termination Assistance Services and
    the schedule for the performance of such tasks (a “Changeover
    Plan”). The Changeover Plan shall
    include descriptions of the services, fees, documentation and access requirements
    that will promote an orderly transition of the manufacture of Shire Product
    to Shire or its designee. 

      Section
    8.3. Know-How,
    Infrastructure, and Software. In connection
    with the Termination Assistance Services, Duramed shall make available to
    Shire or its designee, to the extent owned or controlled by and in the possession
    of Duramed and reasonably required to manufacture the applicable Shire Product,
    (i) copies of all applicable requirements, standards, policies, reports and
    report formats, user manuals, technical manuals, system architecture, processes,
    operating procedures and other documentation, (ii) copies of flow charts
    of the manufacturing procedures and work instructions related to manufacturing
    the relevant Shire Product, (iii) a list of all material equipment, including
    the source of such equipment, utilized in the production of the applicable
    Shire Product, (iv) copies of all current specifications, including packaging,
    for the relevant Shire Product, (v) copies of all standard operating procedures
    for the manufacturing procedures to be made available to Shire, (vi) all
    necessary environmental conditions necessary to manufacture the relevant
    Shire Product and copies of any existing external environmental impact studies
    based on the materials or methods employed in the manufacturing method to
    be made available to Shire, and (vii) such other documentation as the Parties
    may agree.

 ARTICLE IX

  FORCE MAJEURE 

  12 

 

      Section
    9.1. Force
    Majeure. No Party shall be responsible
    for failure or delay in performance hereunder due to reasons beyond its reasonable
    control, including without limitation, by reason of fire, flood, riot, freight
    embargoes, acts of God or of the public enemy, war or civil disturbances,
    general shortage of raw materials (i.e., a shortage that not only affects
    Duramed, but also affects the general market for such raw materials), or
    any future laws, rules, regulations or acts of any government affecting a
    Party that would delay or prohibit performance hereunder (a “Force
    Majeure Event”). Upon the occurrence
    of a Force Majeure Event, the Party whose performance is so affected shall
    promptly give notice to the other Party of the occurrence or circumstance
    upon which it intends to rely to excuse its performance. During the duration
    of the Force Majeure Event, the Party so affected shall use its reasonable
    commercial efforts to avoid or remove such Force Majeure Event and shall
    take reasonable steps to resume its performance under this Agreement with
    the least possible delay. Any Force Majeure Event must be beyond the control
    and without the fault or negligence of the Party claiming excusable delay,
    provided that, breaches by any Party’s subcontractors shall not excuse
    any delay or failure by that Party.

 ARTICLE X

CONFIDENTIALITY 

      Section
    10.1. Confidential
    Information. As used in this Agreement,
    the term “Confidential Information” means
    all secret, confidential or proprietary information or data, whether provided
    in written, oral, graphic, video, computer, electronic or other form, provided
    pursuant to this Agreement or generated pursuant to this Agreement by one
    Party or its Affiliates (the “Disclosing
    Party”) to the other Party or its
    Affiliates (the “Receiving Party”),
    including but not limited to, information relating to the Disclosing Party’s
    existing or proposed research, development efforts, patent applications,
    business or products, and any other materials that have not been made available
    by the Disclosing Party to the general public. Confidential Information shall
    not include any information or materials that: 

  (a) were already known to the Receiving
      Party (other than under an obligation of confidentiality), at the time
      of disclosure by the Disclosing Party, to the extent such Receiving Party
      has documentary evidence to that effect; 

   (b) were generally available to
      the public or otherwise part of the public domain at the time of disclosure
      thereof to the Receiving Party; 

   (c) became generally available to
      the public or otherwise part of the public domain after disclosure or development
      thereof, as the case may be, other than through any act or omission of
      a Party in breach of such Party’s confidentiality obligations under
      this Agreement; 

   (d) were disclosed to a Party, other
      than under an obligation of confidentiality, by a third party who had no
      obligation to the Disclosing Party not to disclose such information to
      others; or 

   (e) were independently discovered
      or developed by or on behalf of the Receiving Party without the use of
      the Confidential Information belonging to the 

  13 

 

   other Party, to the extent such
      Receiving Party has documentary evidence to that effect. 

      Section
    10.2. Confidentiality
    Obligations. Each of Duramed and Shire
    shall keep confidential all Confidential Information of the other Party with
    the same degree of care it maintains the confidentiality of its own Confidential
    Information but in no event less than a reasonable degree of care. Neither
    Party shall use such Confidential Information for any purpose other than
    in performance of this Agreement or disclose the same to any other Person
    other than to such of its and its Affiliates’ directors, managers, employees,
    independent contractors, agents or consultants who are bound by confidentiality
    obligations consistent with those contained herein and who have a need to
    know such Confidential Information to implement the terms of this Agreement
    or enforce its rights under this Agreement. Upon termination of this Agreement,
    the Receiving Party shall return or destroy all documents, tapes or other
    media containing Confidential Information of the Disclosing Party that remain
    in the possession of the Receiving Party and its Affiliates or their directors,
    managers, employees, independent contractors, agents or consultants, except
    that the Receiving Party may keep one copy of the Confidential Information
    in the legal department files of the Receiving Party, solely for archival
    purposes. Such archival copy shall continue to be subject to the provisions
    of this Article X. 

      Section
    10.3. Permitted
    Disclosure and Use. Notwithstanding
    Section 10.2, a Party may disclose Confidential Information belonging to
    the other Party only to the extent such disclosure is reasonably necessary
    to: (a) obtain Regulatory Approval to the extent such disclosure is made
    to a Governmental Authority; (b) comply with or enforce any of the provisions
    of this Agreement; (c) comply with Laws; or (d) comply with applicable stock
    exchange regulations. If a Party deems it necessary to disclose Confidential
    Information of the other Party pursuant to this Section 10.3, such Party
    shall give reasonable advance notice of such disclosure to the other Party
    to permit such other Party sufficient opportunity to object to such disclosure
    or to take measures to ensure confidential treatment of such information.
    In addition, notwithstanding Section 10.2, the Parties shall cooperate to
    prepare standardized public responses to anticipated inquiries from the public,
    press, stockholders, investors and/or analysts with respect to the activities
    hereunder. Despite the foregoing, each Party agrees that the other Party
    is free to disclose this Agreement in its entirety to the United States Federal
    Trade Commission and the United States Department of Justice, or to any court
    with jurisdiction over the litigations settled under the Settlement Agreement
    between Shire Laboratories Inc. and Barr Laboratories Inc. dated August 14,
    2006. 

      Section
    10.4. Unauthorized
    Disclosure. The Receiving Party acknowledges
    and agrees that the Confidential Information of the Disclosing Party constitutes
    proprietary information and trade secrets valuable to the Disclosing Party,
    and that the unauthorized use, loss or outside disclosure of such Confidential
    Information shall be presumed to cause irreparable injury to the Disclosing
    Party. 

      Section
    10.5. Notification.
    The Receiving Party shall notify the Disclosing Party promptly upon discovery
    of any unauthorized use or disclosure of the Disclosing Party’s Confidential
    Information, and shall cooperate with the Disclosing Party in any reasonably
    requested fashion to assist the Disclosing Party to regain possession of
    such Confidential Information and to prevent its further unauthorized use
    or disclosure. The Receiving Party 

  14 

 

 acknowledges that monetary damages
    may not be a sufficient remedy for unauthorized disclosure of Confidential
    Information and that the Disclosing Party may be entitled, without waiving
    other rights or remedies, to such injunctive or equitable relief as may be
    deemed proper by a court of competent jurisdiction in the event of such unauthorized
    disclosure. 

      11.5 Confidentiality
      of this Agreement. The terms of this
      Agreement shall be Confidential Information of each Party and, as such,
      shall be subject to the provisions of this Article X. 

 ARTICLE XI

INDEMNIFICATION 

      Section
    11.1. Indemnification
    by Shire. Shire hereby agrees to hold
    Duramed, its Affiliates, and their respective directors, agents and employees
    harmless from and against any and all Losses arising in connection with any
    and all charges, complaints, actions, suits, proceedings, hearings, investigations,
    claims, demands, judgments, orders, decrees, stipulations or injunctions
    by a third party (each a “Third
    Party Claim”) resulting directly
    from (a) any breach by Shire of any of its representations, warranties, covenants
    or obligations pursuant to this Agreement, (b) the negligence or willful
    misconduct by Shire or its Affiliates or their respective officers, directors,
    employees, agents or consultants in performing any obligations under this
    Agreement, (c) the Shire Product, including the use, handling, storage, sale
    or other disposition of Shire Product (including, without limitation, those
    Third Party Claims that involve product defect, product liability, death
    or bodily injury (or allegations thereof) to any individual or any property,
    or (d) infringement of intellectual property based on the Product Specification,
    Packaging Specifications, manufacture, use, sale, offer for sale, importation
    or other distribution of Shire Product, except to the extent that such Losses
    in (a) through (c) result from the negligence or willful misconduct of Duramed,
    or the breach of this Agreement by Duramed. 

      Section
    11.2. Indemnification
    by Duramed. Duramed hereby agrees to
    hold Shire, its Affiliates, and their respective directors, agents and employees
    harmless from and against any and all Losses arising in connection with any
    and all Third Party Claims resulting directly from (a) any breach by Duramed
    of any of its representations, warranties, covenants or obligations pursuant
    to this Agreement, or (b) the negligence or willful misconduct of Duramed
    or its Affiliates or their respective officers, directors, employees, agents
    or consultants in performing any obligations under this Agreement, or (c)
    claims that involve product defect, product liability, death or bodily injury
    (or allegations thereof) to any individual or any property to the extent
    that such claim results from Duramed’s breach, negligence or willful
    misconduct hereunder,, except to the extent that such Losses in (a) through
    (c) result from the negligence or willful misconduct of Shire, or the breach
    of this Agreement by Shire. 

      Section
    11.3. Notice
    of Claim. All indemnification claims
    in respect of any indemnitee seeking indemnity hereunder (collectively, the “Indemnitees” and
    each an “Indemnitee”)
    shall be made solely by the corresponding Party (the “Indemnified
    Party”). The Indemnified Party
    shall give the indemnifying Party (the “Indemnifying
    Party”) prompt written notice (an “Indemnification
    Claim Notice”) of any Losses or
    the discovery of any fact upon which such Indemnified Party intends to base
    a request for indemnification hereunder, but in no event shall the Indemnifying
    Party be liable for any Losses that result from any delay in providing such
    notice which materially prejudices the defense of such Third Party Claim.
    Each 

  15 

 

 Indemnification Claim Notice must
    contain a description of the claim and the nature and amount of such Loss
    (to the extent that the nature and amount of such Loss are known at such
    time). Together with the Indemnification Claim Notice, the Indemnified Party
    shall furnish promptly to the Indemnifying Party copies of all notices and
    documents (including court papers) received by any Indemnitee in connection
    with the Third Party Claim. The Indemnifying Party shall not be obligated
    to indemnify the Indemnified Party to the extent any admission or statement
    made by the Indemnified Party materially prejudices the defense of such Third
    Party Claim. 

      Section
    11.4. Control
    of Defense. At its option, the Indemnifying
    Party may assume the defense of any Third Party Claim subject to indemnification
    hereunder by giving written notice to the Indemnified Party within thirty
    (30) days after the Indemnifying Party’s receipt of an Indemnification
    Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying
    Party may appoint as lead counsel in the defense of the Third Party Claim
    any legal counsel it selects. Should the Indemnifying Party assume the defense
    of a Third Party Claim, the Indemnifying Party shall not be liable to the
    Indemnified Party or any other Indemnitee for any legal expenses subsequently
    incurred by such Indemnified Party or other Indemnitee in connection with
    the analysis, defense or settlement of the Third Party Claim. 

      Section
    11.5. Right
    to Participate in Defense. Without limiting
    Section 11.4, any Indemnitee shall be entitled to participate in, but not
    control, the defense of a Third Party Claim for which it has sought indemnification
    hereunder and to employ counsel of its choice for such purpose; provided,
    however, that such employment shall be at the Indemnitee’s own expense
    unless (a) the employment thereof has been specifically authorized by the
    Indemnifying Party in writing, or (b) the Indemnifying Party has failed to
    assume the defense and employ counsel in accordance with Section 11.4 (in
    which case the Indemnified Party shall control the defense). 

      Section
    11.6. Settlement.
    With respect to any Losses relating solely to the payment of money damages
    in connection with a Third Party Claim and that shall not result in the Indemnitee’s
    becoming subject to injunctive or other relief or otherwise adversely affect
    the business of the Indemnitee in any manner, and as to which the Indemnifying
    Party shall have acknowledged in writing the obligation to indemnify the
    Indemnitee hereunder, the Indemnifying Party shall have the sole right to
    consent to the entry of any judgment, enter into any settlement or otherwise
    dispose of such Loss, on such terms as the Indemnifying Party, in its reasonable
    discretion, shall deem appropriate (provided, however that such terms shall
    include a complete and unconditional release of the Indemnified Party from
    all liability with respect thereto), and shall transfer to the Indemnified
    Party all amounts which said Indemnified Party shall be liable to pay prior
    to the time of the entry of judgment. With respect to all other Losses in
    connection with Third Party Claims, where the Indemnifying Party has assumed
    the defense of the Third Party Claim in accordance with Section 11.4, the
    Indemnifying Party shall have authority to consent to the entry of any judgment,
    enter into any settlement or otherwise dispose of such Loss provided it obtains
    the prior written consent of the Indemnified Party (which consent shall be
    at the Indemnified Party’s reasonable discretion). The Indemnifying
    Party that has assumed the defense of the Third Party Claim in accordance
    with Section 11.4 shall not be liable for any settlement or other disposition
    of a Loss by an Indemnitee that is reached without the written consent of
    such Indemnifying Party. Regardless of whether the Indemnifying Party chooses
    to defend or prosecute any Third Party Claim, no Indemnitee shall admit any
    liability with respect to, or settle, compromise or discharge, any Third
    Party Claim without first offering to the 

  16 

 

 Indemnifying Party the opportunity
    to assume the defense of the Third Party Claim in accordance with Section
    11.4. 

      Section
    11.7. Cooperation.
    If the Indemnifying Party chooses to defend or prosecute any Third Party
    Claim, the Indemnified Party shall, and shall cause each other Indemnitee
    to, cooperate in the defense or prosecution thereof and shall furnish such
    records, information and testimony, provide such witnesses and attend such
    conferences, discovery proceedings, hearings, trials and appeals as may be
    reasonably requested in connection with such Third Party Claim. Such cooperation
    shall include access during normal business hours afforded to the Indemnifying
    Party to, and reasonable retention by the Indemnified Party of, records and
    information that are reasonably relevant to such Third Party Claim, and making
    Indemnitees and other employees and agents available on a mutually convenient
    basis to provide additional information and explanation of any material provided
    hereunder, and the Indemnifying Party shall reimburse the Indemnified Party
    for all its reasonable out-of-pocket expenses incurred in connection with
    such cooperation. 

      Section
    11.8. Expenses
    of the Indemnified Party. Except as
    provided above, the reasonable and verifiable costs and expenses, including
    fees and disbursements of counsel, incurred by the Indemnified Party in connection
    with any Third Party Claim shall be reimbursed on a calendar quarter basis
    by the Indemnifying Party, without prejudice to the Indemnifying Party’s
    right to contest the Indemnified Party’s right to indemnification and
    subject to refund in the event the Indemnifying Party is ultimately held
    not to be obligated to indemnify the Indemnified Party. 

      Section
    11.9. Insurance.
    At all times from the Effective Date until three (3) years following termination
    or expiration of this Agreement, each of Shire and Duramed will maintain
    product liability insurance (or self insurance), that is reasonable and customary
    in the U.S. pharmaceutical industry for companies of comparable size, but
    in no event less than $10,000,000 per occurrence and $10,000,000
    in the aggregate limit of liability per year. Each of Shire and Duramed shall
    provide written proof of such insurance or self insurance to the other Party
    upon request. 

      11.10. Exclusion
      of Certain Damages. IN NO EVENT SHALL
      ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL,
      PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION
      WITH THIS AGREEMENT, OR FOR ANY DIRECT OR INDIRECT LOSS OF PROFIT, LOST
      BUSINESS OPPORTUNITY, LOSS OF OR DISRUPTION TO PRODUCTION OR GOODWILL,
      EXCEPT TO THE EXTENT SUCH DAMAGES: (A) ARE INCLUDED IN A THIRD-PARTY CLAIM
      FOR WHICH SUCH PARTY IS INDEMNIFIED HEREUNDER; OR (B) ARE FOR BREACH OF
      CONFIDENTIALITY OBLIGATIONS.

 ARTICLE XII

MISCELLANEOUS 

      Section
    12.1. Entire
    Agreement; Amendment. This Agreement,
    together with the Product Development Agreement, including the exhibits attached
    hereto and thereto (each of 

  17 

 

 which is hereby and thereby incorporated
    herein and therein by reference), set forth the complete, final and exclusive
    agreement and all the covenants, promises, agreements, warranties, representations,
    conditions and understandings between the Parties hereto and supersedes and
    terminates all prior agreements and understandings between the Parties, which
    shall continue to govern the obligations of the Parties with respect to information
    disclosed thereunder with respect to periods prior to the Effective Date.
    There are no covenants, promises, agreements, warranties, representations,
    conditions or understandings, either oral or written, between the Parties
    other than as are set forth herein. No subsequent alteration, amendment,
    change or addition to this Agreement shall be binding upon the Parties unless
    reduced to writing and signed by an authorized officer of each Party. For
    the avoidance of doubt, the Parties agree that all covenants, promises, agreements,
    warranties, representations, conditions, and understandings set forth herein
    are made and deemed effective as of the Effective Date, and that the execution
    of this Agreement shall not constitute a waiver of any right or claim of
    either Party as of the Effective Date. 

      Section
    12.2. Notices.
    All notices or other communications that are required or permitted under
    this Agreement shall be in writing and delivered personally, sent by facsimile
    (and promptly confirmed by personal delivery or overnight courier as provided
    in this Agreement), or sent by internationally-recognized overnight courier
    to the addresses below. Any such communication shall be deemed to have been
    given (a) when delivered, if personally delivered or sent by facsimile on
    a Business Day (so long as promptly confirmed by personal delivery or overnight
    courier as provided in this Agreement), and (b) on the second Business Day
    after dispatch, if sent by internationally-recognized overnight courier.
    Unless otherwise specified in writing, the mailing addresses of the Parties
    shall be as described below. 

	For Duramed: 	 	Duramed Pharmaceuticals,
        Inc. 

      400 Chestnut Ridge Road 

      Woodcliff Lake, NJ 07677 

      Phone: 201-930-3300 

      Fax: 201-930-3330 

      Attention: President 
	 	 	 
	 with a copy to: 	 	Barr Pharmaceuticals,
        Inc. 

      400 Chestnut Ridge Road 

      Woodcliff Lake, NJ 07677 

      Phone: 201-930-3300 

      Fax: 888-843-0563 

      Attention: General Counsel 

	For Shire: 	 	Shire LLC 

      725 Chesterbrook Boulevard 

      Wayne, Pennsylvania 19087-5637 

      Fax: (484) 595-8163 

      Attention: General Counsel 
	 	 	 
	 with a copy to: 	 	Morgan, Lewis & Bockius
        LLP 

      502 Carnegie Center 

    18 

 

	 	 	 Princeton, NJ 08540 

      Fax: (609) 919-6701 

      Attention: Randall B. Sunberg 

     Section
    12.3. Independent
    Contractors. In making and performing
    this Agreement, Shire and Duramed shall act at all times as independent contractors
    and nothing contained in this Agreement shall be construed or implied for
    any purpose to create an agency, partnership, limited partnership, joint
    venture or employer and employee relationship between Shire and Duramed and
    this Agreement shall not be construed to suggest otherwise. At no time shall
    one Party make commitments or incur any charges or expenses for or in the
    name of the other Party. Except as otherwise provided in this Agreement,
    each Party shall be solely responsible for its own costs and expenses associated
    with this Agreement. 

      Section
    12.4. Maintenance
    of Records. Each Party shall keep and
    maintain all records required by Law with respect to the Shire Products and
    shall make copies of such records available to the other Party upon reasonable
    request. 

      Section
    12.5. United
    States Dollars. References in this Agreement
    to “Dollars” or “$” shall mean the legal tender of
    the United States. 

      Section
    12.6. No
    Strict Construction. This Agreement
    has been prepared jointly and shall not be strictly construed against either
    Party. 

      Section
    12.7. Assignment.
    Neither Party shall sell, transfer, assign, delegate, pledge or otherwise
    dispose of, whether voluntarily, involuntarily, by operation of Law or otherwise,
    this Agreement or any of its rights or obligations under this Agreement without
    the prior written consent of the other Party (which consent may be granted,
    withheld or conditioned at such other Party’s sole and absolute discretion);
    provided, however, that either Party may assign or transfer this Agreement
    or any of its rights or obligations under this Agreement without the consent
    of the other Party to any Affiliate of such Party, or to any Third Party
    (a) with which it merges or consolidates, or to which it transfers all or
    substantially all of its assets to which this Agreement pertains or (b) in
    part, in connection with the sale or transfer of such Party’s business
    relating to Commercialization of a Collaboration Product within a particular
    country. The assigning Party (unless it is not the surviving entity) shall
    remain jointly and severally liable with, and shall guarantee the performance
    of, the relevant Affiliate or Third Party assignee under this Agreement,
    and the relevant Affiliate assignee, Third Party assignee or surviving entity
    shall assume in writing all of the assigning Party’s obligations under
    this Agreement. Any purported assignment or transfer in violation of this
    Section 12.7 shall be void ab initio and of no force or effect. Notwithstanding
    anything to the contrary herein or in the Product Development Agreement,
    in the event any assignment by Shire hereunder gives rise to any obligation
    to withhold any amounts payable to Duramed, Shire, or its assignee, shall
    be entitled to deduct from all payments due under this Agreement the amount
    of all applicable withholding taxes to the extent Shire, or its assignee,
    pays such taxes to the appropriate governmental authority on behalf of Duramed.
    Shire shall properly furnish Duramed with copies of tax receipts evidencing
    the payment of all such taxes, levies and assessments. Duramed and Shire
    shall cooperate with each other in obtaining any exemption from, a refund
    for, or reduced rate of tax available under any applicable law or tax treaty.
    Notwithstanding the foregoing, Shire shall be liable for, and 

  19 

 

 indemnify Duramed against, any non-U.S.
    taxes, any value-added or sales taxes, any duties or levies and assessments,
    howsoever designated or computed that are required to be paid or withheld
    by Shire on such payments. Shire shall so indemnify Duramed within forty-five
    (45) days of Shire’s receipt of notification from Duramed (in accordance
    with Section 12.2 hereof) that either (i) based upon current facts and circumstances,
    Duramed does not have or will not have during the applicable tax year any
    or sufficient foreign tax credits available to utilize to offset such tax
    liability; or (ii) Duramed has applied for a refund from the taxing authority
    at issue (such notice to include a copy of such refund application). Notwithstanding
    anything in this Agreement to the contrary, in the event that withholding
    taxes are paid on behalf of Duramed by Shire, if Duramed uses a foreign tax
    credit received as a result of the payment of withholding taxes by Shire
    and thereby reduces the amount of U.S. income tax that Duramed otherwise
    would have paid, or otherwise receives a refund, Duramed shall refund to
    Shire the amount of such reduction with respect to such foreign tax credit
    or such refund. 

      Section
    12.8. Counterparts.
    This Agreement may be executed in two counterparts, each of which shall be
    deemed an original, but all of which together shall constitute one and the
    same instrument. Signatures provided by facsimile transmission shall be deemed
    to be original signatures. 

      Section
    12.9. Further
    Actions. Each Party agrees to execute,
    acknowledge and deliver such further instruments, and to do all such other
    acts, as may be reasonably necessary or appropriate in order to carry out
    the purposes and intent of this Agreement. 

      Section
    12.10. Severability.
    If any one or more of the provisions of this Agreement is held to be invalid
    or unenforceable by any court of competent jurisdiction from which no appeal
    can be or is taken, the provision shall be considered severed from this Agreement
    and shall not serve to invalidate any remaining provisions hereof. The Parties
    shall make a good fait effort to replace any invalid or unenforceable provision
    with a valid and enforceable one such that the objectives contemplated by
    the Parties when entering this Agreement may be realized. 

      Section
    12.11. Headings.
    The headings for each article and section in this Agreement have been inserted
    for convenience of reference only and are not intended to limit or expand
    on the meaning of the language contained in the particular article or section. 

      Section
    12.12. No
    Waiver. Any delay in enforcing a Party’s
    rights under this Agreement or any waiver as to a particular default or other
    matter shall not constitute a waiver of such Party’s rights to the future
    enforcement of its rights under this Agreement, excepting only as to an express
    written and signed waiver as to a particular matter for a particular period
    of time. 

 [signature page follows] 

  20 

 

  IN WITNESS WHEREOF, the parties hereto
    have caused this Agreement to be signed by their respective representatives
    thereunto duly authorized, all as of the date first written above.

	 	 SHIRE LLC  
	 	 	 
	 	 	 
	 	By: 	 
	 	 	

	 	Name 	 
	 	 	

	 	Title	 
	 	 	

 

	 	 DURAMED PHARMACEUTICALS, INC. 
	 	 	 
	 	 	 
	 	By: 	 
	 	 	

	 	Name 	 
	 	 	

	 	Title	 
	 	 	

 

SHIRE plc, a British public limited
    company having a principal place of business at Hampshire International Business
    Park, Chineham, Basingstoke, England RG24 8EP, hereby guarantees in the performance
    of Shire of all obligations of Shire under this Agreement, in accordance
    with the terms and conditions of this Agreement, including any applicable
    notice or cure periods.

	 SHIRE LLC  
	 	 	 
	 	 	 
	By: 	 	 
	 	
	 
	Name 	 	 
	 	
	 
	Title	 	 
	 	
	 

 

 [Signature Page to Shire Products
    Supply Agreement] 

 

 EXHIBIT A 

 PRODUCT SPECIFICATIONS 

 All Shire Product supplied hereunder
    shall have a remaining expiry period of: 

(a)       Not
    less than [*] months, if the shelf life is [*] months; 

(b)       Not
    less than [*] months, if the shelf life is [*] months; and 

(c)       Not
    less than [*] months, if the shelf life is [*] months. 

 

 EXHIBIT B 

 PACKAGING SPECIFICATIONS 

 

 EXHIBIT C 

 QUALITY AGREEMENT 

 

 EXHIBIT D 

 SAFETY AGREEMENT 

 

 SCHEDULE 1 

 FORM OF PURCHASE ORDER 

 

 SCHEDULE 2 

 FORM OF COA 

EXHIBIT C 

STEERING COMMITTEE CHARTER 

 

	A.	 Purpose
    and Functions of the Steering Committee. 
	 	 
	 	 The Steering Committee will (i) enable, coordinate
        and guide the activities of the Parties relating to the development of
        Collaboration Products, (ii) define and implement, on an ongoing basis,
        a technology roadmap, and (iii) implement the Agreement and, without
        limiting the rights of the Parties under ARTICLE 16, resolve any disputes
    or disagreements related to the implementation thereof. 
	 	 
	B.	Development Plans.
        Upon delivery of each Development Plan to the Steering Committee, each
        Party shall review the Development Plan and provide written comments
        and suggestions to the Steering Committee within [*] after receipt. The
        Steering Committee may incorporate any such revisions that it deems appropriate
        and will provide a recommendation of the Development Plan to each of
        the Parties. Notwithstanding the foregoing, Shire shall make all final
        decisions with respect to Development Plans affecting the Shire Territory
        and Duramed shall make all final decisions with respect to Development
    Plans in the Duramed Territory.
	 	 
	C. 	Reporting.
        The Steering Committee shall report to the Parties from time to time,
        but in no event less often than once each quarter. Such report shall
        describe all projects undertaken in performance of each Development Plan.
        Such report also shall include any other information reasonably requested
    by the Parties. 
	 	 
	D.	  Steering
            Committee Responsibilities.
            The Steering Committee shall have the duty and authority to perform
    the functions described above and the following additional functions: 

	 	 	 	 
	 	 	(a)   	General oversight of the activities of the
        Parties under this Agreement, including the progress of work under each
    Development Plan. 
	 	 	 	 
	 	 	(b) 	Review of quarterly reports before such reports
        are sent to the Parties regarding the progress of the Parties’ efforts
    under each Development Plan. 
	 	 	 	 
	 	 	(c) 	Review of the technology budget and quarterly
    spending in connection with each Development Plan.

	E.	  Membership
    and Procedure. 
	 	 

	 	1.  	Membership on the Committee. 

	 	 	 	 
	 	 	(a)   	 (a)  Members.
        The Steering Committee members (each a “Member”)
    will include the Collaboration Managers, [*].

 

  	 	 	(b) 	Qualifications.
          The qualifications of any Member shall be determined in the discretion
      of the Party that appoints such Member.
	 	 	 	 
	 	 	(c) 	 Removal
            and Vacancies. Each Party may,
            in its sole discretion, remove any Member appointed by it to the
            Steering Committee. If any Member is removed or resigns from the
            Steering Committee or otherwise ceases to serve on the Steering Committee
            for any reason (e.g., by
            reason of the separation of such Member from employment by the Party
            that appointed such Member, such Member’s death or disability,
            etc.), the Party that appointed such Member shall promptly notify
            the other Party of such Member’s withdrawal from the Steering
            Committee. On notice to the other Party, any vacancy on the Steering
            Committee shall be filled by the Party that appointed the Member
            who resigned from, was removed from, or for any other reason ceased
      to serve on the Steering Committee . 

     2. Additional Attendees at Steering Committee Meetings. The Steering Committee may establish rules with
respect to the attendance at the Steering Committee meetings of staff and other invitees. All such rules shall be consistently applied to both Parties. 

     3. Voting.  Each Member shall be entitled to one (1) vote to be cast by such Member.  No vote may be cast by
proxy.  Except as expressly provided below, all actions, determinations or resolutions of the Steering Committee at a meeting shall require the affirmative vote of the Members present at such meeting at which a quorum (meaning more than half of the
total number of Members) is present; provided that [*] may be [*], and the [*] not be [*] action, decision, determination or resolution.

     4. Notice; Waiver; Meeting Location. The Steering Committee shall meet at least [*]. Such meetings shall be
held upon not less than [*] written notice. Additional meetings of the Steering Committee  shall be held (A) at such other times as may be determined by the Steering Committee, or (B) at the request of the Collaboration Manager of either Party upon
not less than [*] written notice. The Duramed Collaboration Manager shall determine the location of each meeting of the Steering Committee taking into account any travel considerations by Members of the Steering Committee. Notice may be provided in
writing, via facsimile, or email to each Member. The presence of any Member at a meeting shall constitute a waiver of notice of the meeting with respect to such Member, unless such Member declares at the meeting that such Member objects to the
notice as having been improperly given. The Steering Committee shall cause written minutes to be prepared of all actions taken by the Steering Committee and shall cause a copy thereof to be delivered to each Member within [*]. No action may be taken
by the Steering Committee without a meeting to consider the matter unless each Party issues a written waiver of such meeting and unless a consent or consents in writing, setting forth the action so taken, are signed by the Members of the Steering
Committee having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all the Members of the Steering Committee were present and voted. 

     5. Meetings by Telecommunications.  Members of the Steering Committee shall have the right to participate in
all meetings of the Steering Committee in person, by means of a conference telephone, or by videoconference or similar telecommunications service by means of 

  

which all persons participating in the meeting can hear each other at the same time and participation by such means shall constitute presence in person at a meeting. Any reference in this Exhibit to attendance or participation by
a Member at a meeting of the Steering Committee shall be deemed to refer to attendance in person or attendance by means of a telecommunications service pursuant to this paragraph. 

     6. Compensation of Members of the Steering Committee.  The Members of the Steering Committee, in their
capacity as such, shall not receive compensation, except with respect to any Member as such Member and the Party that appointed such Member shall otherwise mutually agree. Each Party shall bear the cost and expenses incurred by its appointed Members
of the Steering Committee in connection with the activities of the Steering Committee. 

     7. Conflicts. In the event of any conflict between the provisions of this Exhibit and the provisions of the
Collaboration Agreement, the provisions of the Collaboration Agreement shall control. 

EXHIBIT D 

DEVELOPMENT PLANS 

(see attached) 

SCHEDULE 7.2.1A 

SEASONIQUE MILESTONE PAYMENTS 

  	
    Event
      	 Payment

        
	
    Filing of Drug Approval Application under
    EMEA for Seasonique 	
    $[*]
      
	
    Regulatory Approval under EMEA for
    Seasonique 	
    $[*]
      
	
    Filing of Drug Approval Application under EMEA for first new indication for Seasonique 	
    $[*]
      
	
    Regulatory Approval under EMEA for first
    new indication for Seasonique 	
    $[*]
      
	
    First calendar year in which annual net sales in
    Shire Territory for Seasonique exceed $50 million 	
    $[*]
      
	
    Second calendar year in which annual net sales
    in Shire Territory for Seasonique exceed $100 million	
    $[*]
      

  

  

  

SCHEDULE 7.2.1B 

RING PRODUCT MILESTONE PAYMENTS 

	 Event 	 Payment 
	 Successful completion
        of Phase I clinical trials for Ring
    Product 	 $[*] 
	 Successful completion
        of Phase I clinical trials for Ring
    Product 	 $[*] 
	 Successful completion
        of Phase III clinical trials for Ring
    Product 	 $[*] 
	 Filing of Drug Approval
    Application under EMEA for Ring Product 	 $[*] 
	 Regulatory Approval under
    EMEA for Ring Product 	 $[*] 
	 First calendar year in
        which annual net sales in Shire Territory
    for Ring Product exceed $50 million 	 $[*] 
	 Second calendar year in which annual
        net sales in Shire Territory for Ring
    Product exceed $100 million 	$[*] 

  

  

SCHEDULE 13.3(b) 

COLLABORATION PRODUCT INDs 

[*] 

[*] 

[*] 

[*] 

[*] 

[*] 

Schedule 13.3(c)

 

  	
    Jurisdiction
      	
    Patent No.
      	
    Grant Date
      	
    Application No.
      	
    Filing Date
      
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 
	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]
      
	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]
      
	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]
      	
    [*]Exhibit 10.3

PRODUCT ACQUISITION AND LICENSE AGREEMENT

(Adderall®) 

BY AND AMONG

SHIRE LLC,

SHIRE PLC 

AND 

DURAMED PHARMACEUTICALS, INC. 

DATED AS OF AUGUST 14, 2006 

	
ARTICLE 1     	     	
          DEFINITION 	     	
1     
	
ARTICLE 2     	     	
          SALE OF ASSETS, LICENSES AND CLOSING       	     	
6     
	
                    2.1     	     	
Sale of Assets        	     	
6     
	
                    2.2     	     	
Licenses and Other Rights     	     	
8     
	
                    2.3     	     	
[*]   	     	
8     
	
                    2.4     	     	
Assumed Liabilities   	     	
8     
	
                    2.5     	     	
Purchase Price        	     	
9     
	
                    2.6     	     	
Independence of Purchase Price Obligation     	     	
9     
	
                    2.7     	     	
Closing       	     	
9     
	
                    2.8     	     	
Allocation of Purchase Price  	     	
9     
	
                    2.9     	     	
Delivery of Purchased Assets  	     	
10    
	
ARTICLE 3     	     	
          REGULATORY MATTERS 	     	
10    
	
                    3.1     	     	
Filings with Regulatory Authorities Regarding Transfer of Registrations       	     	
10    
	
                    3.2     	     	
Responsibility for the Product        	     	
10    
	
                    3.3     	     	
Marketing Activities  	     	
11    
	
                    3.4     	     	
Right of Reference    	     	
11    
	
ARTICLE 4     	     	
          REPRESENTATIONS AND WARRANTIES     	     	
11    
	
                    4.1     	     	
Representations and Warranties of Shire       	     	
11    
	
                    4.2     	     	
Disclaimer of Warranties      	     	
14    
	
                    4.3     	     	
Representations and Warranties of Duramed     	     	
14    
	
                    4.4     	     	
Survival of Representations/Warranties        	     	
15    
	
                    4.5     	     	
Brokers       	     	
15    
	
ARTICLE 5     	     	
          CONDITIONS TO CLOSING      	     	
16    
	
                    5.1     	     	
Conditions to Obligations of Duramed  	     	
16    
	
                    5.2     	     	
Conditions to Obligations of Shire    	     	
16    
	
ARTICLE 6     	     	
          COVENANTS  	     	
17    
	
                    6.1     	     	
HSR Filing    	     	
17    
	
                    6.2     	     	
Conduct of the Business Until Closing 	     	
18    
	
                    6.3     	     	
Post-Closing Orders and Payments      	     	
18    
	
                    6.4     	     	
Right to Investigate  	     	
18    
	
                    6.5     	     	
Retention of Records  	     	
19    
	
                    6.6     	     	
Non-Solicitation      	     	
19    
	
                    6.7     	     	
Managed Markets       	     	
19    

i 

	
                    6.8     	     	
Returns       	    	
20    
	
                    6.9     	     	
Certain Sales 	    	
21    
	
ARTICLE 7     	     	
          INDEMNIFICATION    	    	
21    
	
                    7.1     	     	
Indemnification by Shire      	    	
21    
	
                    7.2     	     	
Indemnification by Duramed    	    	
21    
	
                    7.3     	     	
Limitation of Liability       	    	
22    
	
                    7.4     	     	
No Consequential Damages      	    	
22    
	
                    7.5     	     	
Procedures for Indemnification for Third Party Claims 	    	
23    
	
                    7.6     	     	
Losses That Are Not Third Party Claims        	    	
24    
	
                    7.7     	     	
Termination of Indemnification Obligations    	    	
24    
	
                    7.8     	     	
Other Matters 	    	
24    
	
                    7.9     	     	
Other Limitations     	    	
25    
	
                    7.10    	     	
Exclusive Remedy      	    	
25    
	
                    7.11    	     	
Net Losses and Subrogation    	    	
26    
	
ARTICLE 8     	     	
          TERMINATION        	    	
26    
	
                    8.1     	     	
Termination Prior to Closing  	    	
26    
	
                    8.2     	     	
Effect of Termination Prior to Closing        	    	
27    
	
ARTICLE 9     	     	
          PATENT PROSECUTION, MAINTENANCE AND        	    	    
	   	     	
          ENFORCEMENT        	    	
27    
	
                    9.1     	     	
Discretionary Duty to Maintain        	    	
27    
	
                    9.2     	     	
Abandonment of Maintenance by Shire   	    	
27    
	
                    9.3     	     	
Patent Marking        	    	
27    
	
                    9.4     	     	
Suits for Infringement of the Licensed Patents        	    	
27    
	
ARTICLE 10    	     	
          DISPUTE RESOLUTION 	    	
28    
	
                    10.1    	     	
Disputes      	    	
28    
	
                    10.2    	     	
Litigation    	    	
28    
	
                    10.3    	     	
Injunctive Relief     	    	
28    
	
ARTICLE 11    	     	
          GENERAL PROVISIONS 	    	
28    
	
                    11.1    	     	
Payment of Transaction Expenses       	    	
28    
	
                    11.2    	     	
Access to Information Post-Closing    	    	
28    
	
                    11.3    	     	
Notices       	    	
29    
	
                    11.4    	     	
Entire Agreement; Amendment   	    	
30    
	
                    11.5    	     	
Assignment    	    	
30    

ii 

	
11.6  	     	
Headings      	    	
30    
	
11.7  	     	
Independent Parties   	    	
30    
	
11.8  	     	
No Waiver     	    	
30    
	
11.9  	     	
Severability  	    	
30    
	
11.10 	     	
Counterparts  	    	
31    
	
11.11 	     	
No Third Party Beneficiaries  	    	
31    
	
11.12 	     	
Further Actions       	    	
31    
	
11.13 	     	
No Strict Construction        	    	
31    
	
11.14 	     	
Public Disclosure     	    	
31    
	
11.15 	     	
Bulk Sales Laws       	    	
31    

iii 

PRODUCT ACQUISITION AND LICENSE AGREEMENT 

     THIS PRODUCT ACQUISITION AND LICENSE AGREEMENT is dated as of August 14, 2006, by and among Shire LLC, a Kentucky limited liability company (together with its Affiliates, “Shire”), Shire plc a British public limited company, and Duramed Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“Duramed”). Shire and Duramed are sometimes referred to herein individually as a “Party” and together as the “Parties”. 

RECITALS 

     WHEREAS, Shire is in the business of formulating, manufacturing, marketing and distributing the pharmaceutical product known as Adderall IR®; 

     WHEREAS, Shire owns the pharmaceutical product known as Adderall IR® and all the assets relating to the Adderall Business; and 

     WHEREAS, Shire desires to sell, transfer, convey and license to Duramed, and Duramed desires to purchase, acquire and license from Shire, certain rights to the
Adderall IR® product and certain assets relating to the Adderall Business, and Duramed wishes to assume certain liabilities relating to such product, all on the terms set forth herein; 

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows: 

ARTICLE

1 DEFINITIONS 

     The following terms shall have the following meanings as used in this Agreement: 

     1.1 “Act” means the United States Federal Food, Drug and
Cosmetic Act, as amended. 

     1.2 “Adderall Business” means the business of formulating,
manufacturing, and distributing the pharmaceutical product known as Adderall IR®; provided, however, that the Adderall Business shall not include any Adderall product other than the Product, including Adderall XR or [SPD465]. 

     1.3 “Adderall XR” means the extended release mixed
amphetamine pharmaceutical product currently sold under NDA #21-303. 

     1.4 “Affiliate” means a Person that, directly or indirectly,
through one or more intermediates, controls, is controlled by, or is under common control with, the Person specified. For the purposes of this definition, control shall mean the direct or indirect ownership of (a) in the case of corporate entities,
securities authorized to cast more than fifty percent (50%) of the votes in any election for directors, (b) in the case of non-corporate entities, more than fifty 

percent (50%) ownership interest with the power to direct the management and policies of such non-corporate entity, or (c) such lesser percentage as may be the maximum percentage allowed to be owned by a foreign corporation under
the applicable laws or regulations of a particular jurisdiction of the equity having the power to vote in the election of directors or to direct the management and policies of such Person. 

     1.5 “Agreement” means this Agreement and all exhibits and
schedules attached hereto. 

     1.6 “Books and Records” means all books, records, manuals
and other materials (in any form or medium) relating primarily to the Purchased Assets or the Adderall Business, including all records and materials maintained at the headquarters of Shire,
advertising matter, catalogues, price lists (including any pricing for the Product made available to any Federal, State or local authorities), correspondence, mailing lists, lists of customers, distribution lists, photographs, production data, sales
and promotional materials and records, purchasing materials and records, manufacturing and quality control records and procedures, blueprints, research and development files, records, data and laboratory books, accounting records, and sales order
files. 

     1.7 “Business Day” means any day except a Saturday, Sunday
or a day on which a commercial bank in New York, New York is authorized to close. 

     1.8 “Duramed Labeled Product” means Product sold or
distributed after the Closing by or on behalf of Duramed bearing the NDC number of Duramed or any of its Affiliates. 

     1.9 “Duramed Material Adverse Effect” means any adverse
change, circumstance or effect that, individually or in the aggregate with all other adverse changes, circumstances and effects, has or is reasonably likely to have, a material adverse effect on the ability of Duramed to consummate the transactions
contemplated by this Agreement, including the ability to pay the Purchase Price when due. 

     1.10 “Contract” means any agreement, contract, commitment or
other instrument or arrangements (whether written or oral) (x) by which any of the Purchased Assets are bound or affected or (y) to which Shire is bound relating to the Purchased Assets, in each case as amended, supplemented, waived or otherwise
modified. 

     1.11 “Excluded Intellectual Property” means the (a) Shire
Trademark, (b) Product Trademark, (c) Licensed Patents, (d) Product Trade Dress, and (e) Intellectual Property that does not primarily relate to the Product. 

     1.12 “FDA” means the United States Food and Drug
Administration, and any successor agency thereto. 

     1.13 “Finished Goods” means a manufactured Product packaged
and ready for sale to the ultimate customer in the Territory. 

     1.14 “Governmental Authority” means any federal, state,
local or other government or any court of competent jurisdiction, legislature, governmental agency, administrative agency 

 - 2 - 

or commission or other governmental authority or instrumentality having jurisdiction in the Territory. 

     1.15 “HSR Act” means the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended. 

     1.16 “Intellectual Property” means all (a) Patents, (b) mask
works and copyrights in works of authorship of any type, including computer software and industrial designs, registrations and applications for registration thereof, (c) trademark registrations and applications for registration thereof, (d) trade
secrets, know-how and other confidential or proprietary technical, business and other information, and all rights in any jurisdiction to limit the use or disclosure thereof, and (e) rights to sue and recover damages or obtain injunctive relief for
past and future infringement, dilution, misappropriation, violation or breach thereof; in each case, solely to the extent the foregoing relates to the Territory. 

     1.17 “Liabilities” means any and all debts, liabilities and
obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, or determined or determinable, including those arising under any laws, action or governmental order and those arising under any contract, agreement, arrangement,
commitment or undertaking, or otherwise. 

     1.18 “Licensed Patents” mean the Patent(s) listed in Schedule
1.18.

     1.19 “Lien” means any mortgage, pledge, hypothecation, right
of others, claim, security interest, encumbrance, lease, sublease, license, occupancy agreement, adverse claim or interest, easement, covenant, encroachment, burden, title defect, title retention agreement, voting trust agreement, interest, equity,
option, lien, , whether arising by Contract or otherwise.

     1.20 “Losses” means any and all Liabilities, damages, fines,
penalties, deficiencies, losses and expenses (including interest, court costs, amounts paid in settlement, reasonable fees of attorneys, accountants and other experts or other reasonable expenses of litigation or other proceedings or of any claim,
default or assessment); provided, however, that the term “Losses” shall not include any special, consequential, indirect, punitive or similar damages, except to the extent actually paid by a Party pursuant to any Third Party Claim.

     1.21 “NDA” means a New Drug Application pursuant to Section
505 of the Act (21 U.S.C. Section 355) submitted to the FDA or any successor application or procedure.

     1.22 “Patents” means all patents, patent applications and
statutory invention registrations, including reissues, divisions, continuations, continuations-in-part, supplementary protection certificates, extensions and reexaminations thereof, all inventions disclosed therein, all rights therein provided by
international treaties and conventions, and all rights to obtain patents and registrations thereto. 

     1.23 “Permitted Liens” means (i) Liens for Taxes not yet due
and payable or which are being contested in good faith and by appropriate proceedings if adequate reserves with respect thereto are maintained on Shire’s books or (ii) Liens that, individually and in the aggregate, do not restrict, hinder, or
otherwise encumber or impair the ownership of or right to use the Purchased Assets or sell of Product. 

 - 3 - 

     1.24 “Person” means any individual, firm, corporation,
partnership, limited liability company, trust, unincorporated organization or other entity or a government agency or political subdivision thereto, and shall include any successor (by merger or otherwise) of such Person. 

     1.25 “Pharmacovigilance Agreement” means the
Pharmacovigilance Agreement to be executed at Closing by Shire and Duramed substantially in the form attached hereto as Exhibit A.

     1.26 “Product” means the pharmaceutical product in all dosage forms identified in NDA #11-522. 

     1.27 “Product Domain Name” means the domain name
“adderall.com” and all other domain names that include “Adderall” in any manner or form and that are owned or registered by Shire.

     1.28 “Product Material Adverse Effect” means any adverse
event, circumstance, fact, condition or effect that is materially adverse to the operations or results of operation, properties or prospects of the Adderall Business, the Purchased Assets, the Licenses, or the Product Trademark, other than any
event, change, circumstance or effect relating to (a) the economy of the United States in general, (b) in general to the industries in which the Product is sold and not specifically relating to the Product, or (c) changes, circumstances and effects
relating to the announcement of the transactions contemplated by this Agreement. 

     1.29 “Product NDA” means NDA #11-522, and any and all supplements or
amendments filed pursuant to FDA requirements. 

     1.30 “Product Trade Dress” means the tablet logo, including
the lettering of the Product name and, specifically, the letters “AD”, the size, shape and color of the tablet, together with all other features that are intrinsic to the tablet as currently marketed and sold, provided that Product Trade
Dress does not include any packaging associated with the sale, marketing or distribution of the Product. 

     1.31 “Product Trademark” means the trademark, trade names,
brand names, including all registrations and applications for registration thereof and all renewals, modifications and extensions thereof, listed on Schedule 1.31, used by Shire or its
Affiliates in connection with the manufacture, marketing, sale and distribution of the Product, and any rights existing under common law relating thereto. 

     1.32 “Regulatory Approval” means the technical, medical and
scientific licenses, registrations, authorizations, approvals, permits, consents (including approvals of NDAs, supplements and amendments, pre- and post- approvals, pricing and third party reimbursement approvals, and labeling approvals) of any
Regulatory Authority necessary for the development (including the conduct of clinical trials), distribution, marketing, promotion, offer for sale, use, import, export or sale of Product in the Territory. 

     1.33 “Regulatory Authority” means any national
(e.g., the FDA), regional, state or local regulatory agency, department, bureau, commission, council, court or other Governmental Authority in the Territory. 

 - 4 - 

     1.34 “Settlement Agreement” means that certain Settlement
Agreement, dated as of August 14, 2006, by and between the Parties. 

     1.35 “Shire Labeled Product” means Product bearing the NDC
number of Shire or any of its Affiliates. 

     1.36 “Shire Trademark” means the “Shire” name or
any variation thereof and, other than the Product Trade Dress, the Product Trademark and the Product Domain Name, all trademarks, trade names, brand names, trade dress, logo types, symbols, domain names (including registrations and applications for
registration thereof and all renewals, modifications and extensions thereof) used by Shire or its Affiliates in connection with the manufacture, marketing, sale and distribution of their products. 

     1.37 “Supply Agreement” means the Supply Agreement to be
executed at Closing by Shire or its Affiliate and Duramed for the supply of Product, in substantially the form attached hereto as Exhibit C. 

     1.38 “Survival Period” means the period of survival of
representations and warranties as set forth in Section 4.4. 

     1.39 “Taxes” (and with correlative meaning,
“Tax,” “Taxes,” and “Taxable”) shall mean
all taxes of any kind imposed by a federal, state, local or foreign Governmental Authority, including those on, or measured by or referred to as, income, gross receipts, financial operation, sales, use, ad valorem, value added, franchise, profits,
license, excise, stamp, premium, property, transfer or windfall profits taxes, customs, duties or similar fees, assessments or charges of any kind whatsoever, together with any interest and any penalties, additions to tax or additional amounts
imposed by such Governmental Authority with respect to such amounts. 

     1.40 “Technical Data” means all technical, scientific,
chemical, biological, pharmacological, and toxicological data generated primarily for the Product. 

     1.41 “Territory” means the United States and the states,
territories, possessions and protectorates thereof, the District of Columbia and the Commonwealth of Puerto Rico. 

     1.42 “Trademark License Agreement” means the Trademark
License Agreement to be executed at Closing by Shire or its Affiliate and Duramed relating to the use of the Product Trademark, in substantially the form attached hereto as Exhibit B.

Interpretation.  Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or
singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and other similar words refer to this entire Agreement; (d) “including” shall be deemed followed by “without limitation”,
“but not limited to” or words of similar meaning; and (e) the terms “Article” and “Section” refer to the specified Article and Section of this Agreement. Whenever this Agreement refers to a number of days, unless
otherwise specified, such number shall refer to calendar days. 

 - 5 - 

Additional Definitions.  Each of the following definitions is set forth in the Section of this Agreement indicated below: 

  	 Acquisition
          Transaction 	 Section 6.6 (b) 
	 AMP 	 Section 6.7 (b) 
	 Assumed Liabilities 	 Section 2.4 (a) 
	 Chargeback
          Contracts 	 Section 6.7 (e) 
	 Chargebacks 	 Section 6.7 (a) 
	 Closing 	 Section 2.7 (a) 
	 Closing Date 	 Section 2.7 (a) 
	 Duramed 	 Preamble 
	 Duramed Disclosure
          Schedule 	 Section 4.3 
	 Defaulting
          Party 	 Section 8.1 (c) 
	 DMFs 	 Section 3.4 
	 Excluded Assets 	 Section 2.1 (c) 
	 FDA Letter 	 Section 3.1 
	 Financial Information 	 Section 4.1 (d) 
	 General Assignment
          and Assumption 	 Section 2.7 (c) 
	 Indemnitee 	 Section 7.5 (a) 
	 Indemnitor 	 Section 7.5 (a) 
	 Licenses 	 Section 2.2 (a) 
	 Managed Market
          Activities 	 Section 6.7 (a) 
	 Parties 	 Preamble 
	 Party 	 Preamble 
	 Purchase Price 	 Section 2.5 
	 Purchased Assets 	 Section 2.1 (a) 
	 Rebate Contracts 	 Section 6.7 (d) 
	 Rebates 	 Section 6.7 (a) 
	 Representatives 	 Section 10.1 
	 Retained Liabilities 	 Section 2.4 (b) 
	 SEC 	 Section 11.14 (a) 
	 Shire 	 Preamble 
	 Shire Disclosure
          Schedule 	 Section 4.1 
	 Third Party
          Claim 	 Section 7.5 (a) 
	 Transaction
          Agreements 	 Section 11.4 

  

ARTICLE 2

SALE
OF ASSETS, LICENSES AND CLOSING 

     2.1 Sale of Assets. 

          (a) On the Closing Date, and subject to the terms and conditions of this Agreement, Shire will, and will cause its Affiliates to,
sell, assign, convey and transfer to Duramed, and Duramed will purchase and accept from Shire and its Affiliates, all of Shire’s and its Affiliates’ right, title and interest in and to the following assets (collectively, the
“Purchased Assets”): 

 - 6 - 

               (i) the Product NDA; 

               (ii) the Book and Records; provided that any lists included therein may be redacted as necessary to conceal information
pertaining to products other than the Product; 

               (iii) the Technical Data; 

               (iv) all unfulfilled customer orders for the Product arising in the Territory as of the Closing Date (a list of such orders to be
provided to Duramed on or prior to the Closing) and any future customer orders received by Shire for the Product; 

               (v) to the extent their transfer is permitted by law, all Regulatory Approvals, including all applications therefor; 

               (vi) all refunds or credit of Taxes relating to the foregoing attributable to any period following the Closing; 

               (vii) any guarantees, warranties, indemnities and similar rights in favor of Shire or its Affiliates with respect to any of the
foregoing; and 

               (viii) all rights to causes of action, lawsuits, judgments, claims and demands of any nature available to or being pursued by
Shire or its Affiliates with respect to the Adderall Business or the ownership, use, function or value of any of the foregoing, whether arising by way of counterclaim or otherwise. 

          (b) Notwithstanding Section 2.1(a) above, the transfer of the Product NDA shall occur in accordance with the provisions of
Article 3. 

          (c) For purposes of clarification, the Purchased Assets shall not include any assets, rights or interests other than those
specifically listed or described in Section 2.1(a) . Without limiting the generality of the foregoing, the Parties agree and acknowledge that the Purchased Assets shall not include: (i) the Excluded Intellectual Property, (ii) any and all NDAs or
other product approvals and Technical Data related to Adderall XR or anything else related to the approval, sale, marketing or manufacturing of Adderall XR, (iii) any Adderall product other than the Product, and (iv) any plant, real property,
equipment, accounts receivable, cash and cash equivalents, employees or any refund or credit of Taxes attributable to any period of time prior to the Closing Date (collectively, the “Excluded Assets”). Duramed acknowledges and agrees that Shire may retain a copy of all or part of the Books and Records that it delivers to Duramed under Section 2.1(a)(ii) for use with products of Shire or its Affiliates other than the Product
or to the extent required under applicable law provided that the copy of the Books and Records so retained shall be treated as Duramed’s confidential information. 

     2.2 Licenses and Other Rights. 

          (a) Subject to the terms and conditions of this Agreement, Shire hereby grants, or shall cause its Affiliates to grant, to
Duramed the following licenses (collectively, the “Licenses”): 

 - 7 - 

  

  

  

               (i) a worldwide, irrevocable, perpetual, fully-paid, exclusive (even as to Shire) right and license, with the right to sublicense
under the Licensed Patents, to use, market, have marketed, offer for sale, import for sale, sell and have sold Products in the Territory;

               (ii) an irrevocable, fully-paid, perpetual, exclusive (even as to Shire) right and license under the Product Trade Dress solely
to the extent necessary for Duramed to distribute, market and sell the Product in the Territory.

          (b) With respect to this Agreement, any Intellectual Property or other rights of Shire not expressly granted to Duramed under the
provisions of this Agreement shall be retained by Shire, including the right to conduct such studies and clinical trials within and without the Territory as may be necessary or useful for Shire to obtain Regulatory Approvals solely for the purpose
of selling products other than Product. 

     2.3 [*].  From and after the Closing Date, Shire [*] Duramed or its Affiliates [*] Duramed’s [*] Product in the Territory on
the basis that such [*] Shire or of [*] as of the Closing Date or [*].

     2.4 Assumed Liabilities. 

          (a) As of the Closing Date, Duramed shall assume, be responsible for and pay, perform and discharge when due the following
(collectively, the “Assumed Liabilities”): 

               (i) any Liabilities arising from the sale of any Product after the Closing Date, including any product liability, breach of
warranty, Patent or trademark infringement claim, or any other action or claim (excluding any Liabilities relating to voluntary or involuntary recalls of Shire Labeled Product, or any Liabilities of Shire under the Supply Agreement) brought,
asserted or filed by any third party or Regulatory Authority; 

               (ii) any Liabilities arising after the Closing Date relating to the Purchased Assets; 

               (iii) subject to Section 6.7, all Medicare, Medicaid and state program rebates in connection with Duramed Labeled Product sold
after the Closing Date;

               (iv) subject to Section 6.7, all chargebacks, rebates or any other post-sale rebates, refunds, price adjustments and other
similar payments, credits or liabilities in connection with the Duramed Labeled Product, sold after the Closing Date; and

               (v) subject to Section 6.7, credits, utilization based rebates, reimbursements, and similar payments to buying groups, insurers
and other institutions in connection with Duramed Labeled Product sold after the Closing Date.

          (b) Notwithstanding any provision hereof or any schedule or exhibit hereto or thereto, and regardless of any disclosure to
Duramed, Duramed shall not assume any liabilities, obligations or commitments of Shire other than the Assumed Liabilities, including such liabilities 

 - 8 - 

  

  

  

relating to or arising out of the ownership of the Purchased Assets on or prior to the Closing (the “Retained Liabilities”).

     2.5 Purchase Price.  Subject to the terms and conditions set forth herein, in consideration of
the sale, assignment, conveyance, license and delivery of the Purchased Assets and the Licenses, and as consideration for the execution and delivery of the Trademark License Agreement, Duramed will pay to Shire a cash payment of Sixty-Three Million
Dollars ($63,000,000), in the manner described in Section 2.7(b), (the “Purchase Price”).

     2.6 Independence of Purchase Price Obligation. All payments made or to be made by Duramed to
Shire in respect of Purchase Price shall be non-refundable and independent of any obligations that Shire or its Affiliates may have to Duramed under any other agreement. 

     2.7 Closing. 

          (a) The closing of the transactions contemplated hereby (the “Closing”) will take place at the offices of Morgan, Lewis & Bockius LLP in Princeton, New Jersey at 10:00 A.M. Eastern Time on the third (3rd) Business Day following the satisfaction or waiver of all conditions or obligations of the
Parties set forth in Sections 5.1 and 5.2, or at such other time, date and place as Duramed and Shire agree. The actual date of the Closing is referred to as the “Closing Date.”

          (b) At the Closing, Duramed will pay the Purchase Price in full in cash without any deductions or offsets by wire transfer of
immediately available funds to a bank account or accounts to be designated by Shire prior to Closing. 

          (c) At the Closing, Shire will assign and transfer to Duramed all of Shire’s right, title and interest in and to the
Purchased Assets, by delivery of a general assignment, assumption and bill of sale in the form of Exhibit D (the “General Assignment and
Assumption”) or any other bill of sale or assignment documents reasonably requested by Duramed. 

          (d) At the Closing, Duramed will assume from Shire the due payment, performance and discharge of the Assumed Liabilities by
delivery of the General Assignment and Assumption. 

          (e) At or prior to the Closing, the Parties shall execute and deliver to one another the agreements listed in Sections 5.1(h) and
5.2(h) . 

     2.8 Allocation of Purchase Price. The Purchase Price shall be allocated among the Purchased
Assets, the Licenses, the Trademark License Agreement and the Supply Agreement as set forth on Schedule 2.8 hereto. Duramed and Shire agree to report the sale and purchase of the Purchased
Assets, and the rights granted or assets transferred under the Licenses and the Trademark License Agreement for Tax purposes in accordance with the allocations set forth on Schedule 2.8
hereto, or as otherwise agreed to at a later date by the Parties if such Schedule is not attached as of the Closing Date. 

 - 9 - 

  

  

  

     2.9 Delivery of Purchased Assets. At the Closing or as soon as possible thereafter, Shire shall
deliver to Duramed, all of the Purchased Assets. Following the Closing, Shire shall reasonably cooperate with Duramed and grant to Duramed and its employees, attorneys, accountants, officers, representatives, and agents, reasonable access to
Shire’s personnel to fully transfer and disclose to Duramed all of the Purchase Assets. 

ARTICLE 3

REGULATORY MATTERS 

     3.1 Filings with Regulatory Authorities Regarding Transfer of Registrations. Prior to Closing,
Shire and Duramed will establish a mutually acceptable and prompt communication and interaction process to ensure to Duramed the prompt and orderly transfer of the Product NDA.  Promptly after Closing, the Parties shall file with the FDA and any
other relevant Regulatory Authorities all information required in order to transfer the Product NDA from Shire to Duramed, including the letter to the FDA authorizing the transfer in the form attached hereto as Exhibit
E (the “FDA Letter”). Where required, Duramed shall also promptly file an application or license variation to Regulatory Authorities or other
government/health agencies. Shire shall file the information required of a former owner, and Duramed shall file the information required of a new owner, at each Party’s own expense. Both Duramed and Shire also agree to use all commercially
reasonable efforts to take any actions required by the Regulatory Authorities or other government/health agencies to effect the transfer of the Product NDA from Shire to Duramed, and hereby further agree to cooperate with each other in order to
effectuate the foregoing transfer of Product NDA at Duramed’s expense. The Parties agree to use all commercially reasonable efforts to complete the filing of the transfer of the Product Registrations within [*] from the Closing Date. Shire may
retain an archival copy of the Product Registrations, including supplements and records that are required to be kept under 21 C.F.R. §314.81, but such retention shall not be deemed a license to Shire of such information nor be deemed to
constitute any Shire ownership interest therein.

     3.2 Responsibility for the Product.  From and after the Closing Date, and in no event later than
the effective date of the transfer to Duramed of the applicable NDA, Duramed shall assume all regulatory responsibilities under applicable laws in connection with the Product and the Product NDA, including (a) responding to all medical inquiries,
(b) responsibility for reporting any adverse drug events in connection with the Product, (c) responsibility for compliance with the Prescription Drug Marketing Act of 1987, as the same may be amended from time to time, and (d) responsibility for any
and all fee obligations for holders or owners of approved NDAs and Regulatory Approvals relating to the Product, including those defined under the Prescription Drug User Fee Act of 1992, as the same may be amended from time to time. In connection
therewith, Shire shall promptly after Closing deliver to Duramed all records, documentation and other information that Shire has prepared or has had prepared regarding the development, efficacy, safety and legal compliance of the Product, including
all correspondence with Regulatory Authorities or other government/health agencies related to the Product. Shire acknowledges that pursuant to the terms of the Pharmacovigilance Agreement, Shire shall be responsible for compliance with certain of
the foregoing obligations following the Closing. Without limiting Shire’s obligations under the Pharmacovigilance Agreement, Shire shall cooperate with Duramed following the Closing to provide reasonable assistance in connection with Duramed’s regulatory obligations related to the Product for a period of [*]. 

 - 10 - 

  

  

  

     3.3 Marketing Activities. Immediately following the Closing, Shire and Duramed shall send
correspondence to each customer and supplier of the Product, and any other relevant third party agreed to by Shire and Duramed, informing each such party of the sale and transfer of the Product to Duramed, in substantially the form attached hereto
as Exhibit F.

     3.4 Right of Reference. Duramed shall grant Shire a right of cross-reference or right of
reference, including as that term is defined in 21 C.F.R. Section 314.3(b), to all existing Regulatory Approvals, Drug Master Files (“DMFs”), and other regulatory submissions
relating to the Product.  At Shire’s request [*], Duramed shall provide a copy of any regulatory application or file relating to Product that is the subject of a right of cross-reference or right of reference pursuant to this Section.

ARTICLE 4

REPRESENTATIONS AND WARRANTIES 

     4.1 Representations and Warranties of Shire.  Shire represents and warrants to Duramed solely as
of the date of this Agreement, subject to such exceptions as are specifically disclosed in the disclosure schedule supplied by Shire to Duramed and dated as of the date hereof (the “Shire Disclosure
Schedule”) as follows: 

          (a) Organization and Standing.  Shire is a corporation duly organized, validly existing and in
good standing under the laws of the jurisdiction of its formation, with full corporate power and authority to carry on the Adderall Business and to own or lease and to operate its properties in the places where such business is conducted and such
properties are owned, leased or operated. 

          (b) Power and Authority.  Shire has all requisite corporate power and authority to execute,
deliver, and perform this Agreement, and the other Transaction Agreements, and the other agreements and instruments to be executed and delivered by it pursuant hereto and thereto, and to consummate the transactions contemplated herein and therein.

          (c) No Conflicts.  The execution, delivery and performance by Shire of this Agreement and the
other Transaction Agreement, and the consummation of the transactions contemplated hereby and thereby, do not and will not conflict with or result in a violation of or a default under (with or without the giving of notice or the lapse of time or
both) (i) any applicable law, (ii) the certificate of incorporation or by-laws or other organizational documents of Shire, or (iii) any Contract or other contract, agreement, instrument, judgment, order or decree to which Shire is a party or by
which Shire may be bound or affected. 

          (d) Financial Information. Shire has provided to Duramed [*], and for the [*]
(“Financial Information”).  Such information was derived from the books and records of Shire and was prepared by Shire in good faith and fairly presents, in all material respects,
the sales of Product in the Territory for the periods shown.  No representations or warranties whatsoever are made with respect to any financial projections. 

          (e) Corporate Action; Binding Effect. Shire has duly and properly taken all action required by
law, its organizational documents, or otherwise, to authorize the execution, delivery, and performance by it of this Agreement, the other Transaction Agreements, and the 

 - 11 - 

  

  

  

other agreements and instruments to be executed and delivered by it pursuant hereto and thereto and the consummation of transactions contemplated hereby and thereby.  This Agreement has been duly executed and delivered by Shire
and constitutes, and the other Transaction Agreements and the other agreements and instruments contemplated hereby and thereby when duly executed and delivered by Shire will constitute, legal, valid, and binding obligations of Shire enforceable
against it in accordance with their respective terms, except as enforcement may be affected by bankruptcy, insolvency, or other similar laws and by general principles of equity. 

          (f) Consents.  No consent or approval of, or filing with or notice to, any Regulatory Authority
or Governmental Authority is required or necessary to be obtained by Shire or on its behalf in connection with the execution, delivery, and performance of this Agreement or to consummate the transactions contemplated hereby and thereby, except (i)
in connection with the transfer of the Product Registrations, (ii) the notification requirements of the HSR Act, or (iii) as relates solely to Duramed. 

          (g) Assets. 

          (i) Shire or one of its Affiliates owns and has good and marketable title to all the Purchased Assets, in each case free and
clear of any and all Liens other than Permitted Liens. 

               (ii) Except for Excluded Assets, there are no assets or properties used in the operation of the Adderall Business and owned by
any Person other than Shire that will not be sold or licensed to Duramed hereunder. The Purchased Assets [*] for the [*] or are [*], and [*] and, [*] Shire [*] the Purchased Assets [*] or in the [*] with the [*].

          (a) Litigation
or Disputes. Except as set forth on Schedule
 4.1(h), there is no claim, action, suit,
 demand, citation, grievance, subpoena, inquiry, proceeding, investigation, or
 arbitration relating to the Product, the Purchased Assets or the Adderall Business
 pending or, to Shire’s knowledge, threatened against Shire or any of its Affiliates
 by or before any Regulatory Authority, federal, state, or other governmental
 court, department, commission, or board (whether domestic or foreign). Except
 as set forth on Schedule
4.1(h), there is not currently outstanding
against Shire or any of its Affiliates any judgment, decree, injunction, rule
or order of any Regulatory Authority or Governmental Authority relating to the
Purchased Assets or the Adderall Business.

          (i) Licensed Patents, Technical Data and Other Intellectual Property. 

               (i) Shire owns or has the lawful right and license to use the Licensed Patents.

               (ii) Shire has not received any written notice, and Shire otherwise has no knowledge of, the infringement by any Person of any
Licensed Patent or the Technical Data. 

               (iii) Shire owns all of the Technical Data. The Technical Data contains all of the technical, scientific, chemical, biological,
pharmacological and toxicological data generated by Shire for the Product.

               (iv) Shire has the full right, power and authority to grant the Licenses as described herein. 

 - 12 - 

  

  

  

               (v) The Licensed Patents have been duly registered with, filed in or issued by, as the case may be, the United States Patent and
Trademark Office and the Canadian Intellectual Property Office. 

               (vi) No claim or demand of any Person has been made nor is there any proceeding that is pending, or to the knowledge of Shire,
threatened, which (i) challenges the rights of Shire in respect of the Licensed Patents, Technical Data, Product Trademark or Product Trade Dress or (ii) asserts that Shire or any of its Affiliates is infringing, or is otherwise in conflict with, or
is required to pay any royalty, license fee, charge or other amount with regard to, any such Intellectual Property of any third party. None of the Licensed Patents, Technical Data, Product Trademark or Product Trade Dress is subject to any
outstanding order, ruling, decree, judgment or stipulation by or with any court, arbitrator, or administrative agency. To Shire’s knowledge, the sale of the Product does not infringe or otherwise conflict with any rights of any Person in
respect of any Intellectual Property. 

          (j) Compliance with Laws. Shire has conducted its operations in connection with the Purchased
Assets and the manufacture and sale of the Product in the Territory in material compliance with all applicable laws.  Except as set forth on Schedule 4.1(j), Shire has not received any
written notice of violation of any applicable law from any Regulatory Authority or Governmental Authority relating to the Adderall Business, the Purchased Assets or the Product within the past [*]. 

          (k) Regulatory Issues. Except as set forth in Schedule
4.1(k), during the [*] prior to the date of this Agreement, with respect to the Product in the Territory, the Purchased Assets or the Adderall Business, neither Shire nor any of its Affiliates has received or been
subject to (i) any FDA Form 483’s relating to the Product, (ii) any FDA Notices of Adverse Findings relating to the Product, or (iii) any warning letters or other written correspondence from the FDA or any other Regulatory Authority concerning
the Product in which the FDA or such other Regulatory Authority asserted that the operations of Shire were not in compliance with applicable law, with respect to the Product or the Adderall Business.  Except as discussed in Schedule 4.1(k) or as would not have a Product Material Adverse Effect, during the last [*] there has not been any occurrence of any product recall, market withdrawal or replacement, or post-sale warning
conducted by or on behalf of Shire concerning the Product, any product recall, market withdrawal or replacement conducted by or on behalf of any entity as a result of any alleged defect in the Product or the Technical Data. 

          (l) Product Warranties.  Except for warranties arising solely pursuant to applicable law, (i)
Shire has not made any warranties express or implied, written or oral, to any third party with respect to the Product and (ii) there are no pending or threatened claims with respect to any such warranty, and except for the warranties arising solely
pursuant to applicable law, Shire has no any liability with respect to any such warranty, whether known or unknown, absolute, accrued, contingent or otherwise and whether due or to become due. 

          (m) Taxes.  There are no Liens for Taxes upon the Purchased Assets or the rights granted under
the Licenses except for Permitted Liens. None of the Purchased Assets is “tax-exempt use property” within the meaning of Section 168 of the Code.

 - 13 - 

  

  

  

          (n) Other. In the past [*], to Shire’s knowledge (i) there has not been a Product Material
Adverse Effect that is not otherwise generally known to the public, and (ii) the Product has been distributed by Shire only in the United States. 

     4.2 Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, SHIRE PROVIDES THE PURCHASED
ASSETS AND LICENSES “AS IS” AND SHIRE DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO THE PURCHASED ASSETS AND THE LICENSES, INCLUDING THE WARRANTY OF MERCHANTABILITY AND THE WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE.

     4.3 Representations and Warranties of Duramed.  Duramed represents and warrants to Shire,
subject to such exceptions as are specifically disclosed in the disclosure schedule supplied by Duramed to Shire and dated as of the date hereof (the “Duramed Disclosure Schedule”), as follows: 

          (a) Organization and Standing.  Duramed is a corporation duly organized, validly existing and in
good standing under the laws of the jurisdiction of its formation. 

          (b) Power and Authority.  Duramed has all requisite corporate power and authority to execute,
deliver, and perform this Agreement, and the other Transaction Agreements, and the other agreements and instruments to be executed and delivered by it pursuant hereto and thereto, and to consummate the transactions contemplated herein and therein.

          (c) No Conflicts.  The execution, delivery and performance by Duramed of this Agreement and the
other Transaction Agreement, and the consummation of the transactions contemplated hereby and thereby, do not and will not conflict with or result in a violation of or a default under (with or without the giving of notice or the lapse of time or
both) (i) any law applicable to Duramed, (ii) the certificate of incorporation or by-laws or other organizational documents of Duramed or (iii) except as set forth in Section 4.3(c) of Duramed Disclosure Schedule, any Contract or other contract,
agreement, instrument, judgment, order or decree to which Duramed is a party or by which Duramed may be bound or affected, except in the case of clauses (iii), as would not have a Duramed Material Adverse Effect. 

          (d) Corporate Action; Binding Effect. Duramed has duly and properly taken all action required by
law, its organizational documents, or otherwise, to authorize the execution, delivery, and performance by it of this Agreement, the other Transaction Agreements, and the other agreements and instruments to be executed and delivered by it pursuant
hereto and thereto and the consummation of transactions contemplated hereby and thereby.  This Agreement has been duly executed and delivered by Duramed and constitutes, and the other Transaction Agreements and the other agreements and instruments
contemplated hereby and thereby when duly executed and delivered by Duramed will constitute, legal, valid, and binding obligations of Duramed enforceable against it in accordance with their respective terms, except as enforcement may be affected by
bankruptcy, insolvency, or other similar laws and by general principles of equity. 

 - 14 - 

  

  

  

          (e) Litigation or Disputes; Compliance with Laws.  There is no claim, action, suit, demand,
citation, grievance, subpoena, inquiry, proceeding, investigation, or arbitration pending or, to Duramed’s knowledge, threatened against Duramed by or before any Regulatory Authority, federal, state, or other governmental court, department,
commission, or board (whether domestic or foreign) and, to Duramed’s knowledge, Duramed is not in violation of or in default with any applicable law, the result of any of which, either individually or cumulatively, would have a Duramed Material
Adverse Effect. 

          (f) Consents.  No consent or approval of, or filing with or notice to, any Regulatory Authority
or Governmental Authority is required or necessary to be obtained by Duramed in connection with the execution, delivery, and performance of this Agreement or the other Transaction Agreements or to consummate the transactions contemplated hereby and
thereby, except (i) in connection with the transfer of the Product Registrations, (ii) the notification requirements of the HSR Act or (iii) as relates solely to Shire. 

          (g) Financing. As of the date of this Agreement, Duramed has access to, and as of the Closing
Date, Duramed will have, sufficient funds necessary to pay the Purchase Price. 

     4.4 Survival of Representations/Warranties.  All of the representations and warranties of Shire
contained in Section 4.1 shall survive the Closing and continue in full force and effect for a period of [*] thereafter, provided that (a) all representations and warranties provided in Sections 4.1(b), 4.1(c), 4.1(f), and 4.1(g), shall survive [*]
and (b) the representations and warranties set forth in Section 4.1(m) shall survive until [*] after the end of the applicable statute of limitations. All of the representations and warranties set forth of Duramed contained in Section 4.3 shall
survive the Closing and continue in full force and effect for a period of [*] thereafter, provided that all representations and warranties provided in Sections 4.3(b), 4.3(c), 4.3(d) and 4.3(f) shall survive [*].

     4.5 Brokers.  Each Party represents that no agent, broker, investment banker, financial advisor
or other Person, is or will be entitled to any brokers’ or finder’s fee or any other commission or similar fee in connection with this Agreement or any of the transactions contemplated hereby. 

ARTICLE 5

CONDITIONS TO CLOSING 

     5.1 Conditions to Obligations of Duramed. The obligations of Duramed hereunder to consummate the
transactions contemplated by this Agreement are subject to the fulfillment, at or before the Closing, as applicable, of each of the following conditions (all or any of which may be waived in whole or in part by Duramed, but only in writing, in its
sole discretion): 

          (a) Representations and Warranties.  The representations and warranties made by Shire in this
Agreement shall be true and correct in all material respects on and as of the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a specified date earlier than the Closing Date, on
and as of such earlier date. 

 - 15 - 

  

  

  

          (b) Performance.  Shire shall have performed and complied with, in all material respects, the
agreements, covenants and obligations required by this Agreement to be so performed or complied with by Shire at or before the Closing. 

          (c) Orders and Laws. There shall not be in effect on the Closing Date any judgment, order,
decree, ruling or charge restraining, enjoining or otherwise prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement. No court or other Governmental Authority shall have determined any applicable law
to make illegal the consummation of the transactions contemplated hereby, and no proceeding with respect to the application of any such applicable law to such effect shall be pending.

          (d) HSR. The applicable waiting period under the HSR Act, if any, shall have been terminated or
expired. 

          (e) Effective Date. The Settlement Agreement shall have become effective in accordance with its
terms. 

          (f) Deliveries. Shire shall have executed and delivered the item described in Section 2.7(d) .

          (g) FDA Letter. The FDA Letter shall have been executed by Duramed and Shire in preparation for
filing.

          (h) Product Material Adverse Effect. There shall not have occurred, or be continuing, a Product
Material Adverse Effect. 

          (i) Other Agreements.  Duramed and Shire or its Affiliate shall have executed and delivered the
other Transaction Agreements. 

     5.2 Conditions to Obligations of Shire.  The obligations of Shire hereunder to consummate the
transactions contemplated by this Agreement are subject to the fulfillment, at or before the Closing, as applicable, of each of the following conditions (all or any of which may be waived in whole or in part by Shire, but only in writing, in its
sole discretion): 

          (a) Representations and Warranties.  The representations and warranties made by Duramed in this
Agreement shall be true and correct in all material respects on and as of the Closing Date as though made on and as of the Closing Date or, in the case of representations and warranties made as of a specified date earlier than the Closing Date, on
and as of such earlier date. 

          (b) Performance.  Duramed shall have performed and complied with, in all material respects, the
agreements, covenants, and obligations required by this Agreement to be so performed or complied with by Duramed at or before the Closing. 

          (c) Orders and Laws. There shall not be in effect on the Closing Date any judgment, order,
decree, ruling or charge restraining, enjoining, or otherwise prohibiting or making illegal the consummation of any of the transactions contemplated by this Agreement. No court or other Governmental Authority shall have determined any applicable law
to make illegal 

 - 16 - 

  

  

  

the consummation of the transactions contemplated hereby or by the other Transaction Agreements, and no proceeding with respect to the application of any such applicable law to such effect shall be pending. 

          (d) HSR. The applicable waiting period under the HSR Act, if any, shall have been terminated or
expired. 

          (e) Effective Date. The Settlement Agreement shall have become effective in accordance with its
terms. 

          (f) Deliveries. Duramed shall have executed and delivered to Shire the items described in
Section 2.7(b) and 2.7(d) . 

          (g) FDA Letter.  The FDA Letter shall have been executed by Shire and Duramed in preparation for
filing. 

          (h) Other Agreements.  Duramed and Shire or its Affiliate shall have executed and delivered the
other Transaction Agreements. 

ARTICLE 6

COVENANTS 

     6.1 HSR Filing. 

          (a) To the extent necessary, each of Duramed and Shire shall simultaneously with the filing of the Settlement Agreement with the
Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice, file with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice any notification and report form required of it in the
reasonable opinion of both Parties under the HSR Act with respect to the transactions contemplated hereby. The Parties shall cooperate with one another to the extent necessary in the preparation of any notification and report form required to be
filed under the HSR Act and in the response to any request for information, including any Second Request for information issued under the HSR Act. Each Party shall be responsible for its own costs and expenses associated with any filing under the
HSR Act; provided, however, that Duramed shall be responsible for all filing fees required by the HSR Act. 

          (b) Duramed and Shire will cooperate and use all reasonable efforts to make all other registrations, filings and applications, to
give all notices and to obtain as soon as practicable all governmental and other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things, necessary or desirable for the
consummation of the transactions contemplated hereby. 

          (c) Duramed shall be [*] of this Agreement, or [*] of the HSR waiting period by the FTC and/or DOJ, including [*] Section 7A(e)
of the Clayton Act and 16 C.F.R. Section 803.20 . 

 - 17 - 

     6.2 Conduct of the Business Until Closing. Except for the actions taken or omitted to be taken
pursuant to the prior written consent of Duramed, which consent shall not be unreasonably withheld or delayed, from the date of this Agreement until the Closing, Shire shall: 

          (a) carry on the Adderall Business in, and only in, the ordinary course, in substantially the same manner as heretofore
conducted; 

          (b) perform in all material respects all of its obligations under any agreements and instruments relating to or affecting the
Purchased Assets, and comply in all material respects with all laws applicable to it, the Purchased Assets or the Adderall Business; 

          (c) not enter into or assume any material agreement, contract or instrument relating to the Purchased Assets, or enter into or
permit any material amendment, supplement, waiver or other modification in respect thereof; and 

          (d) not make any material change in the selling, distribution, pricing, advertising or collection practices for the Product,
including any special effort or program to sell, consign or solicit order for the Product to customers or to discount, factor or collect sooner than normal any accounts receivable. 

     6.3 Post-Closing Orders and Payments.  From and after the Closing Date, Shire shall (i) not
accept any purchase orders on behalf of Duramed, (ii) promptly deliver to Duramed any purchase orders for Product received after the Closing and any payments received from third parties for Product purchased from Duramed after the Closing, and (iii)
refer all inquiries it shall receive with respect to the Product, to Duramed or its designee.  Likewise, Duramed shall promptly deliver to Shire any payments Duramed receives from third parties for Product purchased from Shire prior to the Closing.

     6.4 Right to Investigate. After the date hereof up to the Closing, Shire shall afford to
representatives of Duramed reasonable access to offices, plants, properties, books and records of Shire relating to the Product and the Purchased Assets, during normal business hours, in order that Duramed may have an opportunity to make such
reasonable investigations as it desires with respect to the Product. 

     6.5 Retention of Records. Shire will, and will cause each of its Affiliates to, retain all books
and records relating to the Adderall Business and the Purchased Assets in the United States in accordance with Shire’s record retention policies as presently in effect or as otherwise required by law.

     6.6 Non-Solicitation.

          (a) During the period commencing upon the signing of this Agreement and ending upon the first anniversary of the Closing Date,
Duramed (which for purposes of this Section 6.6 includes its Affiliates) shall not, either directly or indirectly, solicit, recruit, induce, encourage or attempt to solicit, recruit, induce or encourage any employee of Shire or its Affiliates who
work, or at any time within [*] prior to the Closing Date, worked, on matters involving the Product to terminate his or her employment relationship with Shire or its Affiliates and become employed by Duramed or become employed by an independent
contractor for 

 - 18 - 

Duramed, whether or not such employee is a full-time employee and whether or not such employment relationship is pursuant to a written agreement or is at-will.  Nothing in this Section 6.6(a) shall apply if the employee is hired
in response to a public advertisement or general solicitation disseminated by either Party. 

          (b) Prior to the Closing Date, neither Shire nor any of its Affiliates or any Person acting on their behalf shall (i) solicit or
encourage any inquiries or proposals for, or enter into any discussions with respect to, the acquisition of any properties and assets held for use in connection with, necessary for the conduct of, or otherwise material to, the Adderall Business (an
“Acquisition Transaction”) or (ii) furnish or cause to be furnished any non-public information concerning the Adderall Business to any Person (other than Duramed), for purposes of
facilitating an Acquisition Transaction.  Shire shall promptly notify Duramed of any inquiry or proposal received by Shire with respect to any such Acquisition Transaction. Shire shall not sell, transfer or otherwise dispose of, grant any option or
proxy to any Person with respect to, create any Lien upon, or transfer any interest in, any Purchased Asset, other than in the ordinary course of business and consistent with this Agreement. 

     6.7 Managed Markets.

          (a) On the Closing Date and to the extent permitted by applicable law, Duramed shall become responsible for the marketing and
promotion of Duramed Labeled Product across all managed market and government segments in the Territory and with respect thereto, shall have exclusive responsibility for: (i) contract execution, (ii) government reporting, rebate and chargeback
processing and payment, federal supply schedule calculations and pricing schedules, (iii) contract compliance, monitoring and audits, and (iv) contract administration and claims processing (collectively, the “Managed Market Activities”).  Without limiting the generality of the foregoing, with respect to rebates under Medicaid and federal supply service contracts, Duramed shall assume following the Closing
Date responsibility therefor under its own Medicaid and federal supply service contracts. On or prior to the Closing Date Duramed shall have obtained its own NDC number for the Product and shall ensure that all sales of Product by Duramed can be
accomplished under the NDC number of Duramed. Duramed shall use its new NDC numbers on all invoices, orders and other communications with customers and Regulatory Authorities or other governmental entities.  Following the Closing Date, Duramed shall
be responsible for the processing, payment, administration and support of (x) all chargebacks under any government,  managed market or other contract (“Chargebacks”) and (y) all rebates due pursuant to any United States government (federal or state) rebate program under any government, managed
market or other contract (“Rebates”) for Duramed Labeled Product. Shire shall be responsible for the processing, payment, administration and support of all Chargebacks and Rebates
for Shire Labeled Product. 

          (b) Shire shall provide Duramed with all information relating to the Product and the prices thereof that Duramed reasonably
requires in order to comply with applicable rules and regulations relating to Medicaid Rebates.  When requested, such information shall be provided by Shire to Duramed promptly, and in any event, within [*] after Duramed’s written request
therefor. Promptly after the Closing Date, Shire shall provide Duramed with the baseline Average Manufacturers Price (“AMP”) for the Product. Within [*] after the end of the [*]
after 

 - 19 - 

the Closing Date, Duramed shall calculate a unit (tablet/capsule) AMP and “Best Price” for the Product and provide such calculations in writing to Shire. 

          (c) Shire shall provide to Duramed within [*] after request therefor all information reasonably requested by Duramed to enable
Duramed to calculate the price to be paid for each Product by a “covered entity” under the Public Health Service Act, as defined in 42 U.S.C. § 256b(a)(4). 

          (d) Shire shall use reasonable best efforts to terminate all Contracts providing for the payment of commercial Rebates with
respect to the Product (“Rebate Contracts”) as of the [*] following the Closing. Shire shall not assign to Duramed, and Duramed shall not assume from Shire, any of the Rebate
Contracts. Shire shall continue processing Rebates owed under the Rebate Contracts with respect to Product dispensed prior to the termination of such Rebate Contracts. Upon Closing, Shire shall issue a letter to commercial Rebate customers advising
such customers of Shire’s responsibilities in connection with Rebate Contracts and associated Rebates. 

          (e) Shire shall use reasonable best efforts to terminate all Contracts providing for payment of Chargebacks to government and
commercial customers with respect to Product (“Chargeback Contracts”) upon Closing. Shire shall not assign to Duramed, and Duramed shall not assume from Shire, any of the
Chargeback Contracts. Upon Closing, Shire shall issue a letter to the trade (wholesalers and distributors) and to commercial Chargeback customers advising such customers of Shire’s responsibilities in connection with Chargeback Contracts and
associated Chargebacks and administrative fees. 

     6.8 Returns. From and after the Closing Date (a) Shire shall be solely responsible, at its own
cost and expense, for the processing, payment, administration and support of all returns of Shire Labeled Product, regardless of when the return is made, and (b) Duramed shall be solely responsible, at its own cost and expense, for the processing,
payment, administration and support of all returns of Duramed Labeled Product. If any quantities of Duramed Labeled Products are returned to Shire, Shire shall notify Duramed as soon as practicable and ship them to the facility designated by Duramed
at Duramed’s cost. Shire, at its option, may advise the customer who made the return that Duramed Labeled Products should have been returned to Duramed.  At Duramed’s request, Shire shall destroy the Duramed Labeled Products and Duramed
shall reimburse Shire for such cost of destruction.  If any quantities of Shire Labeled Products are returned to Duramed, Duramed shall notify Shire as soon as practicable and ship them to the facility designated by Shire at Shire’ cost.  At
Shire’s request, Duramed shall destroy Shire Labeled Products and Shire shall reimburse Duramed for such cost of destruction. 

     6.9 Certain Sales. Duramed shall not sell any Product following the Closing Date under
Shire’s NDC Number or any Shire labeling or packaging material for the Product. Shire shall not sell any Product following the Closing except pursuant to the Supply Agreement.

ARTICLE 7

INDEMNIFICATION 

     7.1 Indemnification by Shire. From and after the Closing, Shire shall reimburse and indemnify
Duramed, Duramed’s Affiliates, and their respective officers, directors, employees, 

 - 20 - 

  

  

  

and agents in respect of, and hold each of them harmless from and against, any and all Losses suffered, incurred, or sustained by any of them or to which any of them becomes subject, resulting from, arising out of, or relating to:

          (a) the Retained Liabilities or the Excluded Assets; 

          (b) any misrepresentation or breach of representation or warranty by Shire made or contained in this Agreement; 

          (c) any failure of Shire to materially perform or observe any covenant or agreement to be performed or observed by Shire pursuant
to this Agreement; 

          (d) any action or inaction of Shire with respect to the Purchased Assets prior to the Closing Date, except for Losses arising as
a result of Liabilities expressly included in the Assumed Liabilities; and 

          (e) any product liability claim with respect to the Shire Labeled Product sold prior to the Closing.

     7.2 Indemnification by Duramed.  From and after the Closing, Duramed shall reimburse and
indemnify Shire, Shire’s Affiliates and their respective officers, directors, employees, and agents in respect of, and hold each of them harmless from and against, any and all Losses suffered, incurred, or sustained by any of them or to which
any of them becomes subject, resulting from, arising out of, or relating to: 

          (a) the Assumed Liabilities; 

          (b) any misrepresentation or breach of representation or warranty by Duramed made or contained in this Agreement;

          (c) any failure by Duramed to materially perform or observe any covenant or agreement to be performed or observed by Duramed
pursuant to this Agreement; and 

          (d) any action or inaction of Duramed with respect to the Purchased Assets after the Closing Date. 

     7.3 Limitation of Liability. 

          (a) Notwithstanding anything to the contrary contained in this Agreement, no amounts of indemnity shall be payable as a result of
any claim in respect of a Loss arising under Section 7.1 unless and until the indemnified parties thereunder have suffered, incurred, sustained, or become subject to Losses referred to in such Sections in excess of [*] in the aggregate (in which
event the indemnifying Party shall be liable for the entire amount of such Losses). 

          (b) The maximum aggregate liability of Shire under this Article 7 shall not exceed [*], provided, however, that Losses related to
or arising out of any Third Party Claim shall not be subject to any such limitation. 

 - 21 - 

  

  

  

          (c) Notwithstanding anything to the contrary contained in this Agreement, no amounts of indemnity shall be payable as a result of
any claim in respect of a Loss arising under Sections 7.1 or 7.2: 

               (i) with respect to any Loss, to the extent that the Party seeking indemnification had a reasonable opportunity, but failed, in
good faith to mitigate the Loss; or 

               (ii) with respect to any Loss, to the extent that such Loss is caused by (A) any misrepresentation or breach of warranty,
covenant or agreement by the Party seeking indemnification in the Agreement or (B) the gross negligence or intentional misconduct of such Party or its Affiliates or any of their respective officers, directors, employees, or agents. 

          (d) No Party hereto shall be entitled to any indemnification under Section 7.1(b) or Section 7.2(b), as applicable, if (i) the
other Party shall have notified such Party in writing on or prior to the Closing Date, or disclosed to such Party in the Shire Disclosure Schedule or the Duramed Disclosure Schedule, as applicable and as may be supplemented or amended prior to the
Closing Date, of the breach of, or inaccuracy in, such representation or warranty and (ii) such Party has permitted the Closing to occur. 

     7.4 No Consequential Damages.  IN NO
EVENT SHALL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EXCEPT TO THE EXTENT THAT SUCH DAMAGES ARISE FROM THIRD PARTY
CLAIMS SUBJECT TO INDEMNIFICATION UNDER ARTICLE 7.

     7.5 Procedures for Indemnification for Third Party Claims. 

          (a) In the case of a third party claim or demand (“Third Party Claim”) made by any Person who is not a Party to this Agreement (or an Affiliate thereof) as to which a Party (the “Indemnitor”) may be obligated to provide
indemnification pursuant to this Agreement, such Party seeking indemnification hereunder (“Indemnitee”) will notify the Indemnitor in writing of the Third Party Claim (and
specifying in reasonable detail the factual basis for the Third Party Claim and to the extent known, the amount of the Third Party Claim) reasonably promptly after becoming aware of such Third Party Claim; provided, however, that failure to give
such notification will not affect the indemnification provided hereunder except to the extent the Indemnitor shall have been actually prejudiced as a result of such failure. 

          (b) If a Third Party Claim is made against an Indemnitee, the Indemnitor will be entitled, within [*] after receipt of written
notice from the Indemnitee of the commencement or assertion of any such Third Party Claim, to assume the defense thereof (at the expense of the Indemnitor) with counsel selected by the Indemnitor and reasonably satisfactory to the Indemnitee, for so
long as the Indemnitor is conducting a good faith and diligent defense. Should the Indemnitor so elect to assume the defense of a Third Party Claim:

               (i) the Indemnitor will not be liable to the Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee
in connection with the defense thereof; provided, however, that if under applicable standards of professional conduct a conflict of 

 - 22 - 

  

  

  

interest exists between the Indemnitor and the Indemnitee in respect of such claim, such Indemnitee shall have the right to employ separate counsel (which shall be reasonably satisfactory to the Indemnitor) to represent such
Indemnitee with respect to the matters as to which a conflict of interest exists and in that event the reasonable fees and expenses of such separate counsel shall be paid by such Indemnitor; and provided further, that the Indemnitor shall only be
responsible for the reasonable fees and expenses of one separate counsel for such Indemnitee;

               (ii) so long as the Indemnitor is conducting the defense of the Third Party Claim in accordance with Section 7.1 or 7.2, as the
case may be, the Indemnitee may retain separate co-counsel at its sole cost and expense and participate if reasonably practicable in the defense of the Third Party Claim; 

               (iii) the Indemnitor will promptly supply to the Indemnitee copies of all material correspondence and documents relating to or in
connection with such Third Party Claim and keep the Indemnitee informed of developments relating to or in connection with such Third Party Claim, as may be reasonably requested by the Indemnitee (including providing to the Indemnitee on reasonable
request updates and summaries as to the status thereof); and

               (iv) all Indemnitees shall reasonably cooperate with the Indemnitor in the defense thereof (such cooperation to be at the
expense, including reasonable legal fees and expenses, of the Indemnitor).

          (c) If the Indemnitor does not elect to assume control of the defense of any Third Party Claim within the [*] period set forth
above, or if such good faith and diligent defense is not being or ceases to be conducted by the Indemnitor, the Indemnitee shall have the right, at the expense of the Indemnitor, after [*] notice to the Indemnitor of its intent to do so, to
undertake the defense of the Third Party Claim for the account of the Indemnitor (with counsel selected by the Indemnitee), and to compromise or settle such Third Party Claim, exercising reasonable business judgment. 

          (d) If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee
will agree to any settlement, compromise, or discharge of such Third Party Claim that the Indemnitor may recommend that by its terms obligates the Indemnitor to pay the full amount of Losses (whether through settlement or otherwise) in connection
with such Third Party Claim and unconditionally and irrevocably releases the Indemnitee completely from all Liability in connection with such Third Party Claim; provided, however, that, without the Indemnitee’s prior written consent, the
Indemnitor shall not consent to any settlement, compromise, or discharge (including the consent to entry of any judgment), and the Indemnitee may refuse to agree to any such settlement, compromise, or discharge, that provides for injunctive or other
nonmonetary relief affecting the Indemnitee. If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee shall not (unless required by law) admit any liability with respect to, or
settle, compromise or discharge, such Third Party Claim without the Indemnitor’s prior written consent (which consent shall not be unreasonably withheld or delayed). 

 - 23 - 

  

  

  

     7.6 Losses That Are Not Third Party Claims.  Any claim on account of Losses which does not
involve a Third Party Claim shall be asserted by reasonably prompt written notice (stating in reasonable detail, the basis of such claim and a reasonable estimate of the amount thereof) given by the Indemnitee to the Indemnitor. For a period of [*]
from and after receipt of the written notice, the Parties shall attempt in good faith to resolve such claim for indemnification. If the Parties are unable to resolve such claim, the Indemnitee may thereafter pursue any and all remedies at its
disposal to enforce said indemnification claim. 

     7.7 Termination of Indemnification Obligations. The obligations of each Party to indemnify,
defend and hold harmless the other Party and other Indemnitees (a) pursuant to Sections 7.1(b) and 7.2(b) shall terminate when the applicable Survival Period expires pursuant to Section 4.4, and (b) pursuant to Sections 7.1(a), (c), (d) and (e), and
Sections 7.2(a), (c) and (d) shall survive until the earlier of the expiration of the applicable statute of limitations, if any, and the sixth (6th) anniversary of the Closing Date; provided, however, that such obligations to indemnify, defend, and
hold harmless shall not terminate with respect to any individual item as to which the Indemnitee shall have before the expiration of the Survival Period, made a claim by delivering a written notice (stating in reasonable detail the basis of such
claim and a reasonable estimate of the amount thereof) to the Indemnitor. 

     7.8 Other Matters.  In the event of payment in full by an Indemnitor to any Indemnitee in
connection with any Third Party Claim, such Indemnitor will be subrogated to and shall stand in the place of such Indemnitee as to any events or circumstances in respect of which such Indemnitee may have any right or claim relating to such Third
Party Claim against any claimant or plaintiff asserting such Third Party Claim or against any other Person.  Such Indemnitee will cooperate with such Indemnitor in a reasonable manner, and at the cost and expense of such Indemnitor, in prosecuting
any subrogated right or claim. 

     7.9 Other Limitations. 

          (a) For the avoidance of doubt and without limitation to the provisions of Articles 4 and 5, an Indemnitor shall have no
obligation to indemnify, defend and hold harmless an Indemnitee from and against any portion of Losses under Section 7.1 or Section 7.2 to the extent that such portion of such Losses results directly from any action taken by, or at the express
written request of, such Indemnitee. Neither Party nor any of its respective Affiliates shall have or be subject to any liability to the other Party, its Affiliates or any other Person resulting from the distribution to, or use of any information,
documents or materials made available to it by the other Party, including any information, documents or materials in any data rooms, management presentations or other form in expectation of the transactions contemplated hereby. 

          (b) No liability shall arise in respect of any breach of any representation, warranty, covenant or agreement herein to the extent
that liability for such breach occurs (or is increased) directly as a result of any retrospective application of a change in applicable law, or in accounting policies, procedures or practices, announced by a Governmental Authority or, if not
announced in advance of taking effect, taking effect, after the Closing Date, unless Shire or Duramed, as the case may be, knew of any such retrospective application of a change in applicable law, or in such accounting policies, procedures or
practices at the time of Closing. 

 - 24 - 

  

  

  

          (c) No Party shall be entitled to recover any Losses or other amounts due from the other Party pursuant to this Agreement by
retaining or setting off amounts (whether or not such amounts are liquidated or reduced to judgment) against any amounts due or to become due from such first Party to such second Party hereunder or under any Transaction Agreement or under any
document or instrument delivered pursuant hereto or thereto or in connection herewith or therewith. For the avoidance of doubt, the foregoing is without prejudice to any right of set-off expressly provided for in any Transaction Agreement, which
does not involve setting off amounts due under this Agreement. 

          (d) All amounts paid by Shire or Duramed under this Article 7 shall be treated for all purposes as adjustments to the Purchase
Price except to the extent such treatment is not permitted by applicable law. In the event that treatment as an adjustment to the Purchase Price is disputed by any taxing authority, the Party receiving notice of such dispute shall promptly notify
and consult with the other Party concerning resolution of such dispute. 

     7.10 Exclusive Remedy. Other than in the case of fraud, the indemnification provided to any
Person pursuant to this Article 7 shall be such Person’s sole remedy for  any claims arising hereunder, or otherwise in connection with or arising out of the transactions described herein, including any breach by any Party hereto of any
representation, warranty, or covenant contained in this Agreement, or in any certificate or document (to the extent such certificate or documents relate to matters covered by the representation, warranties, or covenants contained herein) required to
be delivered in connection herewith, provided that nothing herein shall limit the rights of either Party to seek and obtain injunctive relief to specifically enforce the other Party’s obligations. 

     7.11 Net Losses and Subrogation. 

          (a) Notwithstanding anything contained herein to the contrary, the amount of any Losses incurred or suffered by an Indemnitee
shall be calculated after giving effect to: (i) any insurance proceeds received by the Indemnitee (or any of its Affiliates) with respect to such Losses; (ii) any Tax benefit realized by the Indemnitee (or any of its Affiliates) arising from the
facts or circumstances giving rise to such Losses; and (iii) any recoveries obtained by the Indemnitee (or any of its Affiliates) from any other third party. Each Indemnitee shall exercise its reasonable efforts to obtain such proceeds, benefits and
recoveries, provided that the Indemnitee shall not be obligated to make such an insurance claim if the Indemnitee in its reasonable judgment believes that the cost of pursuing such an insurance claim together with any corresponding increase in
insurance premiums or other chargebacks to the Indemnitee, as the case may be, would exceed the value of the claim for which the Indemnitee is seeking indemnification. If any such proceeds, benefits or recoveries are received by an Indemnitee (or
any of its Affiliates) with respect to any Losses after the Indemnitee (or any Affiliate) has received the benefit of any indemnification hereunder with respect thereto, the Indemnitee (or such Affiliate) shall pay to the Indemnitor the amount of
such proceeds, benefits or recoveries (up to the amount of the Indemnitor’s payment). 

          (b) Upon making any payment to an Indemnitee in respect of any Losses, the Indemnitor will, to the extent of such payment, be
subrogated to all rights of the Indemnitee (and its Affiliates) against any third party in respect of the Losses to which such payment relates. Such 

 - 25 - 

  

  

  

Indemnitee (and its Affiliates) and Indemnitor will execute upon request all instruments reasonably necessary to evidence or further perfect such subrogation rights. 

ARTICLE 8

TERMINATION 

     8.1 Termination Prior to Closing. This Agreement may be terminated at any time prior to Closing:

          (a) by mutual written consent of Duramed and Shire; 

          (b) by Duramed or Shire in the event that any competent Governmental Authority indicates its intention to initiate a judicial or
administrative action to obtain an order, decree or ruling to restrain, enjoin, or otherwise prohibit the transactions contemplated by this Agreement, and such order, decree, ruling, or other action shall have become final and non-appealable; or

          (c) by a Party in the event that the other Party (the “Defaulting Party”) shall have breached, or failed to comply with, any of such Defaulting Party’s obligations under this Agreement, or any representation or warranty made by the Defaulting Party shall have been incorrect in any material
respects when made; or 

          (d) by either Duramed or Shire if the Closing is not consummated pursuant to the terms of this Agreement prior to December 31,
2006, provided that the right to terminate the Agreement under this Section 8.1 (c) shall not be available to a Party hereto if such Party has failed to perform in all material respects its obligation under this Agreement and such failure has been
the cause of, or results in, the failure of the Closing to occur on or before such date.

     8.2 Effect of Termination Prior to Closing.  In the event of termination of this Agreement as
provided in Section 8.1, this Agreement shall forthwith become void and there shall be no liability on the part of either Party hereto except (a) as set forth in Section 11.1, and (b) nothing herein shall relieve either Party from Liability for any
breach of this Agreement prior to such termination. 

ARTICLE 9 

PATENT PROSECUTION, MAINTENANCE AND ENFORCEMENT 

     9.1 Discretionary Duty to Maintain.  Shire may, at its sole discretion and cost, maintain the
Licensed Patents. 

     9.2 Abandonment of Maintenance by Shire.  Shire shall notify Duramed in the event it decides at
any time to discontinue the maintenance of any Licensed Patent.  Such notification shall be given at least [*] prior to the date on which such patent will become abandoned. Duramed shall then have the option, exercisable upon written notification to
Shire, to assume full responsibility, at its discretion and sole cost, for prosecution of the affected maintenance of such patent. In the event Duramed exercises such option, such Licensed Patent shall be assigned to Duramed. Shire shall provide all
assistance reasonably necessary to assign to the Duramed all rights, interests and titles of such Licensed Patent. 

 - 26 - 

  

     9.3 Patent Marking.  Duramed and its sublicensees and Affiliates shall mark all Products made
under this Agreement with a notice in accordance with 35 U.S.C. §287. 

     9.4 Suits for Infringement of the Licensed Patents. If Shire or Duramed becomes aware of
infringement of any patent included in the Licensed Patents by a third party, such Party shall promptly notify the other Party in writing to that effect. If, prior to the expiration of [*] from said notice, Shire has not obtained a discontinuance of
such infringement or brought suit in such country against the third party infringer and such infringement is relevant in a material respect to a Product or the Purchased Assets, then Duramed shall have the right to bring suit in such country against
such infringer and join Shire as a party. The foregoing shall not preclude the Parties from jointly seeking such discontinuance or bringing suit and, in any event, each Party will cooperate with the other in any suit and will have the right to
consult with the other and be represented by its own counsel at its own expense. Prior to disposition of any moneys recovered, the expenses of the Parties in bringing suit shall be reimbursed out of the moneys recovered, with the Party bringing the
suit being reimbursed first, then fifty percent (50%) of the remainder, if any, of moneys recovered by either Party upon final judgment or settlement of any infringement suit shall be retained by the Party bringing the suit, and fifty percent (50%)
shall be paid to the other Party; provided, however, that (a) if Shire has not obtained a discontinuance of such infringement or brought suit against the third party infringer and Duramed determines to bring such suit, Duramed shall be entitled to
one hundred percent (100%) of such remainder, and (b) in no event shall any Party who has not voluntarily joined in the relevant action be entitled to recovery of any damages hereunder. No settlement by a Party bringing a suit shall diminish the
rights or interests of the other Party without the other Party’s written consent. 

ARTICLE 10 

DISPUTE RESOLUTION 

     10.1 Disputes. The Parties hereby agree that all disputes arising under this Agreement shall be
referred to a senior executive of Duramed and a senior executive of Shire (the “Representatives”). If any such matter has not been resolved within [*] of such referral to the
Representatives either Party may invoke the provisions of Section 10.2 for such dispute.  No dispute resolution procedure set forth in this Agreement shall be construed as an agreement to arbitrate under any federal or state arbitration Law,
including the Federal Arbitration Act, and shall not deprive a court of competent jurisdiction from resolving any dispute arising under, or related to, this Agreement. 

     10.2 Litigation. Any dispute that is not resolved as provided in the preceding Section 10.1,
whether before or after termination of this Agreement, may be submitted by either Party only to any court of competent jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of New York.  The
Parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in New York, NY and waive any objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby and further agree not to commence any such action, suit or proceeding except in any such court.

     10.3 Injunctive Relief. Notwithstanding anything to the contrary in this Agreement, either Party
shall have the right to seek temporary injunctive relief in any court of competent 

 - 27 - 

jurisdiction as may be available to such Party under the Laws and rules applicable in such jurisdiction with respect to any matters arising out of the other Party’s performance of its obligations under this Agreement.

ARTICLE 11 

GENERAL PROVISIONS 

     11.1 Payment of Transaction Expenses. All legal fees and other expenses incurred on behalf of
Shire in connection with the negotiation of this Agreement and the consummation of the transactions contemplated herein will be borne by Shire, whether or not the Closing shall have occurred. All legal fees and other expenses incurred on behalf of
Duramed in connection with the negotiation of this Agreement and the consummation of the transactions contemplated herein will be borne by Duramed, whether or not the Closing shall have occurred. 

     11.2 Access to Information Post-Closing.  After the Closing, Duramed agrees to cooperate with
Shire and to grant to Shire and its employees, attorneys, accountants, officers, representatives, and agents, during normal business hours and upon at least [*] advance notice, reasonable access to Duramed’s management personnel and to the records
relating to the Product (including the Product Registrations) and to permit copying at Shire’s expense or, where reasonably necessary, to loan original documents relating to the Purchased Assets during the period the Purchased Assets were owned
by Shire for the sole purposes of (a) any financial reporting or tax matters (including any financial and tax audits, tax contests, tax examination, preparation of any Shire’s tax returns or financial records) relating to the Product, (b) any
claims or litigation involving Shire and the Purchased Assets relating to the Product, (c) any investigation of Shire being conducted by any federal, state, or local governmental authority relating to the Product, (d) any matter relating to any
indemnification or representation or warranty or any other term of this Agreement, or (e) any similar or related matter. Duramed shall maintain, to the extent required by applicable law, but in any event for not less than six (6) years, all such
records and documents in the United States of America and shall not destroy or dispose of any such records and documents prior to the end of such required or six (6) year period without the prior written consent of Shire. 

     11.3 Notices. All notices or other communications that are required or permitted under this
Agreement shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses
below. Any such communication shall be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal delivery or overnight courier as provided in this
Agreement), and (b) on the second Business Day after dispatch, if sent by internationally-recognized overnight courier.  Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

  	For Duramed:	Duramed Pharmaceuticals, Inc. 

400 Chestnut Ridge Road

Woodcliff Lake, NJ 07677

Phone: 201-930-3300

Fax: 201-930-3330
	 	 

 - 28 - 

 

  	 	Attention: President
	 	 
	with a copy to:	Barr Pharmaceuticals, Inc.

400 Chestnut Ridge Road

Woodcliff Lake, NJ 07677

Phone: 201-930-3300

Fax: 888-843-0563

Attention: General Counsel
	 	 
	For Shire:	Shire LLC 

      725 Chesterbrook Boulevard

Wayne, Pennsylvania 19087-5637

Fax: (484) 595-8163 

Attention: General Counsel 
	 	 
	with a copy to: 
	Morgan, Lewis & Bockius LLP

502 Carnegie Center 

Princeton, NJ 08540 

Fax: (609) 919-6701

Attention: Randall B. Sunberg 

     11.4 Entire Agreement; Amendment.  This Agreement, the Pharmacovigilance Agreement, the
Trademark License Agreement and the Supply Agreement, including the exhibits and schedules attached hereto and thereto (each of which is herby and thereby incorporated herin and therein by reference) (collectively, the “Transaction Agreements”), sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the
Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties, which shall continue to govern the obligations of the Parties with respect to information disclosed thereunder with respect to periods prior to
the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein.  No subsequent alteration, amendment, change
or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance of doubt, the Parties agree that all covenants, promises, agreements, warranties,
representations, conditions, and understandings set forth herein are made and deemed effective as of the Effective Date, and that the execution of this Agreement shall not constitute a waiver of any right or claim of either Party as of the Effective
Date. 

     11.5 Assignment. Neither this Agreement nor any of the rights or obligations of the Parties
hereunder may be assigned by either Party without the prior written consent of the other Party; provided, however, that (a) Shire or Duramed may assign this Agreement to an Affiliate, and (b) following the Closing, either Party shall be entitled,
without the prior written consent of the other, to assign its rights and obligations hereunder in connection with a merger or similar reorganization or the sale or all or substantially all of its assets. Any attempted assignment or delegation in
contravention hereof shall be null and void.  Subject to the foregoing, this 

 - 29 - 

Agreement and all rights and powers granted and obligations created hereby will bind and inure to the benefit of the Parties and their respective successors and assigns. 

     11.6 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

     11.7 Independent Parties.  In making and performing this Agreement, Shire and Duramed shall act
at all times as independent contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an agency, partnership, limited partnership, joint venture or employer and employee relationship between Shire
and Duramed and this Agreement shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. 

     11.8 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter
for a particular period of time. 

     11.9 Severability. If any one or more of the provisions of this Agreement is held to be invalid
or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make
a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

     11.10 Counterparts. This Agreement may be executed in counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument.  Signatures provided by facsimile transmission shall be deemed to be original signatures. 

     11.11 No Third Party Beneficiaries.  No Person other than Shire and Duramed and permitted
assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any term of this Agreement. 

     11.12 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

     11.13 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against either Party. 

     11.14 Public Disclosure.  No announcement or other disclosure, public or otherwise, concerning
the financial or other terms of this Agreement shall be made, either directly or indirectly, by any Party without first obtaining the written approval of the other Party and agreement upon the nature and text of such announcement or disclosure, such
approval and agreement not to be unreasonably withheld or delayed. Notwithstanding the foregoing: 

 - 30 - 

          (a) Each Party agrees that disclosures may need to be made to the Securities and Exchange Commission (“SEC”) and other Regulatory Authorities and each Party agrees that it shall reasonably cooperate with the other with respect to all disclosures regarding this Agreement to such Regulatory Authorities.
In addition, the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement with respect to any SEC filings, and each Party shall use reasonable efforts to seek confidential treatment
for such terms; provided, however, that each Party shall ultimately retain control over what information to disclose to the SEC or any other such agencies.

          (b) The Parties shall be free to publicly disclose information contained in any materials that have been previously approved for
disclosure by the other Party, without further approvals from the other Party hereunder, to the extent there have been no material additions or changes thereto. 

     11.15 Bulk Sales Laws. The Parties hereby waive compliance with any UCC bulk sales or comparable
statutory provisions of each applicable jurisdiction. 

[Remainder of page intentionally left blank] 

 - 31 - 

      IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed as of the date first above written 

  	SHIRE PLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  

  	SHIRE LLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  

  	DURAMED PHARMACEUTICALS,
      INC.
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

[Signature Page to Product Acquisition and License Agreement] 

EXHIBIT A 

ADDERALL® IR PHARMACOVIGILANCE AGREEMENT

 

DATE:           As of August 14, 2006 

PARTIES: 

	(1)	SHIRE DEVELOPMENT, INC., having
          its place of business at 725 Chesterbrook Boulevard, Wayne, PA 19087-5637
    (“Shire”) 

	 	 
	(2)	DURAMED PHARMACEUTICALS,
            INC., having its place of business
    at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”). 

	 	 

RECITALS 

	(A)	With effect from August 14, 2006, Shire and
        Duramed entered into a Product Acquisition and License Agreement (the “Acquisition
        and License Agreement”) with
        respect to the promotion of the Product (as defined below) in the Territory
    (as defined below).
	 	 
	(B)	Pursuant to the terms of the Acquisition and
        License Agreement, the Parties are obligated to enter into this Agreement
        to provide for the Parties’ respective obligations in relation to
    medical information and pharmacovigilance services for the Product.
	 	 
	(C)	In consideration of the above recitals and
        the mutual promises, covenants and obligations as set out in this Agreement,
        and for other good and valuable consideration, the receipt and sufficiency
        of which is acknowledged, and intending to be legally bound, the Parties
    agree as follows.
	 	 

OPERATIVE PROVISIONS 

	
1       	
INTERPRETATION 
	 
	
1.1            	
In this Agreement:    
	 
	 	
“Acquisition and License Agreement” has the meaning given to it in Recital (A).  
	 
	 	
“Adverse Event” means any untoward medical occurrence in a patient or clinical investigator subject administered the Product and which does not necessarily have a causal relationship with
this treatment for which the Product is used. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the       
	 

	 	use of a medicinal (investigational)
          product, whether or not related to the Product. A pre-existing condition
          that worsened in severity after administration of the Product would
          be considered an adverse event. 

       “Awareness Date” or “Clock
            Date” means the
            date on which a Party first becomes aware of an Adverse Event or
            a Suspected Adverse Drug Reaction and, in relation to a third party
            Representative of a Party, such as clinical research organizations
            or distributors, that have contractual and/or regulatory obligations
            to report Adverse Events or a Suspected Adverse Drug Reaction to
            that Party, the date on which such third parties first become aware
            of that Adverse Event or a Suspected Adverse Drug Reaction. For both
            Parties this is considered day zero. 

       “Business Day” means
          a day (other than a Saturday or Sunday) on which banks in the United
          States are open for business. 

       “Confidential Information” means
          all secret, confidential or proprietary information or data, whether
          provided in written, oral, graphic, video, computer, electronic or
          other form, provided pursuant to this Agreement or generated pursuant
          to this Agreement.

       “Effective Date” has
          the meaning given to it in the Acquisition and License Agreement. 

       “Marketing Authorization” means
          any authorization granted by a Regulatory Authority required to permit
          the commercial marketing and sale of the Product in the Territory. 

       “Medical Information” means
          information about the Product including, but not limited to, clinical
          and technical matters such as therapeutic uses for both the licensed
          and unlicensed indications, drug interactions, drug-disease information,
          Adverse Events, product stability and other product characteristics. 

       “Periodic Safety Report” means
          a safety report generated at set times and in accordance with FDA guidelines
          for the purpose of demonstrating the current risk/benefit analysis
          of the Product according to present knowledge and produced to provide
          a historical perspective on the safety issues surrounding the Product. 

       “Product” has
          the meaning given to it in the Acquisition and License Agreement. 

       “Reference Safety Information” means the
          recognized Adverse Reactions to the Product contained in all or any
          one of Shire’s Developmental
          Core Safety Information (DCSI) in an investigator’s brochure,
          Shire’s Company Core Safety Information (CCSI) in a marketed product
          Company Core Data Sheet (CCDS) and Shire’s official local product
    labeling (including the local Summary of Product Characteristics (SPC)).

	 	 

	 	“Regulatory
            Approval” means the granting
            of all necessary regulatory and governmental approvals by a regulatory
            or other governmental body required to market and sell the Product
            in the Territory. 

       “Regulatory Authority” means
          any competent regulatory authority or other governmental body responsible
          for granting any Regulatory Approval. 

       “Representatives” has
          the meaning set forth in Section 16.1.

       “Safety Issue” means
          any event, report, data or information, which could cause a re-evaluation
          of the safety of the Product including, but not limited to, Suspected
          Adverse Drug Reaction and Unexpected Suspected Adverse Drug Reaction. 

       “Serious Adverse Event” means
          any Adverse Event in relation to any dose of the administered Product
    that:
    
	 	 

	 	A.	results in death;
	 	 	 
	 	B.	is life threatening;
	 	 	 
	 	C.	requires in-patient hospitalization
    or prolongation of existing hospitalization;
	 	 	 
	 	D.	results in persistent or significant disability
    or incapacity; or
	 	 	 
	 	E.	is a congenital anomaly or birth defect.
	 	 	 
	 	Medical and scientific judgment
        should be exercised in deciding whether expedited reporting for the Product
        is appropriate in other situations, such as medically important events
        that may not be immediately life-threatening or result in death or hospitalization
        but may jeopardize the patient or may require intervention to prevent
        one of the other outcomes listed above. These should also usually be
    considered as Serious Adverse Events.
	 	 	 
	 	“Serious Suspected Adverse
          Drug Reaction” means any
          Suspected Adverse Drug Reaction in relation to any dose of the administered
    Product that:
	 	 	 
	 	A.	results in death;
	 	 	 
	 	B.	is life threatening;
	 	 	 
	 	C.	requires in-patient hospitalization or prolongation
        of existing hospitalization;
	 	 	 
	 	D.	results in persistent or significant disability
        or incapacity; or
	 	 	 
	 	E.	is a congenital anomaly or birth defect.
	 	 	 

	 	Medical and scientific judgment
          should be exercised in deciding whether expedited reporting for the
          Product is appropriate in other situations, such as medically important
          events that may not be immediately life-threatening or result in death
          or hospitalization but may jeopardize the patient or may require intervention
          to prevent one of the other outcomes listed above. These should also
          usually be considered as Serious Suspected Adverse Drug Reactions. 

       “Signal” means
          an unexpected observation of an event in relation to treatment with
          the Product which deviates so much from expectations that it calls
          for immediate and greater attention, including (but not limited to)
          unlabelled Suspected Adverse Drug Reactions, increased frequency or
          severity of labeled Suspected Adverse Drug Reactions and any change
          in the risk/benefit/profile of the Product. 

       “Spontaneous Report” means
          a communication from an individual (e.g., a health care professional,
          consumer) to a company or regulatory authority that describes a Suspected
          Adverse Drug Reaction or medication error. It does not include cases
          identified from information solicited by the applicant or contractor,
          such as individual case safety reports or findings derived from a study,
          company-sponsored patient support program, disease management program,
          patient registry, including pregnancy registries, or any organized
          data collection scheme. It also does not include information compiled
          in support of class action lawsuits. 

       “Suspected Adverse
            Drug Reaction” means a
            noxious and unintended response to any dose of the Product for which
            there is a reasonable possibility that the Product caused the response.
            In this definition, the phrase “a reasonable possibility” means
            that the relationship cannot be ruled out. 

       “Territory” has
          the meaning given to it in the Acquisition and License Agreement. 

       “Unexpected
            Suspected Adverse Drug Reaction” means
            any Suspected Adverse Drug Reaction that is not included in the current
            U.S. labeling for the Product. 

        “Valid Safety Reports” means
          the minimum information required for expedited reporting which should
          at least include all of the following:
    
	 	 

	 	A.	an identifiable patient; 
	 	 	 
	 	B.	a suspected medicinal product
    or therapeutic device;
	 	 	 
	 	C.	an identifiable reporter; and
	 	 	 
	 	D.	a Suspected Adverse Drug Reaction or an Adverse
    Event.
	 	 	 

 

	 	
“Warm Transfer” means the direct connection of a patient, and such patient’s name and contact information, to an appropriate party following receipt of that patient’s initial
telephone call.  
	 
	
1.2            	
In this Agreement, unless the context otherwise requires:     
	 

	 	
A.             	
references to “persons” includes individuals, bodies corporate (wherever incorporated), unincorporated associations and partnerships;       
	 
	 	
B.             	
reference to a “Party” is to a Party to this Agreement and “Parties” is to both of them;  
	 
	 	
C.             	
the headings are inserted for convenience only and do not affect the construction of the Agreement;   
	 
	 	
D.             	
references to one gender includes both genders; and   
	 
	 	
E.             	
any reference to an enactment or statutory provision is a reference to it as it may have been, or may from time to time be amended, modified, consolidated or re-enacted.     
	 

	
1.3            	
The Schedules comprise part of and shall be construed in accordance with the terms of this Agreement. In the event of any inconsistency between the Schedules and the terms of this Agreement, the terms of this Agreement shall
prevail. 
	 
	
1.4            	
Terms used in this Agreement, which are not otherwise defined within the Agreement or the Acquisition and License Agreement shall have the meaning given to them in accordance with FDA Regulations or Guidelines and Shire Standard
Operating Procedures (SOPs). In the event of any conflict between Shire’s SOP’s and FDA guidelines, FDA guidelines shall prevail.      
	 
	
2       	
PURPOSE        
	 
	
2.1            	
In consideration of the mutual obligations contained in this Agreement, the Parties have agreed to provide for the procedures relating to the exchange of safety and pharmacovigilance information for the Product between Shire and
Duramed in order to comply with worldwide regulatory reporting requirements for the Product.     
	 
	
2.2            	
As between Shire and Duramed, Shire shall have the following responsibilities:        
	 

	 	
a.             	
Shire shall handle all telephone calls and other communications that it may receive regarding the items in Section 3.1, including Adverse Events and/or Suspected Adverse Drug Reactions in accordance with the terms of this
Agreement. Except to the extent required by law, responding to private third parties regarding complaints, notices and inquiries as to Adverse Events, Suspected Adverse Drug Reactions, or data, documents      
	 

	 	 	
or reports related to any of them. Shire shall process all Adverse Events and/or Suspected Adverse Drug Reactions and prepare the data, documents or reports related to them in a final format that is suitable for Duramed to submit
to the Regulatory Authority.     
	 
	 	
b.             	
Shire shall inform Duramed within three (3) Business Days of any communications of any kind received by Shire from any Regulatory Authority involving safety issues in relation to the Product outside of the Territory, although the
Parties acknowledge that the Product is not sold outside of the Territory. To the extent that Shire is required by law to respond, Shire shall, if there is time to do so, submit its response to Duramed before submitting it to the Regulatory
Authority. Duramed will provide Shire access to Duramed’s safety data required to respond to a Regulatory Authority request and written approval of and/or comments on such response within a timeframe sufficient to meet any deadlines imposed by
the requesting Regulatory Authority. Shire shall, to the extent permitted by law, cooperate fully with Duramed and keep Duramed fully informed as to Regulatory Agency requests received by Shire within the scope of this paragraph and Shire’s
responses.       
	 
	 	
c.             	
Shire shall, within three (3) Business Days inform Duramed in the event that, at any time, Shire identifies potential safety issues, including calls or communications that Shire receives directly from, private or government, third
party in relation to the Product and will provide such further assistance, as Shire and Duramed shall agree.     
	 

	
2.3            	
Except as specifically set forth in paragraph 2.2 above, Duramed shall have following responsibilities:       
	 

	 	
a.             	
Duramed shall refer all drug safety and pharmacovigilance related queries from healthcare providers or their staff, or any third party in relation to the Product. The Shire contact to receive this information is identified in
Section 11.1 of this agreement as the “Appointed Medical Information Contact”. 
	 
	 	
b.             	
Duramed shall ensure compliance and correspond with the U.S. Regulatory Authority on reporting requirements related to Adverse Events and Suspected Adverse Drug Reactions, including but not limited to FDA requirements, submission
of Periodic Safety Reports, 15-day safety reports and MedWatch reports. Duramed reserves the right to exercise final control over its submissions and response to Regulatory Agency communications directed to, and requiring a response from,
Duramed. 
	 
	 	
c.             	
Duramed shall ensure that there is a mechanism available during normal business hours to receive notices regarding any safety issue under this Agreement;     
	 

	 	
d.             	
Duramed shall handle all telephone calls and other communications that it may receive regarding Adverse Events and/or Suspected Adverse Drug Reactions in accordance with the terms of this Agreement;        
	 
	 	
e.             	
Duramed shall inform Shire within three (3) Business Days of any communications of any kind received by Duramed from any Regulatory Authority involving safety issues in relation to the Product in the Territory. To the extent that
Duramed is required by law to respond, Duramed shall, if there is time to do so, submit its response to Shire before submitting it to the Regulatory Authority. Shire will provide Duramed with safety data required to respond to a Regulatory Authority
request and written approval of and/or comments on such response within a timeframe sufficient to meet any deadlines imposed by the requesting Regulatory Authority. Duramed reserves the right to exercise final control over its response to Regulatory
Agency communications directed to, and requiring a response from, Duramed, to the extent required by Duramed, in its sole judgment, in order to maintain Duramed’s compliance with all applicable legal requirements. Duramed shall, to the extent
permitted by law, cooperate fully with Shire and keep Shire fully informed as to Regulatory Agency requests received by Duramed within the scope of this paragraph and Duramed responses.        
	 
	 	
f.             	
Duramed shall within three (3) Business Days inform Shire in the event that, at any time, Duramed identifies potential safety issues in relation to the Product and will provide such further assistance, as Shire and Duramed shall
agree.   
	 

	
3        	
SCOPE  
	 
	
3.1            	
This Agreement covers:        
	 

	 	
a.             	
all Spontaneous Reports of Adverse Events and Suspected Adverse Drug Reactions in relation to the Product;    
	 
	 	
b.             	
all Serious Suspected Adverse Drug Reactions arising from post- marketing surveillance with the Product;      
	 
	 	
c.             	
all information required for periodic reporting in relation to the Product;   
	 
	 	
d.             	
all other information as required by Regulatory Authorities for the Product; and      
	 
	 	
e.             	
the provision of Medical Information to support third party inquiries.        
	 

	
4       	
LANGUAGE OF ALL EXCHANGE AND TERMINOLOGY       
	 
	
4.1            	
The language of all information exchanged pursuant to this Agreement, including reports to Regulatory Authorities, shall (unless specifically stated otherwise) be in English, or if any other language, accompanied by a translation
into English. In the event of any conflict between the English text and the text in any other language, the English text shall prevail.  
	 
	
5       	
CONTACT PERSONNEL AND METHODS FOR ADVERSE EVENT TRANSMISSION   
	 
	
5.1            	
The names and details of contact personnel for Shire and Duramed are detailed in Schedule 1. 
	 
	
5.2            	
Any changes in names or details of any of the contact personnel for a Party in relation to the Product must be notified by that Party to the other Party in writing to the address set out in Schedule 1 as soon as reasonably
practicable after the change occurs.     
	 
	
5.3            	
Any notice given under this Agreement shall be in writing and (i) personally delivered or (ii) sent by fax or (iii) e-mail to the address of the other Party as set out in Schedule 1 (or such other address as may have been notified
in writing from time to time by a Party to the other Party) and any such notice shall be deemed to have been served at the time of delivery (if personally delivered) or upon receipt of confirmation of transmission by the sender’s fax machine
(if sent by fax) and in the case of email upon receipt of delivery confirmation by the sender’s computer (if sent by e-mail).       
	 
	
6       	
SAFETY DATABASE        
	 
	
6.1            	
The safety information generated pursuant to this Agreement shall be added to the safety database for the Product and shall be held and maintained by Shire and shall be the central repository for all drug safety information
received worldwide for the Product.      
	 
	
6.2            	
The safety database shall be used for all drug safety and pharmacovigilance regulatory responses and purposes for the Product.        
	 
	
6.3            	
Shire shall provide all safety information reasonably requested by Duramed from Shire’s safety database to provide a response to answer any drug safety and pharmacovigilance related queries in relation to the Product and to
meet all regulatory requirements. Shire will provide the information within a reasonable timeline according to the urgency of request. Upon termination of this Agreement, Shire shall transfer the safety database for the Product to Duramed as soon as
reasonably practicable.  
	 

	
6.4            	
With the exception of FDA exchange, which may be implemented at some future point in time, and except as otherwise set forth herein, Duramed shall not have direct access to the safety database for security and data privacy
reasons. 
	 
	
7       	
EXCHANGE OF ADVERSE EVENT AND SUSPECTED ADVERSE DRUG REACTION INFORMATION      
	 
	
7.1            	
All notification and response periods referred to in this Agreement (unless otherwise specified) will be in calendar days in accordance with FDA regulations. 
	 
	
7.2            	
The relevant period for any notification or response for either Party (including their Representatives) will commence on the Awareness Date.  
	 
	
7.3            	
Duramed will attempt to Warm Transfer all calls related to the Product covered in Section 3.1 including Adverse Event and Suspected Adverse Drug Reactions calls to Shire at (888) 300-6414 at the time of receipt. Prior to
transferring the call, Duramed staff will obtain a name and contact number. If the Warm Transfer is not successful, Duramed will fax the caller’s name and contact information to Shire’s Pharmacovigilance Department at (866) 557-4473 within
two Business Days of receipt. Shire will be responsible for the intake of the Adverse Events and Suspected Adverse Drug Reactions and preparing MedWatch reports for any Adverse Reaction occurring. All written Adverse Events and Suspected Adverse
Drug Reactions received by Duramed will be forwarded to Shire within two Business Days of receipt. If Shire directly receives calls related to the Product that is an Adverse Event or Suspected Adverse Drug Reactions, Shire will inform Duramed’s
“Appointed Medical Information Contact” within two Business Days of receipt    
	 
	
7.4            	
Shire shall ensure that there is a mechanism available 24-hour/7 days per week to receive notices for any safety issue under this Agreement.  
	 
	
7.5            	
Upon receipt of any report from Duramed under Section 7.3, Shire will notify Duramed of receipt of the report as soon as possible; however in no event longer than two Business Days thereafter. Any report from is considered
transmitted only after an acknowledgement of receipt is received from Shire.     
	 
	
7.6            	
Shire will provide final written reports to Duramed by day 12 for an expedited (15 day) report and at least 5 days prior the periodic due date in order for Duramed’s submissions to meet all 15-day safety report and
periodic/PSUR regulated timelines.       
	 
	
7.7            	
No later than the 15th day of each month, Shire will provide a line listing including reported term, manufacturing number, demographics and a narrative for each report
received from Duramed the previous month.        
	 

	 	
Reports received from Literature Reviews        
	 
	
7.8            	
Shire will be responsible for monitoring the worldwide scientific literature to meet global regulatory reporting requirements and for monitoring drug safety for the Product. Once an Adverse Event or a Suspected Adverse Drug
Reaction has been identified, Shire will assess it according to seriousness and where appropriate report it as a literature report quoting the reference for the article for onward reporting by Duramed to the appropriate Regulatory Authority in the
Territory.       
	 
	 	
Management of Follow up information     
	 
	 	
Follow up of initial reports    
	 
	
7.9            	
Shire shall be responsible for all follow-up activities for any Adverse Events occurring in the Territory.    
	 
	
7.10           	
Duramed shall notify Shire of any additional information it reasonably requires regarding an Adverse Event occurring in the Territory that Shire has notified it of pursuant to this Section 7 and Shire will use its reasonable
endeavors to obtain the additional information within two (2) Business Days. Shire shall notify Duramed of the outcome of the additional information obtained by Shire for submission to the Regulatory Authority, if necessary. 
	 
	
8       	
ASSESSMENT OF ADVERSE EVENTS   
	 
	 	
Assessment of Listedness (Expectedness)       
	 
	
8.1            	
All Adverse Events and Suspected Adverse Drug Reactions will be reported to Shire irrespective of any assessment regarding listedness (expectedness). 
	 
	
8.2            	
Shire shall be responsible for assessing all Adverse
Events and Suspected Adverse Drug Reactions in the Territory and shall determine
if any report is required to be made to the Regulatory Authorities in accordance
with Section 10. Pursuant to Section 2.3, . Duramed reserves the right to exercise
final control over its submissions and response to the Regulatory Authority communications
directed to, and requiring a response from, Duramed.     
	 
	
9       	
SAFETY ISSUES/SIGNALS AND REGULATORY INQUIRIES INVOLVING SAFETY ISSUES 
	 
	
9.1            	
Shire shall, within 24 hours of it becoming aware, notify Duramed of any significant safety issues other than individual ADRs referenced in Section 7 in relation to the Product. Shire and Duramed shall discuss in good faith how to
deal with any such significant safety issues and shall co-operate with the reasonable requests of the other Party in relation to such issues. Significant safety issues relating to the Product may occur as a result of a request from a Regulatory
Authority; potential changes in the risk/benefit of the Product; Product quality 
	 

	 	
issues that may have a clinical impact such as Product contamination or deterioration; external influences such as media or literature and ongoing safety surveillance.       
	 
	
9.2            	
Shire and Duramed agree to reasonably collaborate on any labeling changes that are safety related. Duramed is responsible for the maintenance of labeling changes to the Product and will notify Shire of all safety related
changes. 
	 
	
9.3            	
Should Shire become aware of any potential safety signal, Shire shall promptly notify Duramed.        
	 
	
10              	
REGULATORY AUTHORITY INTERACTION       
	 
	 	
Expedited Reporting Responsibilities   
	 
	
10.1           	
Subject to Sections 7.6 to 7.10, Shire will be responsible for assessing the “reportability” and submitting reports of Serious Suspected Adverse Drug Reactions for the Product (according to current FDA regulations) to
Duramed to be submitted to the Regulatory Authority.     
	 
	
10.2           	
Either Party shall permit the other Party or its representatives to inspect, review and audit of its operations concerning Pharmacovigilance and adverse event collection and reporting in line with FDA regulations, in accordance
with the terms of this Agreement. Any information obtained through such inspections, reviews and audits shall be treated as confidential information of the audited Party. Such audits,
reviews and inspections shall be conducted during normal business hours, upon reasonable notice, and no more than once per year (other than in an emergency situation), and in a manner that does not unreasonably interfere with ongoing operations. The
date and time of the audit will be determined and agreed on by both parties, but shall be scheduled to occur within four (4) weeks of the audit request, unless otherwise agreed. It is understood that Regulatory Agency inspections of each
Party’s facilities occur periodically and audits will not be conducted in such a way as to conflict with those inspections. 
	 
	 	
Periodic Reporting       
	 
	
10.3           	
Shire shall prepare and submit to Duramed pursuant to Section 7.6 the Periodic Safety Report for the Product in the Territory, according to its internal standard operating procedures and in the format as detailed in 21CFR 314. The
periodicity of the Periodic Safety Report will be according to the International Birth Date of the Product.      
	 
	
10.4           	
Prior to regulatory submission, there should be discussion between the Parties to promote harmonization and co-ordination if any safety signals or proposed amendments to the Reference Safety Information are recommended. However,
this must be achieved within the applicable regulatory timeframe.        
	 

	11	MEDICAL INFORMATION/QUESTIONS
	 	 
	11.1	Duramed shall transfer all Medical Information
        inquiries received from third Parties in the Territory regarding the
        Product to the person or persons specified in Schedule 1 (“Appointed
        Medical Information Contact”)
    .
	 	 
	11.2	If the inquiry is a request for information
        in connection with a report of an Adverse Event or Suspected Adverse
        Drug Reaction, Duramed shall confirm to the Appointed Medical Information
        Contact that the report has been notified to Shire in accordance with
    Sections 7.3 and 7.6.
	 	 
	12	AMENDMENTS TO THIS SAFETY AGREEMENT
	 	 
	12.1	This Safety Agreement becomes effective on
    the Effective Date.
	 	 
	12.2	If a Party becomes aware of any change of
        law or regulation which affects any of the matters the subject of this
        Agreement, it shall notify the other Party of any such change. The Parties
        shall promptly meet and discuss any such changes and negotiate in good
        faith any amendments to this Agreement, which either Party honestly believes
    are necessary or desirable as a result of such changes.
	 	 
	12.3	Revision of attachments (Schedules) will not
        require that this Safety Agreement be re-issued and signed off, but shall
    require the written agreement of both Parties. 
	 	 
	12.4	Changes in company personnel and methods of
        communication must be conveyed immediately to both Parties, to ensure
    the correct and timely flow of information. 
	 	 
	13	CONFIDENTIALITY 

	 	 
	13.1    	Each Party agrees and undertakes that it
          will treat and keep confidential all Confidential Information, which
    may become known, to that Party from the other Party. 

	 	 
	14	DURATION AND TERMINATION 

	 	 
	14.1	This Agreement commences on the Effective
        Date and shall continue in force until terminated by either Party in
    accordance with Section Error!! Reference source not found.. .
	 	 
	14.2	[*]
	 	 
	15	CONSEQUENCES OF TERMINATION 

	 	 
	15.1	Articles 13, 15, 16 and 17 shall survive the
    termination of this Agreement. 
	 	 

	
15.3           	
The termination or expiration of this Agreement shall not release either of the Parties from any liability which at the time of termination or expiration has already accrued to the other Party, nor affect in any way the survival
of any other right, duty or obligation of the Parties which is expressly stated elsewhere in this Agreement to survive such termination or expiration.   
	 
	
16              	
RESOLVING DISPUTES     
	 
	
16.1           	
The Parties hereby agree that all disputes arising under this Agreement shall be referred to a senior executive of Duramed and a senior executive of Shire (the “Representatives”). If any such matter has not been resolved within fifteen (15) Business Days of such referral to the Representatives either Party may invoke the provisions of Section 16.2 for such dispute. No dispute resolution procedure set
forth in this Agreement shall be construed as an agreement to arbitrate under any federal or state arbitration Law, including but not limited to the Federal Arbitration Act, and shall not deprive a court of competent jurisdiction from resolving any
dispute arising under, or related to, this Agreement.    
	 
	
16.2           	
Any dispute that is not resolved as provided in the preceding Section 16.1, whether before or after termination of this Agreement, may be submitted by either Party only to any court of competent jurisdiction. This Agreement shall
be governed by, and construed in accordance with, the Laws of the State of New York. The Parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in New York, NY and waive any objection with
respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby and further agree not to commence any such action, suit or proceeding except in any such
court.   
	 
	
16.3           	
Notwithstanding anything to the contrary in this Agreement, either Party shall have the right to seek temporary injunctive relief in any court of competent jurisdiction as may be available to such Party under the Laws and rules
applicable in such jurisdiction with respect to any matters arising out of the other Party’s performance of its obligations under this Agreement.   
	 
	
17              	
GENERAL PROVISIONS     
	 
	
17.1           	
Except as expressly provided for in this Agreement, no variation to the terms of this Agreement shall be effective unless in writing and signed on behalf of each Party by a director or other authorised person.     
	 
	
17.3           	
Failure by either Party on one or more occasions to avail itself of a right conferred by this Agreement shall not be construed as a waiver of such Party’s right to enforce such right or any other right.       
	 

	
17.4           	
This Agreement and the Acquisition and License Agreement contain the entire agreements and understandings between the Parties and supersede all previous agreements and understandings between the Parties with respect to the subject
matter of this Agreement. In the event of a conflict between the terms of any of the aforementioned agreements, the Acquisition and License Agreement shall control to the extent of any inconsistency. Each Party acknowledges that, in entering into
this Agreement, it is not relying on any representation or warranty (whether made orally or in writing) except as expressly provided in this Agreement.  
	 

      In Witness Whereof, this Agreement has been signed by the authorized representatives of the Parties on the day and year first written above. 

	 	 	 	 
	SIGNED for and on behalf of	)	 	
    
	SHIRE DEVELOPMENT, INC.	)	 	Signature
	 	 	 	 
	 	 	 	

	 	 	 	Print Name and Title
	 	 	 	 
	 	 	 	 
	SIGNED for and on behalf of	)	 	 
	DURAMED PHARMACEUTICALS, INC	 	
    
	 	 	 	Signature
	 	 	 	 
	 	 	 	

	 	 	 	Print Name and Title

 

[Signature Page to Pharmacovigilance Agreement] 

SCHEDULE 1 

Contact Information 

EXHIBIT B 

TRADEMARK LICENSE AGREEMENT 

     This TRADEMARK LICENSE AGREEMENT (this “Agreement”) is entered into as of August 14, 2006, by and among Shire LLC, a Kentucky
limited liability company (together with its Affiliates, “Shire”), and Duramed Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware
(“Duramed”) (each a “Party” and collectively, the “Parties”). 

RECITALS 

     WHEREAS, Shire is in the business of formulating, manufacturing, marketing and distributing the pharmaceutical product known as Adderall IRTM and owns the pharmaceutical product known as Adderall
IRTM; 

     WHEREAS, pursuant to that certain Product Acquisition and License Agreement, executed concurrently herewith (the “Product Acquisition Agreement”) Shire is selling to Duramed certain rights to the Adderall IRTM product and certain assets relating to the Adderall Business (as defined in the Product Acquisition Agreement); 

     WHEREAS, pursuant to the terms and conditions of this Agreement, Shire desires to license to Duramed, and Duramed desires to acquire, a license to use certain trademark rights related to the Adderall
Business; and

     WHEREAS, the execution of this Agreement is a condition of the Parties entering into the Product Acquisition Agreement. 

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement and in the Product Acquisition Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE I

DEFINITIONS 

     1.1 Any capitalized terms used but not otherwise defined in this Agreement shall have the meanings set forth in the Product Acquisition
Agreement. The following capitalized terms shall have the following meanings when used in this Agreement: 

     1.2 “Affiliate” means a Person that, directly or indirectly, through one
or more intermediates, controls, is controlled by, or is under common control with, the Person specified. For the purposes of this definition, control shall mean the direct or indirect ownership of (a) in the case of corporate entities, securities
authorized to cast more than fifty percent (50%) of the votes in any election for directors, (b) in the case of non-corporate entities, more than fifty percent (50%) ownership interest with the power to direct the management and policies of such
non-corporate entity, or (c) such lesser percentage as may be the maximum percentage allowed

 1 

to be owned by a foreign corporation under the applicable laws or regulations of a particular jurisdiction of the equity having the power to vote in the election of directors or to direct the management and policies of such
Person. 

     “Licensed Activities” shall mean the manufacture, advertising, marketing, promoting, selling and distributing of the Product.

     “Licensed Marks” shall mean the trademarks set forth on the attached Schedule A. 

     “Losses” means any and all liabilities, damages, fines, penalties, deficiencies, losses and expenses (including interest, court
costs, amounts paid in settlement, reasonable fees of attorneys, accountants and other experts or other reasonable expenses of litigation or other proceedings or of any claim, default or assessment); provided, however, that the term
“Losses” shall not include any special, consequential, indirect, punitive or similar damages, except to the extent actually paid by a Party pursuant to any Third Party Claim. 

      “Product” shall mean the pharmaceutical product in all dosage forms identified in NDA # 11-522, as may be amended or supplemented from time-to-time in accordance with applicable law. 

     “Promotional Materials” shall mean any materials used in connection with the Licensed Activities, including web sites, press
releases, finished and unfinished commercials, and copies of related text and story boards, and other content, for all television, radio, online, print or other advertisements, and all packaging, labels, documentation and all other materials that
either include any of the Licensed Marks or are used or distributed in connection with a Product. 

      “Person” shall mean an individual or a corporation, partnership, trust, incorporated or unincorporated association, joint venture,
joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind. 

     “Term” shall have the meaning set forth in Article IV of this Agreement. 

     “Territory” shall mean the United States, and its territories and possessions. 

ARTICLE II 

TERMS AND CONDITIONS 

     2.1 Grant of License. Subject to the terms and conditions of this Agreement, Shire grants to Duramed an
exclusive, fully-paid-up, royalty-free, license during the Term of this Agreement to use the Licensed Marks in connection with the Licensed Activities in the Territory. During the Term of this Agreement, Shire shall have no right to license any
third party to use any Licensed Mark, or to use any Licensed Mark itself or through any of its Affiliates, in connection with an oral immediate release mixed amphetamine salt pharmaceutical product or other oral immediate release pharmaceutical
product for treating Attention Deficit Hyperactivity Disorder. 

2 

     2.2 Limitations on Use. All rights not expressly granted to Duramed under this Agreement are reserved to
Shire. Without limiting the generality of the foregoing, Duramed shall not have the right to use any of the Licensed Marks: (i) other than in connection with the Licensed Activities, (ii) as a trade name, Duramed name, or fictitious business name,
or (iii) other than in accordance with this Agreement. Duramed shall not use or authorize any other Person to use the Licensed Marks outside the Territory during or after the Term. 

     2.3 Ownership. As between the Parties, Shire owns all right, title and interest in and to the Licensed Marks
and the goodwill associated with the Licensed Marks, and any use of the Licensed Marks by Duramed and any associated goodwill shall inure to the benefit of Shire. Except as expressly set forth in this Agreement, Duramed shall have no right, title or
interest in or to the Licensed Marks. Duramed shall not, during or after the Term, in any jurisdiction: (i) challenge Shire’s title or rights in and to the Licensed Marks, or the validity of the Licensed Marks or any applications and
registrations thereof, or (ii) register, attempt to register or assist any Person other than Shire in registering, any of the Licensed Marks or any confusingly similar variations thereof. In no event shall Duramed use any of the Licensed Marks in a
manner that may tarnish or disparage Shire or Shire’s rights in any of the Licensed Marks.

     2.4 Marking. All Promotional Materials shall clearly state that Shire owns the Licensed Marks. Duramed shall
use the following form of such notice, in a clearly visible or audible (as appropriate) manner: “ADDERALL® is a registered trademark of Shire LLC, used under license.”
Duramed shall have the right to use the Licensed Marks in combination with other marks, names or symbols of Duramed without Shire’s consent (so long as they do not include terms identical or confusingly similar to terms that Shire uses).

     2.5 Protection of the Licensed Marks. At Shire’s request and sole expense, Duramed shall cooperate fully
and in good faith with Shire in securing, protecting, enforcing and defending Shire’s rights in the Licensed Marks. Without limiting the generality of the foregoing, Duramed shall execute any and all documents, and take any actions, as deemed
necessary in the reasonable opinion of Shire, to confirm or otherwise establish or maintain the validity, or enforceability of, and Shire’s rights in and to, the Licensed Marks. 

     2.6 Domain Name. Shire acknowledges that Duramed shall have the right to register and maintain a web site at
www.adderallir.com. Upon termination of this Agreement, Duramed shall transfer to Shire any domain names that incorporate any of the Licensed Marks.

       2.7 Quality
  Control Standards. Duramed shall maintain the quality of the Product at the
  same or better level of quality as the therapeutic equivalent of the Product
  marketed by Barr Laboratories, Inc. under ANDA No. 40-422 as of the Effective
  Date and comply materially with all applicable laws and regulations governing
  the provision of the Product. Duramed shall not alter or modify the Licensed
  Marks in any way. As long as this Agreement is in effect, Duramed shall provide
  to Shire representative samples of the Product and Promotional Materials pursuant
  to Shire’s request;
provided that such request shall not be made more than once every six (6) months. 

3 

ARTICLE III

INFRINGEMENT 

     3.1 If Shire or Duramed becomes aware of infringement of any Licensed Marks by a third party, such Party shall promptly notify the other Party
in writing to that effect. If, prior to the expiration of ninety (90) days from said notice, Shire has not obtained a discontinuance of such infringement or brought suit in the Territory against the third party infringer and such infringement is
relevant in a material respect to the Product, then Duramed shall have the right to bring suit against such infringer and join Shire as a party. The foregoing shall not preclude the Parties from jointly seeking such discontinuance or bringing suit
and, in any event, each Party will cooperate with the other in any suit and will have the right to consult with the other and be represented by its own counsel at its own expense. Prior to disposition of any moneys recovered, the expenses of the
Parties in bringing suit shall be reimbursed out of the moneys recovered, with the Party bringing the suit being reimbursed first, then the remainder, if any, of moneys recovered by either Party upon final judgment or settlement of any infringement
suit shall be retained by the Party bringing the suit. No settlement by a Party bringing a suit shall diminish the rights or interests of the other Party without the other Party’s written consent. 

ARTICLE IV 

TERM AND TERMINATION 

     4.1 Term. This Agreement shall commence on the Effective Date and shall continue for an initial term of ten
(10) years (the “Initial Term”). This Agreement shall automatically renew for successive additional ten (10) year terms (each a “Renewal
Term”) unless earlier terminated in accordance with this Article IV (the Initial Term, together with any successive Renewal Terms, being the “Term”). 

     4.2 Termination for Cause. Shire may terminate this Agreement at any time in the event Duramed materially
breaches this Agreement and such material breach continues uncured for a period of 180 days after written notice thereof; provided, however, in the event Duramed has in good faith commenced cure within such 180 day period, but cannot practically complete such cure within such 180 day period, Duramed shall have an additional 180 day cure period. In the event a material
breach of this Agreement is incapable of cure, without limiting any other rights of Shire, including the right to seek injunctive relief, Shire shall not have the right to terminate this Agreement if (i) Duramed is providing full cooperation to
mitigate the breach, and (ii) the breach was not caused by the willful misconduct by Duramed. 

     4.3 Non-Use. Shire may terminate this Agreement on written notice to Duramed if Duramed ceases using the
Licensed Marks in connection with the Licensed Activities for a period of two (2) years or more.

     4.4 Upon Termination. Upon any termination of this Agreement by either Party for any reason: (i) all rights
granted to Duramed shall immediately terminate, and (ii) Duramed shall immediately cease all use of the Licensed Marks. 

4 

ARTICLE V 

LIMITED WARRANTIES, DISCLAIMER AND LIMITATIONS 

     5.1 Mutual Representations. Each Party hereby represents and warrants to the other Party as follows:

     (a) Due Authorization. Such Party is a corporation duly incorporated and in good standing (where such concept
applies) as of the Effective Date, and the execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary action on the part of such Party. 

     (b) Due Execution. This Agreement has been duly executed and delivered by such Party and constitutes a legal,
valid and binding obligation of such Party, enforceable against such Party in accordance with its terms. 

     (c) No Conflict. Such Party’s execution, delivery and performance of this Agreement do not: (i) violate,
conflict with or result in the breach of any provision of the charter or by-laws (or similar organizational documents) of such Party; (ii) conflict with or violate any law, rule, regulation or governmental order applicable to such Party or any of
its assets, properties or businesses; or (iii) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to
others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of any agreement to which it is a party. 

     (d) Duly Licensed. Such Party is duly licensed, authorized or qualified to do business and is in good standing
(where such concept applies) in every jurisdiction in which a license, authorization or qualification is required for the ownership or leasing of its assets or the transaction of business of the character transacted by it, except where the failure
to be so licensed, authorized or qualified would not have a material adverse effect on such Party’s ability to fulfill its obligations hereunder. 

     5.2 Shire Representations and Warranties. Shire hereby represents and warrants to Duramed that, as of the
Effective Date: 

     (a) There is no action or proceeding pending or, to Shire’s knowledge, threatened, with respect to any Licensed Marks. There are no
material unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or by an arbitrator) against Shire or its Affiliates with respect to any Licensed
Marks.

     (b) To Shire’s knowledge, the use of the Licensed Marks does not infringe or misappropriate the intellectual property rights of any third
party. Neither Shire nor any of its Affiliates has received any written notice from any Person, or has knowledge of, any actual or threatened claim or assertion that the use of the Licensed Marks infringes or misappropriates the intellectual
property rights of any third party. 

5 

     (c) Shire has the right to grant to Duramed the licenses set forth in this Agreement, free of any rights or claims of any third party and
without payment by Shire of any royalties, license fees or other amounts to any Third Party. 

     (d) All Licensed Marks are subsisting and, to Shire’s knowledge, valid and enforceable.

     (e) To Shire’s knowledge, there is no infringement by a third party of any Licensed Marks. 

     5.3 DISCLAIMER. EXCEPT TO THE EXTENT EXPRESSLY SET FORTH IN ARTICLE V, SHIRE DOES NOT MAKE, AND SPECIFICALLY
DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE CONCERNING ANY MATTER SUBJECT TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NONINFRINGEMENT. 

ARTICLE VI

INDEMNIFICATION 

     6.1 Indemnification by Shire. Shire hereby agrees to hold Duramed, its Affiliates, and their respective
directors, agents and employees harmless from and against any and all Losses arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations
or injunctions by a third party (each a “Third Party Claim”) resulting directly from (a) any breach by Shire of any of its representations, warranties, covenants or obligations
pursuant to this Agreement, and (b) any claim that the use of the Licensed Marks as permitted hereunder infringes the intellectual property rights of any third party. 

     6.2 Indemnification by Duramed. Duramed hereby agrees to hold Shire, its Affiliates, and their respective
directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Third Party Claims resulting directly from (a) any breach by Duramed of any of its representations, warranties, covenants or
obligations pursuant to this Agreement, (b) except for such matters as Shire is obligated to indemnify Duramed under 6.1, use of the Licensed Marks in connection with Licensed Activities, including claims based on product liability of the Product.

     6.3 Notice of Claim. All indemnification claims in respect of any indemnitee seeking indemnity under 6.1 or
6.2 (collectively, the “Indemnitees” and each an “Indemnitee”) shall be made solely by the corresponding Party
(the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party (the “Indemnifying Party”)
prompt written notice (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon which such Indemnified Party intends to base a request for indemnification
under 6.1 or 6.2, but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such Third Party Claim. Each Indemnification Claim Notice shall
contain a description of the claim and the nature and amount of such Loss (to 

6 

the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim Notice, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all notices and documents
(including court papers) received by any Indemnitee in connection with the Third Party Claim. The Indemnifying Party shall not be obligated to indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party
materially prejudices the defense of such Third Party Claim. 

     6.4 Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim
subject to indemnification as provided for in under 6.1 and 6.2 by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a
Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party shall not be
liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 

     6.5 Right to Participate in Defense. Without limiting 6.3, any Indemnitee shall be entitled to participate in,
but not control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnitee’s own expense unless
(a) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with 6.3 (in which case the Indemnified Party shall
control the defense). 

     6.6 Settlement. With respect to any Losses relating solely to the payment of money damages in connection with
a Third Party Claim that shall not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the Indemnifying Party shall have
acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the
Indemnifying Party, in its reasonable discretion, shall deem appropriate (provided, however that such terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto), and shall transfer to
the Indemnified Party all amounts which said Indemnified Party shall be liable to pay prior to the time of the entry of judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the
defense of the Third Party Claim in accordance with 6.3, the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent
of the Indemnified Party (which consent shall be at the Indemnified Party’s reasonable discretion). The Indemnifying Party that has assumed the defense of the Third Party Claim in accordance with 6.3 shall not be liable for any settlement or
other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee shall admit any
liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with 6.3. 

7 

     6.7 Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party shall, and shall cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings,
hearings, trials and appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the
Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of
any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 

     6.8 Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable costs and
expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying
Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

ARTICLE VII

MISCELLANEOUS 

     7.1 Entire Agreement; Amendment. This Agreement, together with the Product Acquisition Agreement, including
the exhibits attached hereto and thereto (each of which is hereby and thereby incorporated herein and therein by reference), set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties,
representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties, which shall continue to govern the obligations of the Parties with respect to
information disclosed thereunder with respect to periods prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as
are set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance of doubt, the Parties
agree that all covenants, promises, agreements, warranties, representations, conditions, and understandings set forth herein are made and deemed effective as of the Effective Date, and that the execution of this Agreement shall not constitute a
waiver of any right or claim of either Party as of the Effective Date. 

     7.2 Notices. All notices or other communications that are required or permitted under this Agreement shall be
in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses below. Any such
communication shall be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal

 8 

delivery or overnight courier as provided
    in this Agreement), and (b) on the second Business Day after dispatch, if
    sent by internationally-recognized overnight courier. Unless otherwise specified
in writing, the mailing addresses of the Parties shall be as described below. 

  	For Duramed:	Duramed Pharmaceuticals, Inc. 

          400 Chestnut Ridge Road

          Woodcliff Lake, NJ 07677

          Phone: 201-930-3300

        Fax: 201-930-3330

      Attention: President
      
	 	 
	with a copy to:	Barr Pharmaceuticals, Inc.

        400 Chestnut Ridge Road

        Woodcliff Lake, NJ 07677

        Phone: 201-930-3300

        Fax: 888-843-0563

        Attention: General Counsel
	 	 
	For Shire:	Shire LLC 

        725 Chesterbrook Boulevard

        Wayne, Pennsylvania 19087-5637

        Fax: (484) 595-8163 

        Attention: General Counsel 
	 	 
	with a copy to: 
	Morgan, Lewis & Bockius LLP

        502 Carnegie Center 

        Princeton, NJ 08540 

        Fax: (609) 919-6701

        Attention: Randall B. Sunberg 

     7.3 Independent Contractors. In making and performing this Agreement, Shire and Duramed shall act at all times
as independent contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an agency, partnership, limited partnership, joint venture or employer and employee relationship between Shire and Duramed and
this Agreement shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. Except as otherwise provided in this Agreement, each Party shall be
solely responsible for its own costs and expenses associated with this Agreement. 

     7.4 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed
against either Party. 

     7.5 Governing Law. This Agreement shall be governed by and construed under the substantive laws of the State
of New York without giving effect to the choice of law provisions thereof. 

9 

     7.6 Assignment. Neither Party shall sell, transfer, assign, delegate, pledge or otherwise dispose of, whether
voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other Party (which consent may be granted, withheld or conditioned at such
other Party’s sole and absolute discretion); provided, however, that either Party may assign or transfer this Agreement or any of its rights or obligations under this Agreement without the consent of the other Party to any Affiliate of such
Party, or to any third party with which it merges or consolidates, or to which it transfers all or substantially all of its assets to which this Agreement pertains. The assigning Party (unless it is not the surviving entity) shall remain jointly and
severally liable with, and shall guarantee the performance of, the relevant Affiliate or third party assignee under this Agreement, and the relevant Affiliate assignee, third party assignee or surviving entity shall assume in writing all of the
assigning Party’s obligations under this Agreement. Any purported assignment or transfer in violation of this 7.6 shall be void ab initio and of no force or effect. 

     7.7 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission shall be deemed to be original signatures. 

     7.8 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do
all such other acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

     7.9 Severability. If any one or more of the provisions of this Agreement is held to be invalid or
unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a
good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

     7.10 Headings. The headings for each article and section in this Agreement have been inserted for convenience
of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

     7.11 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a
particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a
particular period of time. 

[signature page follows] 

10 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their respective representatives thereunto duly authorized, all as of the date first written above.

  	SHIRE PLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  

  	SHIRE LLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  

  	DURAMED PHARMACEUTICALS,
            INC.
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

 

[Signature Page to Trademark License Agreement] 

 11

SCHEDULE A 

Licensed Marks 

	
Mark  	
Owner 	
Country       	
Goods/Services        	
Serial No./

Filing Date      	
Reg. No./

Reg. Date        
	
[*]   	
[*]   	
[*]   	
[*]   	
[*]   	
[*]   

1

EXHIBIT C 

SUPPLY AGREEMENT 

  BETWEEN 

  SHIRE LLC 

  AND 

  DURAMED LABORATORIES, INC. 

  DATED AS OF 

AUGUST 14, 2006 

SUPPLY AGREEMENT 

     This SUPPLY AGREEMENT (this “Agreement”), dated as of August 14, 2006, by and among Shire LLC, a Kentucky limited liability company
having a place of business at 725 Chesterbrook Boulevard, Wayne, Pennsylvania 19087 (“Shire”), and Duramed Pharmaceuticals, Inc., a Delaware corporation having a place of business
at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”) (each a “Party” and collectively, the
“Parties”). 

RECITALS 

     WHEREAS, the Parties have entered into that certain Product Acquisition and License Agreement (the “Product Acquisition
Agreement”), dated as of the date hereof, pursuant to which Shire shall sell and license to Duramed assets and rights relating to the Products (as defined in the Product Acquisition Agreement) Shire (capitalized
terms used herein but not defined herein shall have the meanings set forth in the Product Development Agreement); 

     WHEREAS, the Product Acquisition Agreement contemplates the Parties entering into this Agreement to govern the supply of Products by Shire to Duramed; and 

     WHEREAS, Shire desires to manufacture and/or supply the Products to Duramed upon the terms and subject to the conditions of this Agreement. 

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE I

DEFINITIONS 

     “Affiliate” means, with respect to a Party, any entity that directly or indirectly controls, is control led by, or is under common
control with, such Party, but only for so long as such control continues. For purposes of this definition, “control” means the power to direct the management and affairs of an entity, directly or indirectly, whether through the ownership
of voting securities, by contract or otherwise. In the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding voting shares shall in any case be deemed to confer control, provided that, the direct
or indirect ownership of a lower percentage of such securities shall not necessarily preclude the existence of control. 

     “API Cost” for a Product means the actual cost paid by Shire on a pass-through basis for the active pharmaceutical ingredient in
such Product.

     “Changeover Plan” has the meaning set forth in Section 8.2. 

      “Effective Date” shall mean the Closing Date, as such term is defined in the Product Acquisition Agreement. 

     “Force Majeure Event” has the meaning set forth in Section 9.1. 

      “Losses” means any and all liabilities, damages, fines, penalties, deficiencies, losses and expenses (including interest, court
costs, amounts paid in settlement, reasonable fees of attorneys, accountants and other experts or other reasonable expenses of litigation or other proceedings or of any claim, default or assessment); provided, however, that the term
“Losses” shall not include any special, consequential, indirect, punitive or similar damages, except to the extent actually paid by a Party pursuant to any Third Party Claim. 

     “Manufacturing” shall mean all activities related to the manufacturing of a Product or any component or ingredient thereof,
including packaging, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities
related to any of the foregoing. 

     “Packaging Specifications” means the existing packaging and labeling specifications for Product, other than changes resulting from
a new NDC Number and replacement of the Shire name with Duramed’s name, as amended or supplemented from time to time in accordance with Section 3.13. 

     “Product Specifications” means the specifications for Product set forth in the Product NDA. 

     “Purchase Order” has the meaning set forth in Section 3.2. 

     “Rolling Forecast” has the meaning set forth in Section 3.1. 

     “Product” has the meaning set forth in the Product Acquisition Agreement. 

     “Supply Price” means (a) with respect to Products included in the Initial Order, [*] 

     “Term” has the meaning set forth in Section 7.1. 

     “Termination Assistance Services” has the meaning set forth in Section 8.1. 

ARTICLE II

SUPPLY OF PRODUCTS 

     Section 2.1. Purchase of Products. Pursuant to the terms and conditions of this Agreement, Duramed shall purchase from Shire, and Shire shall
supply to Duramed Products.

     Section 2.2. Initial Forecast and Purchase Order. (a) Promptly following the date hereof, Duramed shall submit to Shire (i) an initial
non-binding forecast (the “Initial Forecast”), which Initial Forecast shall be updated thereafter in accordance with
Section 3.1; and (ii) Duramed’s initial Purchase Order (the “Initial Order”) for Products.

 2 

     (b) Refund for Certain Product Included in the Initial Order. After the Effective Date, Duramed will use its commercially reasonable efforts
to sell the Products included in the Initial Order on a first-in, first-out basis. In the event that any product included in the Initial Order cannot be sold by Duramed prior to the date on which such Product has reached twelve (12) months of
remaining shelf life, Shire will reimburse Duramed for amounts paid by Duramed under Section 6.1 of this Agreement for such unsellable Products included in the Initial Order. For reference purposes, Schedule 3 sets forth the quantities of inventory
of Products in finished goods form held by Shire as of the date hereof.

     (c) No later than the Closing Date, Shire shall sell and deliver to Duramed such quantities of Products reflected in such Initial Order, all in Shire labeled packaging, unless Duramed engages a
Third-Party to repackage the Product with Duramed labeling at Duramed’s sole cost and expense. Other than the Initial Order, in no event shall Duramed submit a Purchase Order for Products less than three (3) months prior to the required
delivery date for such order.

     Section 2.3. Assignment of Shire Supply Agreement. At Duramed’s request, commencing as of and after the date hereof, Shire shall use its
commercially reasonable best efforts to provide reasonable cooperation to assist in the assignment of Shire’s existing third party supply agreement with respect to the Product to Duramed, including assisting Duramed in obtaining diligence
information and other data in connection with such third party supply agreement. Duramed shall not be obligated to accept assignment of such third party supply contract other than at Duramed’s sole option and discretion. 

     Section 2.4 CBE 30 Request. As promptly as practicable (but in no event more than three business days ) following the date hereof, Shire
shall file a “CBE 30” request to designate Duramed (or such other party as Duramed may designate in its discretion) as an alternative packager/repackager for the Products using Duramed labels. Share shall provide reasonable assistance, at
Duramed’s costs, to assist Duramed in obtaining a minimum of [*] of saleable finished goods inventory of the Products bearing Duramed labeling and artwork no later than two business days following Closing.

     Section 2.5 Purchase Prior to Closing. Prior to the Effective Date, Duramed (or its designee) shall have the option to purchase such amount
of existing Shire inventory of the Products existing and in the possession of Shire for the purpose of repackaging such inventory into finished goods inventory bearing Duramed labeling and artwork. Any such purchase of inventory prior to the
Effective Date shall correspondingly reduce the amount of inventory Duramed is obligated to purchase in the Initial Order pursuant to Section 2.3 hereof. 

ARTICLE III 

FORECASTS, ORDERS AND SHIPMENT 

     Section 3.1. Forecasted Quantities. At the beginning of each calendar month following the Initial Forecast under Section 2.3 and each month
thereafter, Duramed shall provide an updated rolling forecast of Duramed’s estimated requirements for quantities of such Product over the [*] period commencing after the date of such forecast, with expected order amounts, order dates and
delivery dates (each such forecast a “Rolling Forecast”). Except as provided below, such Rolling Forecasts shall represent Duramed’s reasonable estimates for 

 3 

planning purposes only and shall not obligate Duramed to purchase any such quantities. Each Rolling Forecast shall be made by Duramed in good faith, taking into account reasonable projections of demand for Products including,
without limitation, demand in line with prescription trends, and allowing for reasonable safety stock. Shire shall use commercially reasonable efforts to ensure sufficient manufacturing capacity to meet the Rolling Forecast. Duramed shall forecast
in amounts comprising full batch quantities for each Product. The first three (3) months of any given Rolling Forecast for a Product delivered after the Effective Date shall be binding upon Duramed and Duramed shall be required to issue a Purchase
Order for such amount of Product. No portion of any Rolling Forecast issued by Duramed prior to the Effective Date shall be binding upon Duramed. 

     Section 3.2. Purchase Order Form. Duramed shall submit all orders for the purchase of Products using the form of purchase order attached
hereto as Schedule 1 (each a “Purchase Order”). Each Purchase Order will be delivered to such location as Shire
designates in writing to Duramed from time to time. After Shire receives a Purchase Order, Shire shall acknowledge receipt thereof in writing within five (5) business days, either (i) accepting the Purchase Order, or (ii) seeking clarification of
the Purchase Order, if necessary. Shire shall have no obligation to accept any Purchase Order that does not include all information required on Schedule 1 or that is inconsistent with the
terms and conditions of this Agreement. In the event that an order is rejected, Shire and Duramed will cooperate in good faith to resolve any supply issues raised by such order. The minimum size of any order placed by Duramed will be a full
batch.

     Section 3.3. Delivery of Product. Upon acceptance of a Purchase Order, Shire shall deliver all Product by the delivery date covered by such
Purchase Order in accordance with the terms of this Agreement and such Purchase Order, including the quantities accepted in each Purchase Order. At the time of delivery to Duramed, all Product manufactured hereunder shall meet the Product
Specification applicable thereto in all material respects, and shall be finished, packaged, labeled and/or ready for commercial sale by Duramed as required in accordance with the Packaging Specifications. 

     Section 3.4. Expedited Delivery. Upon the request of Duramed to supply the quantities of Product under a Purchase Order on an expedited
basis, Shire shall notify Duramed of any expected increased costs that Shire anticipates it will incur. Subject to prior written approval by Duramed of these increased costs, Shire shall use reasonable efforts to supply the quantities of Product on
an expedited basis. Shire shall not have any liability for any failure to meet any such requested expedited delivery schedule. 

     Section 3.5. Excess Purchase Orders. Shire shall use commercially reasonable efforts to, but shall not be obligated to supply quantities of
any Product in excess of 120% of the quantities set forth in the most recent forecast for such quarter. If Shire believes it will be unable to deliver any additional volume on the date specified by Shire in the applicable Purchase Order, Shire shall
notify Duramed in writing as promptly as practicable, and shall provide a proposed alternative delivery schedule. Any agreement on the delivery schedule for such additional volume shall be documented in writing and shall become effective only upon
mutual written agreement of both Parties to the terms and conditions thereof.

 4 

     Section 3.6. Cancellation of Orders. Duramed may not cancel an order without payment to Shire in full for the order. Shire shall, in good
faith, use commercially reasonable efforts to mitigate the costs of cancellation of any Purchase Order. 

     Section 3.7. Conflict. The terms of this Agreement shall prevail over any conflicting, inconsistent or additional terms set forth in any
Purchase Order. 

     Section 3.8. Delivery and Risk of Loss. All Products shipped under this Agreement will be shipped Ex-Works (Incoterms 2000) Shire’s
manufacturing facility to such location designated by Duramed in the applicable accepted Purchase Order. Duramed will pay all freight, insurance charges, taxes, import and export duties, inspection fees and other charges applicable to the sale and
transport of Products. Risk of loss to Products shall pass to Duramed upon delivery to Duramed’s designated carrier. Title to all Products manufactured hereunder shall pass to Duramed on payment by Duramed for the applicable Product or pro-rata
portion thereof.

     Section 3.9. Certificate of Analysis. A Certificate of Analysis (“COA”)
will accompany each shipment of Products in the form attached hereto as Schedule 2. 

     Section 3.10. Location of Manufacturing. All Products shall be manufactured in a facility that has been designated as an approved
manufacturing facility by the applicable Regulatory Approval for such Product. Should Shire desire to change any of the manufacturing site for a Product, or any component thereof, to a site other than those designated in the applicable Regulatory
Approval, Shire shall notify Duramed in writing and the Parties shall thereafter meet to discuss the potential consequences of such a change. Shire shall not change manufacturing sites for any Product, or any component thereof, except in accordance
with the authorization of the applicable Governmental Authority, and the procedures and requirements set forth in this Agreement. 

     Section 3.11. Shortage of Materials. In the event that the materials and/or resources required to manufacture and deliver Products to Duramed
in accordance with this Agreement are, or are reasonably anticipated to become, in short supply such that Shire may be unable to provide Duramed with the quantities of Products set forth in a Purchase Order, Shire shall notify Duramed of such
shortage as promptly as practicable. If Shire so notifies Duramed, Shire and Shire shall promptly meet to discuss how to address the potential shortage. In the event that Shire, at any time, has any information indicating that it may not be able to
supply Duramed with all Products in accordance with a confirmed Purchase Order, Shire shall as soon as practicable provide Duramed a written notice to that effect. Any failure by Shire to meet its obligations under this Agreement as a result of a
general shortage of raw materials shall not be considered a breach of this Agreement provided that Shire is meeting its obligations under Article IX. To the extent (other than as a result of a Force Majeure Event) that Shire fails to supply at least
80% of the quantities of Product in the aggregate ordered for a particular calendar quarter for two consecutive calendar quarters, Duramed may request and Shire shall, at its cost and expense, qualify a second source of supply. Such second source
shall be qualified and ready to manufacture Product within 12 months following such Duramed request. If Shire fails to qualify and have ready such second source, then Duramed shall have the right to qualify and make ready such second source and
Shire shall promptly reimburse Duramed for costs and 

 5 

expenses incurred by it in so doing. Such second source shall be used by Shire to supply Product to Duramed under this Agreement at least to the extent required to maintain the second source as a qualified manufacturer of Product.

     Section 3.12. Product Specifications. Shire shall manufacture all Product so that, at the time of delivery to Duramed, the Product conforms,
in all material respects, to the Product Specifications, cGMP and any reasonable requests communicated by Duramed to Shire in order for Duramed to comply with any legal or regulatory obligations applicable to Duramed. At the time of shipment of
Products, the Products shall have a minimum remaining shelf life of not less than 18 months. On mutual agreement of the Parties, the Parties may modify the Product Specifications of the Product by amendment, unless such changes are required by any
regulatory authority, in which case Duramed may unilaterally modify the Product Specifications of the Product. Upon modification of such Product Specifications, Shire shall use commercially reasonable efforts to alter its manufacturing processes to
meet such Product Specifications and shall not be liable for any failure to meet its obligations hereunder while acting in good faith to meet the new Product Specifications. 

     Section 3.13. Packaging Specifications. After the initial Purchase Order, Shire shall package all Products in accordance with the Packaging
Specifications. Changes in the Packaging Specifications shall be subject to the mutual agreement of the Parties on a schedule to be agreed by the Parties, taking into account the time and cost required for Shire to implement any necessary
manufacturing or packaging modifications. Duramed shall compensate Shire for the cost of any inventory of old packaging that cannot be used as a result of any modification by Duramed to the Packaging Specifications, and for any other costs incurred
as a result of the implementation of the modifications to the Packaging Specifications requested by Duramed. Duramed will be responsible for ensuring the accuracy of all information contained on all labels for Products and for the compliance of all
such labels with applicable Laws and Regulatory Approvals. 

     Section 3.14. Facility Maintenance; Inspection; Reports. Shire shall, at all times, maintain and operate all facilities where Products are
manufactured, packaged or tested, and implement required quality control procedures to perform its obligations under this Agreement. Not more than once every [*] (or more often in the case of a deficiency), Shire shall permit, or cause its
contractors to permit, quality assurance representatives of Duramed or designated third parties and representatives of the applicable Government Authority to inspect such facilities upon reasonable advance notice, during normal business hours and on
a confidential basis. Shire shall promptly provide, or cause its contractor to provide, Duramed with a copy of any notice from the applicable Government Authority received at the conclusion of an inspection relating to any Product. 

     Section 3.15. Subcontracting. Shire shall have the right to subcontract manufacture and supply under this Agreement to any Affiliate of Shire
or to a Third Party, provided that, (i) Shire shall procure that such Affiliates and Third Parties comply with the terms and conditions of this Agreement, (ii) Shire shall be liable for any
non-performance or breach by such Affiliate or Third Party, and (iii) any subcontracting to a Third Party shall be subject to Duramed’s approval, which approval shall not be unreasonably withheld.

 6 

     Section 3.16. Competing Products. Subject to the Product Development Agreement, each of the Parties recognizes and acknowledges that the
other and/or its Affiliates have been, and will continue to be, actively involved in the field in which the Products may be sold. Each Party acknowledges that the other Party and/or its Affiliates currently, or may in the future, market, sell and
distribute products that compete directly with any Product, and may continue to market, sell and distribute these and other competing products throughout the Term of this Agreement. 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES 

     Section 4.1. Mutual Representations. Each Party hereby represents and warrants to the other Party, as of the date hereof, as follows:

     (a) Due Authorization. Such Party is a corporation duly incorporated and in good standing (where such concept applies) as of the Effective
Date, and the execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary action on the part of such Party. 

     (b) Due Execution. This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding obligation of
such Party, enforceable against such Party in accordance with its terms. 

     (c) No Conflict. Such Party’s execution, delivery and performance of this Agreement do not: (i) violate, conflict with or result in the
breach of any provision of the charter or by-laws (or similar organizational documents) of such Party; (ii) conflict with or violate any law, rule, regulation or governmental order applicable to such Party or any of its assets, properties or
businesses; or (iii) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of
termination, amendment, acceleration, suspension, revocation or cancellation of any agreement to which it is a party. 

     (d) Duly Licensed. Such Party is duly licensed, authorized or qualified to do business and is in good standing (where such concept applies)
in every jurisdiction in which a license, authorization or qualification is required for the ownership or leasing of its assets or the transaction of business of the character transacted by it, except where the failure to be so licensed, authorized
or qualified would not have a material adverse effect on such Party’s ability to fulfill its obligations hereunder. 

ARTICLE V

QUALITY ASSURANCE 

     Section 5.1. Shire Compliance. Shire shall manufacture, fill, package, handle and warehouse the Products in conformity with all applicable
laws, cGMP requirements and the Product Specifications. Duramed  shall maintain all Regulatory Approvals and all permits and licenses issued by any Governmental Authority that are necessary
to permit Shire to manufacture and supply the Products. Shire shall advise Duramed of any information of which it becomes 

 7 

aware arising out of Shire’s activities hereunder that have adverse regulatory compliance and/or reporting consequences affecting the Products. 

     Section 5.2. Inspections. Shire shall advise Duramed of any requests by any Governmental Authority for inspections of the premises used to
manufacture Products. In the event the portion of Shire’s facilities at which Product are manufactured is inspected by any Governmental Authority, Shire shall use commercially reasonable efforts to ensure that Duramed shall have the right to be
present during such inspection. To the extent relating directly to a Product, Shire shall notify Duramed of any alleged violations or deficiencies relating to a facility at which any Products are manufactured, packaged or stored, and, to the extent
relating directly to a Product, shall disclose to Duramed all relevant portions of any notice of observations or potential violations as well as a copy of its response thereto. 

     Section 5.3. Duramed Compliance. Duramed shall hold, store, handle, ship, deliver, distribute and/or sell the Products (i) in accordance with
applicable cGMP requirements, laws and Regulatory Approvals; and (ii) in compliance with the Product Specifications. Duramed shall enter into all necessary compliance agreements as may be reasonably required or designated by Shire, including but not
limited to the quality agreement attached hereto as Exhibit A (the “Quality Agreement”) and any other agreements to cover quality assurance and adverse incident reporting,
including the safety agreement. 

     Section 5.4. Quality Control. Upon delivery of Products to Duramed, Duramed shall be solely responsible for compliance with all Laws and
Regulatory Approvals with respect to the Products. 

     Section 5.5. Rejection of Delivered Products.
Within [*] of receipt of any Product, Duramed shall inspect the Product and advise
Shire of any defect whereby the Product does not conform to the Product Specifications.
Any Product not refused within [*] shall be deemed accepted subject to Section
5.6 below; provided,
however, that such acceptance or deemed acceptance shall not adversely affect any claim for indemnification provided in Article XI. If Duramed desires to refuse acceptance, Duramed shall,
within such [*] period, inform Shire of its refusal to accept the defective Product and the reason(s) therefor. In the event that Duramed refuses acceptance, Shire, upon confirmation of the reasons for refusal of the Product, will replace the
defective Product or refund the purchase price thereof, at Duramed’s option. If Shire and Duramed do not agree on the refusal or rejection of Product, then any Party may refer the matter for final analysis to a specialized laboratory of
national reputation acceptable to both Parties for the purpose of determining the results. Any determination by such laboratory shall be final and binding upon the Parties. The cost of any such review by a laboratory shall be borne by Duramed if it
is determined that the Product conforms to the Product Specifications, and by Shire if determined that it does not. 

     Section 5.6. Latent Defects. Duramed shall have the right to refuse and reject any Collaboration Product within [*] from the date Duramed
becomes aware of a defect in a Product delivered hereunder, in the case of defects that are not evident upon a reasonable initial inspection but which subsequently become evident. 

 8 

     Section 5.7. Non-Conforming Products. Notwithstanding any other provisions of this Agreement, Duramed shall return to Shire or its designee
any Products that do not conform with the Product Specifications at the time of shipment to Duramed, or if Duramed and Shire mutually agree, to dispose of such Products as Shire may direct. Shire shall be responsible for the costs associated with
the proper disposal of all such Products not in conformance with the Product Specifications at the time of shipment and shall promptly replace or credit, at the option of Shire, such non-conforming Products.

     Section 5.8. Cost of Recall. In the event that any Product is quarantined or recalled, or is subject to a stop-sale action, whether voluntary
or by the action of any Governmental Authority, or as a result of the revocation or expiration of any Regulatory Approval, any expenses, including any out-of-pocket administrative costs and reasonable fees of any experts or attorneys that may be
utilized by either Party, government fines or penalties, related to such recall, quarantine or stop-sale, shall be borne by Duramed unless it is determined that the reason for the quarantine, recall or stop-sale action is the result of the breach by
Shire of its obligations under this Agreement, and in such case such expenses shall be shared according to the relative responsibility of each Party. Such determination may be made by the Governmental Authority involved, or by mutual agreement of
the Parties following examination and review of all records pertinent to the manufacture of the Product subject to such recall. 

     Section 5.9 Regulatory Actions. If any regulatory authority in the Territory takes any action with respect to a Product that requires a
response or action by Shire, Shire shall use commercially reasonable efforts, at the expense of Duramed, to carry out the response or action, at all times in consultation with Duramed, and promptly thereafter Shire shall meet with Duramed and agree
a suitable plan of action in order to try and rectify and/or address any problem(s) identified by the Regulatory Authority within a reasonable period of time at the expense of Duramed. Notwithstanding the foregoing, if any of the above expenses
result from Shire’s breach, negligence or willful misconduct hereunder, then any expenses incurred under this Section 5.9 shall be Shire’s responsibility. 

ARTICLE VI

PRICE AND PAYMENTS 

     Section 6.1. Supply Prices. The unit price payable by Duramed for each Product shall be [*]. 

     Section 6.2. Unit Price Negotiation. [*] 

     Section 6.3. Records, Audit. Shire shall keep complete and accurate records, consistent with GAAP, of the Supply Price. Duramed shall have
the right to have an independent certified public accounting firm of internationally recognized standing, reasonably acceptable to Shire, to have access during normal business hours, and upon reasonable prior written notice, to such of the records
of Shire as may be reasonably necessary to verify the accuracy of amounts paid by Duramed under this Agreement for any calendar year ending not more than three (3) years prior to the date of such request; provided, however, that, Duramed shall not
have the right to conduct more than one such audit in any twelve (12) month period and that Duramed shall not be permitted to audit the same period of time more than once. The 

 9 

accounting firm shall disclose to Duramed only whether the various expenses subject to reimbursement under this Agreement are correct or incorrect and the specific details concerning any discrepancies. Duramed shall bear all costs
of such audit, unless the audit reveals a discrepancy in Duramed’s favor of more than[*], in which case Shire shall bear the cost of the audit. If Shire disputes the findings pursuant to this Section 6.3, the Parties shall meet and discuss such
dispute. If such dispute is not resolved within forty-five (45) days, then it shall be subject to the dispute resolution provisions contained herein. 

     Section 6.4. Invoices. Shire may invoice for Product at any time following tender thereof to Duramed’s carrier. All invoices shall be
sent to a single address specified in writing by Duramed. Payment for Product shall be due within forty-five (45) days after the date of the invoice by check or electronic funds transmission in United States dollars without any offset or deduction
of any nature whatsoever. All electronic payments shall be made to such account as Shire shall have specified in writing to Duramed with written confirmation of payment sent by facsimile to such address as Shire shall have specified in writing to
Duramed. If Duramed fails to pay any undisputed invoiced amount when due, a service charge will be imposed by Shire equal to [*]. 

     Section 6.5. Taxes. The Supply Price shall be exclusive of any applicable value added tax and any other taxes, duties and impositions that,
if applicable, shall be paid by Duramed to Shire at the same time as the purchase price for such Product. Duramed shall bear the cost of any such taxes, duties or impositions of any kind, nature or description applicable to the sale and
transportation of Product, and Duramed will forthwith pay to Shire all such amounts upon demand.

     Section 6.6. Separate Sale. Each shipment of Product shall constitute a separate sale, obligating Duramed to pay therefor, whether such
shipment is in whole or only partial fulfillment of any Purchase Order. 

     Section 6.7. Deductions. Duramed shall not to make any deductions of any kind from any payments due to Shire hereunder unless Duramed will
have received prior written authorization from Shire authorizing such deduction. 

     Section 6.8. Audit. 

     (a) Audit.  Duramed shall have the right to have an independent certified public accounting firm of internationally recognized standing,
reasonably acceptable to Shire, to have access during normal business hours, and upon reasonable prior written notice, to such of the records of Shire as may be reasonably necessary to verify the accuracy of amounts paid by Duramed under this
Agreement for any calendar year ending not more than [*] prior to the date of such request; provided, however, that, Duramed shall not have the right to conduct more than one such audit in any [*] period and that Duramed shall not be permitted to
audit the same period of time more than once. The accounting firm shall disclose to Duramed only whether the various expenses subject to reimbursement under this Agreement are correct or incorrect and the specific details concerning any
discrepancies. Duramed shall bear all costs of such audit, unless the audit reveals a discrepancy in Duramed’s favor of more than [*], in which case Shire shall bear the 

 10 

cost of the audit. If Shire disputes the findings pursuant to this Section 6.8, the Parties shall meet and discuss such dispute.

     (b) Payment of Additional Amounts. If, based on the results of any audit, (a) additional payments are owed by Duramed to Shire under this
Agreement, then Duramed shall make such additional payments, or (b) the payments previously made by Duramed to Shire under this Agreement are in excess of the amounts that were actually required to be made, then Shire shall return such excess
payments, in each case within fifteen (15) Business Days after the accounting firm’s written report is delivered to the Parties.

ARTICLE VII 

TERM AND TERMINATION 

     Section 7.1. Term. Subject to the occurrence of the Closing, the term of this Agreement shall commence on the Effective Date and shall
continue until terminated in accordance with this Article VII (the “Term”). Duramed may terminate this Agreement as to the supply of particular Product at any time on six (6)
months written notice to Shire. Subject to Article VIII, Shire may terminate this Agreement as to the supply of particular Product at any time on eighteen (18) months written notice to Duramed, provided that Shire may not terminate this Agreement
under this sentence until ten (10) years following the Effective Date. Termination of this Agreement with respect to one or more Products shall not relieve the Parties of any obligations with respect to any other Products, and this Agreement shall
remain in effect as to such other Products. 

     Section 7.2. Termination Upon Assignment. Duramed shall also have the right to terminate this Agreement in the event that Shire’s
existing Third Party supply agreement is assigned to Duramed, effective immediately upon the effectiveness of such assignment but subject to Section 7.4. 

     Section 7.3 Termination for Cause. Either Party may terminate this Agreement as to the supply of a particular Product at any time in the
event that the other Party materially breaches this Agreement and such material breach continues uncured for a period of ninety (90) days after written notice thereof; provided,
however, in the event that the breaching Party has in good faith commenced cure within such ninety (90) day period, but cannot practically complete such cure within such ninety (90) day
period, the breaching Party shall have an additional ninety (90) day cure period. In the event a material breach of this Agreement is incapable of cure or cannot be cured in the time periods set forth in the previous sentence acting using
commercially reasonable efforts, without limiting any other rights of the non-breaching Party, including the right to seek injunctive relief, the non-breaching Party shall not have the right to terminate this Agreement if (i) the breaching Party is
providing full cooperation to resolve and/or mitigate the breach, and (ii) the breach was not caused by willful misconduct by the breaching Party. 

     Section 7.4. Survival. The provisions of Sections 5.8 and 7.4, and Articles VIII, X, XI and XII shall survive termination or expiration of
this Agreement. Termination of this Agreement shall not affect the obligation of any Party to pay the other Party any amounts due hereunder accrued prior to the termination date hereof. Except in the event of termination by Shire under Section 7.3,
upon termination of this Agreement Shire shall deliver to Duramed on 

 11 

an ex-works basis all manufactured and work-in progress quantities of Product in its possession that have been manufactured in respect of a specific Purchase Order(s) accepted by Shire hereunder subject to payment in advance
therefor by Duramed. The right to terminate this Agreement shall not prejudice any other right or remedy in equity or at law of a Party in respect of any breaches of this Agreement. 

ARTICLE VIII

TERMINATION ASSISTANCE SERVICES 

     Section 8.1. Termination Assistance Services. If (i) Shire terminates this Agreement as to the supply of Product under Section 7.1 (and
Duramed intends to continue marketing and selling the Product), or (ii) Duramed terminates this Agreement under Section 7.1 or 7.2 (and Duramed intends to continue marketing and selling the Product), Shire shall for a period of one (1) year
thereafter, upon Duramed’s request, provide any cooperation reasonably requested by Duramed that may be required to facilitate the transfer of the manufacture of the applicable Product to Duramed or Duramed’s designee
(“Termination Assistance Services”). Duramed shall reimburse Shire for the reasonable costs of Shire in providing Termination Assistance Services. The rights of Duramed under this
Section 8.1 shall be without prejudice to the Parties’ rights to pursue legal remedies for breach of this Agreement, either for breaches prior to termination or during the period this Agreement is continued in force post termination.

     Section 8.2. Development of Changeover Plan. If and to the extent requested by Duramed, whether prior to, upon, or following termination of
this Agreement by Duramed, Shire shall use commercially reasonable efforts to assist Duramed in developing a plan that shall specify the tasks to be performed by the Parties in connection with the Termination Assistance Services and the schedule for
the performance of such tasks (a “Changeover Plan”). The Changeover Plan shall include descriptions of the services, fees, documentation and access requirements that will promote
an orderly transition of the manufacture of Product to Duramed or its designee. 

     Section 8.3. Know-How, Infrastructure, and Software. In connection with the Termination Assistance Services, Shire shall make available to
Duramed or its designee, to the extent owned or controlled by and in the possession of Shire and reasonably required to manufacture the applicable Product, (i) copies of all applicable requirements, standards, policies, reports and report formats,
user manuals, technical manuals, system architecture, processes, operating procedures and other documentation, (ii) copies of flow charts of the manufacturing procedures and work instructions related to manufacturing the relevant Product, (iii) a
list of all material equipment, including the source of such equipment, utilized in the production of the applicable Product, (iv) copies of all current specifications, including packaging, for the relevant Product, (v) copies of all standard
operating procedures for the manufacturing procedures to be made available to Duramed, (vi) all necessary environmental conditions necessary to manufacture the relevant Product and copies of any existing external environmental impact studies based
on the materials or methods employed in the manufacturing method to be made available to Duramed, and (vii) such other documentation as the Parties may agree.

ARTICLE IX

FORCE MAJEURE 

 12 

     Section 9.1. Force Majeure. No Party shall be responsible for failure or delay in performance hereunder due to reasons beyond its reasonable
control, including without limitation, by reason of fire, flood, riot, freight embargoes, acts of God or of the public enemy, war or civil disturbances, general shortage of raw materials, or any future laws, rules, regulations or acts of any
government affecting a Party that would delay or prohibit performance hereunder (a “Force Majeure Event”). Upon the occurrence of a Force Majeure Event, the Party whose performance
is so affected shall promptly give notice to the other Party of the occurrence or circumstance upon which it intends to rely to excuse its performance. During the duration of the Force Majeure Event, the Party so affected shall use its reasonable
commercial efforts to avoid or remove such Force Majeure Event and shall take reasonable steps to resume its performance under this Agreement with the least possible delay. Any Force Majeure Event must be beyond the control and without the fault or
negligence of the Party claiming excusable delay, provided that, breaches by any Party’s subcontractors shall not excuse any delay or failure by that Party.

ARTICLE X

CONFIDENTIALITY 

     Section 10.1. Confidential Information. As used in this Agreement, the term “Confidential
Information” means all secret, confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer, electronic or other form, provided pursuant to this Agreement or
generated pursuant to this Agreement by one Party or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving
Party”), including but not limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products, and any other materials that
have not been made available by the Disclosing Party to the general public. Confidential Information shall not include any information or materials that: 

  (a) were already known to the Receiving
        Party (other than under an obligation of confidentiality), at the time of
        disclosure by the Disclosing Party, to the extent such Receiving Party has
        documentary evidence to that effect; 

  
    (b) were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the Receiving Party; 

  
    (c) became generally available to the public or otherwise part of the public domain after disclosure or development thereof, as the case may be, other than through any act or omission of a Party in breach of such Party’s
    confidentiality obligations under this Agreement; 

  
    (d) were disclosed to a Party, other than under an obligation of confidentiality, by a third party who had no obligation to the Disclosing Party not to disclose such information to others; or 

  
    (e) were independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to
    that effect. 

 13 

     Section 10.2. Confidentiality Obligations. Each of Duramed and Shire shall keep confidential all Confidential Information of the other Party
with the same degree of care it maintains the confidentiality of its own Confidential Information but in no event less than a reasonable degree of care. Neither Party shall use such Confidential Information for any purpose other than in performance
of this Agreement or disclose the same to any other Person other than to such of its and its Affiliates’ directors, managers, employees, independent contractors, agents or consultants who are bound by confidentiality obligations consistent with
those contained herein and who have a need to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this Agreement. Upon termination of this Agreement, the Receiving Party shall return or destroy all
documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the possession of the Receiving Party and its Affiliates or their directors, managers, employees, independent contractors, agents or
consultants, except that the Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall continue to be subject to the provisions of
this Article X. 

     Section 10.3. Permitted Disclosure and Use. Notwithstanding Section 10.2, a Party may disclose Confidential Information belonging to the
other Party only to the extent such disclosure is reasonably necessary to: (a) obtain Regulatory Approval to the extent such disclosure is made to a Governmental Authority; (b) comply with or enforce any of the provisions of this Agreement; (c)
comply with Laws; or (d) comply with applicable stock exchange regulations. If a Party deems it necessary to disclose Confidential Information of the other Party pursuant to this Section 10.3, such Party shall give reasonable advance notice of such
disclosure to the other Party to permit such other Party sufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such information. In addition, notwithstanding Section 10.2, the Parties shall
cooperate to prepare standardized public responses to anticipated inquiries from the public, press, stockholders, investors and/or analysts with respect to the activities hereunder. Despite the foregoing, each Party agrees that the other Party is
free to disclose this Agreement in its entirety to the United States Federal Trade Commission and the United States Department of Justice, or to any court with jurisdiction over the litigations settled under the Settlement Agreement between Shire
Laboratories Inc. and Barr Laboratories Inc. dated August 14, 2006. 

     Section 10.4. Unauthorized Disclosure. The Receiving Party acknowledges and agrees that the Confidential Information of the Disclosing Party
constitutes proprietary information and trade secrets valuable to the Disclosing Party, and that the unauthorized use, loss or outside disclosure of such Confidential Information shall be presumed to cause irreparable injury to the Disclosing Party.

     Section 10.5. Notification. The Receiving Party shall notify the Disclosing Party promptly upon discovery of any unauthorized use or
disclosure of the Disclosing Party’s Confidential Information, and shall cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of such Confidential Information and to prevent
its further unauthorized use or disclosure. The Receiving Party acknowledges that monetary damages may not be a sufficient remedy for unauthorized disclosure of Confidential Information and that the Disclosing Party may be entitled, without

 14 

waiving other rights or remedies, to such injunctive or equitable relief as may be deemed proper by a court of competent jurisdiction in the event of such unauthorized disclosure. 

     Section 10.6. Confidentiality of this Agreement. The terms of this Agreement shall be Confidential Information of each Party and, as such,
shall be subject to the provisions of this Section 10.6. 

ARTICLE XI 

INDEMNIFICATION 

     Section 11.1. Indemnification by Duramed. Duramed hereby agrees to hold Shire, its Affiliates, and their respective directors, agents and
employees harmless from and against any and all Losses arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a
third party (each a “Third Party Claim”) resulting directly from (a) any breach by Duramed of any of its representations, warranties, covenants or obligations pursuant to this
Agreement, (b) the negligence or willful misconduct by Duramed or its Affiliates or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement, (c) the Product, including the use,
handling, storage, sale or other disposition of Product (including, without limitation, those Third Party Claims that involve product defect, product liability, death or bodily injury (or allegations thereof) to any individual or any property, or
(d) infringement of intellectual property based on the Product Specification, Packaging Specifications, manufacture, use, sale, offer for sale, importation or other distribution of Product, except to the extent that such Losses in (a) through (d)
result from the negligence or willful misconduct of Shire or it’s third party supplier of Product or breach of this Agreement by Shire. 

     Section 11.2. Indemnification by Shire. Shire hereby agrees to hold Duramed, its Affiliates, and their respective directors, agents and
employees harmless from and against any and all Losses arising in connection with any and all Third Party Claims resulting directly from (a) any breach by Shire of any of its representations, warranties, covenants or obligations pursuant to this
Agreement, or (b) the negligence or willful misconduct of Shire or its Affiliates or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement, or (c) claims that involve product
defect, product liability, death or bodily injury (or allegations thereof) to any individual or any property to the extent that such claim results from Shire’s breach, negligence or willful misconduct hereunder, or the negligence or willful
misconduct of Shire’s third party supplier of Products, except to the extent that such Losses in (a) through (c) result from the negligence or willful misconduct of Duramed, or the breach of this Agreement by Duramed. 

     Section 11.3. Notice of Claim. All indemnification claims in respect of any indemnitee seeking indemnity hereunder (collectively, the
“Indemnitees” and each an “Indemnitee”) shall be made solely by the corresponding Party (the
“Indemnified Party”). The Indemnified Party shall give the indemnifying Party (the “Indemnifying Party”) prompt
written notice (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon which such Indemnified Party intends to base a request for indemnification
hereunder, but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such Third Party Claim. Each 

 15 

Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim
Notice, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. The Indemnifying Party shall not be
obligated to indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party materially prejudices the defense of such Third Party Claim. 

     Section 11.4. Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim subject to
indemnification hereunder by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying
Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party or
any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 

     Section 11.5. Right to Participate in Defense. Without limiting Section 11.4, any Indemnitee shall be entitled to participate in, but not
control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnitee’s own expense unless (a) the
employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 11.4 (in which case the Indemnified Party shall
control the defense). 

     Section 11.6. Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim
and that shall not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the Indemnifying Party shall have acknowledged in writing
the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in
its reasonable discretion, shall deem appropriate (provided, however that such terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto), and shall transfer to the Indemnified Party
all amounts which said Indemnified Party shall be liable to pay prior to the time of the entry of judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third
Party Claim in accordance with Section 11.4, the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the
Indemnified Party (which consent shall be at the Indemnified Party’s reasonable discretion). The Indemnifying Party that has assumed the defense of the Third Party Claim in accordance with Section 11.4 shall not be liable for any settlement or
other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee shall admit any
liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the 

 16 

Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with Section 11.4. 

     Section 11.7. Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and
shall cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals
as may be reasonably requested in connection with such Third Party Claim. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder,
and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 

     Section 11.8. Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable costs and expenses, including fees
and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest
the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

     Section 11.9. Insurance. At all times from the Closing Date until [*] following termination or expiration of this Agreement, each of Shire
and Duramed will maintain product liability insurance (or self insurance), that is reasonable and customary in the U.S. pharmaceutical industry for companies of comparable size, but in no event less than [*] per occurrence and [*] in the aggregate
limit of liability per year. Each of Shire and Duramed shall provide written proof of such insurance or self insurance to the other Party upon request. 

     Section 11.10. Exclusion of Certain Damages. IN NO EVENT SHALL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL,
PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, OR FOR ANY DIRECT OR INDIRECT LOSS OF PROFIT, LOST BUSINESS OPPORTUNITY, LOSS OF OR DISRUPTION TO PRODUCTION OR GOODWILL, EXCEPT TO THE EXTENT SUCH
DAMAGES: (A) ARE INCLUDED IN A THIRD-PARTY CLAIM FOR WHICH SUCH PARTY IS INDEMNIFIED HEREUNDER; OR (B) ARE FOR BREACH OF CONFIDENTIALITY OBLIGATIONS.

ARTICLE XII

MISCELLANEOUS 

     Section 12.1. Entire Agreement; Amendment. This Agreement, together with the Product Acquisition Agreement, including the exhibits attached
hereto and thereto (each of which is hereby and thereby incorporated herein and therein by reference), set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, 

 17 

representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties, which shall continue to govern the obligations of the Parties
with respect to information disclosed thereunder with respect to periods prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the
Parties other than as are set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance of
doubt, the Parties agree that all covenants, promises, agreements, warranties, representations, conditions, and understandings set forth herein are made and deemed effective as of the Effective Date, and that the execution of this Agreement shall
not constitute a waiver of any right or claim of either Party as of the Effective Date. 

     Section 12.2. Notices. All notices or other communications that are required or permitted under this Agreement shall be in writing and
delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses below. Any such communication shall be
deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal delivery or overnight courier as provided in this Agreement), and (b) on the second Business Day
after dispatch, if sent by internationally-recognized overnight courier. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

  	For Duramed:	Duramed Pharmaceuticals, Inc. 

          400 Chestnut Ridge Road

          Woodcliff Lake, NJ 07677

          Phone: 201-930-3300

          Fax: 201-930-3330

      Attention: President

	 	 
	with a copy to:	Barr Pharmaceuticals, Inc.

        400 Chestnut Ridge Road

        Woodcliff Lake, NJ 07677

        Phone: 201-930-3300

        Fax: 888-843-0563

        Attention: General Counsel
	 	 
	For Shire:	Shire LLC 

        725 Chesterbrook Boulevard

        Wayne, Pennsylvania 19087-5637

        Fax: (484) 595-8163 

        Attention: General Counsel 
	 	 
	with a copy to: 
	Morgan, Lewis & Bockius LLP

        502 Carnegie Center 

        Princeton, NJ 08540 

        Fax: (609) 919-6701

        Attention: Randall B. Sunberg 

18 

     Section 12.3. Independent Contractors. In making and performing this Agreement, Shire and Duramed shall act at all times as independent
contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an agency, partnership, limited partnership, joint venture or employer and employee relationship between Shire and Duramed and this Agreement
shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. Except as otherwise provided in this Agreement, each Party shall be solely responsible
for its own costs and expenses associated with this Agreement. 

     Section 12.4. Maintenance of Records. Each Party shall keep and maintain all records required by Law with respect to the Products and shall
make copies of such records available to the other Party upon reasonable request. 

     Section 12.5. United States Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of
the United States. 

     Section 12.6. No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party.

     Section 12.7. Assignment. Neither Party shall sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of Law or otherwise, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other Party (which consent may be granted, withheld or conditioned at such other
Party’s sole and absolute discretion); provided, however, that either Party may assign or transfer this Agreement or any of its rights or obligations under this Agreement without the consent of the other Party to any Affiliate of such Party, or
to any Third Party (a) with which it merges or consolidates, or to which it transfers all or substantially all of its assets to which this Agreement pertains or (b) in part, in connection with the sale or transfer of such Party’s business
relating to Commercialization of a Collaboration Product within a particular country. The assigning Party (unless it is not the surviving entity) shall remain jointly and severally liable with, and shall guarantee the performance of, the relevant
Affiliate or Third Party assignee under this Agreement, and the relevant Affiliate assignee, Third Party assignee or surviving entity shall assume in writing all of the assigning Party’s obligations under this Agreement. Any purported
assignment or transfer in violation of this Section 12.7 shall be void ab initio and of no force or effect. Notwithstanding anything to the contrary herein or in the Product Acquisition Agreement, in the event any assignment by Duramed hereunder
gives rise to any obligation to withhold any amounts payable to Shire under this Agreement, Duramed shall pay Shire in full, without regard to any amounts so withheld, subject to Shire’s obligation to reimburse Duramed upon Shire’s
recovery from the applicable taxing authority of any amounts so withheld. Notwithstanding the foregoing, Duramed shall be liable for, and indemnify Shire against, any non-U.S. taxes, any value-added or sales taxes, any duties or levies and
assessments, howsoever designated or computed that are required to be paid or withheld by Duramed on such payments. Duramed shall so indemnify Shire within forty-five (45) days of Shire’s receipt of notification from Shire (in accordance with
Section 12.2 hereof) that either (i) based upon current facts and circumstances, Shire does not have or will not have during the applicable tax year any or 

 19 

sufficient foreign tax credits available to utilize to offset such tax liability; or (ii) Shire has applied for a refund from the taxing authority at issue (such notice to include a copy of such refund application).
Notwithstanding anything in this Agreement to the contrary, in the event that withholding taxes are paid on behalf of Shire by Duramed, if Shire uses a foreign tax credit received as a result of the payment of withholding taxes by Duramed and
thereby reduces the amount of U.S. income tax that Shire otherwise would have paid, or otherwise receives a refund, Shire shall refund to Duramed the amount of such reduction with respect to such foreign tax credit or such refund. 

     Section 12.8. Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Signatures provided by facsimile transmission shall be deemed to be original signatures. 

     Section 12.9. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts,
as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

     Section 12.10. Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of
competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good fait effort to replace any
invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

     Section 12.11. Headings. The headings for each article and section in this Agreement have been inserted for convenience of reference only and
are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

     Section 12.12. No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time.

[signature page follows] 

 20 

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their respective representatives thereunto duly authorized, all as of the date first written above.

  	SHIRE LLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  

  	DURAMED PHARMACEUTICALS,
            INC.
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

SHIRE plc, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, hereby guarantees in the performance of Shire of all obligations
of Shire under this Agreement, in accordance with the terms and conditions of this Agreement, including any applicable notice or cure periods.

	SHIRE PLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

[Signature Page to Adderall IR Supply Agreement] 

 1 

EXHIBIT A 

QUALITY AGREEMENT 

 2 

SCHEDULE 1 

FORM OF COA 

3 

SCHEDULE 3 – REFERENCE INVENTORY AMOUNTS OF FINISHED GOODS PRODUCT

HELD BY SHIRE AS OF THE DATE HEREOF 

	ADDERALL IR
	DOSAGE	# OF BOTTLES OF 100 TABLETS
	[*]	[*]
	[*]	[*]
	[*]	[*]
	[*]	[*]
	[*]	[*]
	[*]	[*]
	[*]	[*]

4 

EXHIBIT D 

GENERAL ASSIGNMENT AND BILL OF SALE 

     THIS GENERAL ASSIGNMENT AND BILL OF SALE (this “General Assignment”), dated as of September 29, 2006, is made and entered into by and between Shire LLC, a Kentucky limited liability company (“Shire”), and Duramed Pharmaceuticals, Inc., a Delaware
corporation (“Duramed”). All capitalized words and terms used in this General Assignment and not defined herein shall have the respective meanings ascribed to them in the Product Acquisition and License Agreement, dated as of August 14,
2006 (the “Agreement”).

     WHEREAS, Shire and Duramed have entered into the Agreement pursuant to which Shire, among other things, desires to sell, transfer, convey and license to Duramed
Shire’s right, title and interest in and to certain rights to the Product and the Purchased Assets, and Duramed wishes to assume certain liabilities relating to the Product; and 

     WHEREAS, in performance of their respective obligations under the Agreement, Shire and Duramed desire to execute and deliver this General Assignment. 

     NOW, THEREFORE, for and in consideration of the Purchase Price and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows: 

     1. Shire does hereby sell, assign, convey and transfer unto Duramed the Purchased Assets. Duramed and its successors and assigns are to have
and to hold all of such Purchased Assets unto Duramed and its successors and assigns forever. 

     2. This General Assignment shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, successors,
trustees, transferees and permitted assigns. 

     3. Each of the parties agrees that it will, from time to time after the date hereof, without further consideration, execute, acknowledge and
deliver all such further acts, assignments, transfers, conveyances, evidences of title, assumptions and assurances as may be required to carry out the intent of this General Assignment and to sell, assign, convey, transfer and deliver the Purchased
Assets to Duramed. 

     4. This General Assignment is made in accordance with, and is subject to, all of the terms and conditions set forth in the Agreement. Except as
otherwise expressly set forth herein, the terms and conditions of the Agreement shall control the terms and conditions of this General Assignment. 

     5. This General Assignment may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. This General Assignment may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures. 

     IN WITNESS WHEREOF, the parties hereto have executed this General Assignment and Assumption as of the date first above written. 

  	SHIRE LLC
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

  	DURAMED PHARMACEUTICALS,
      INC.
	 	 	 
	By:	 
	 	

	 	Name:	 
	 	Title:	 

EXHIBIT E 

Form of FDA Letter 

[DATE]

 

Thomas Laughren, MD

  Director, Division of Psychiatry Products

  Office of Drug Evaluation I

  Centre for Drug Evaluation and Research

  Document Control Room

  Food and Drug Administration

  5901-B Ammendale Road

  Beltsville, MD  20705-1266

 

NDA 11-522

  Adderall (mixed salts of a single-entity amphetamine product) Tablets

  CHANGE IN OWNERSHIP OF AN APPLICATION

Reference is made to NDA 11-522 for Adderall Tablets; and
    to 21 CFR § 314.72
  pertaining to a change in ownership of an application.

  This is to notify the agency that Duramed Pharmaceuticals, Inc., (“Duramed”),
  a subsidiary of Barr Pharmaceuticals, Inc, is the regulatory agent for Duramed
  Pharmaceuticals, Inc.  In accordance with provisions of  §314.72,
  we are submitting an application form signed by the new owner along with the
  following information:

	Duramed commits to the agreements, promises, and conditions made by Shire,
    the former owner of NDA 11-522, and contained in the application;

    

  
	The change in ownership is effective [DATE]; and

    

  
	Duramed has a complete copy of the approved application,
    including supplements and records that are to be kept under 21 CFR  § 314.81

All future correspondence regarding NDA 11-522 should be directed to:

  

Joseph A. Carrado, M.Sc., R.Ph.

  Vice President, Clinical Regulatory Affairs

  Duramed Research, Inc.

  One Belmont Avenue, 11th Floor

  Bala Cynwyd, PA 19004

  Phone (610) 747 2910

  Fax: (610) 747 6607

Also, please find attached a copy of Shire’s Transfer of Ownership letter,
  dated [DATE], for the Division’s convenience.

  If you have any questions or require any additional information, please contact
  the undersigned at (610) 747-2910.

Sincerely,

Joseph A. Carrado, M.S.c., R.Ph.

  Vice President

  Clinical Regulatory Affairs

 

EXHIBIT F 

Form of Correspondence to Third Parties  

SCHEDULE 1.18 

Licensed Patents 

[*] 

SCHEDULE 1.31 

Product Trademark

	 Mark 	 Owner 	 Country 	 Goods/Services 	 Serial No./

      Filing Date 	 Reg. No./

      Reg. Date 
	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 	 [*] 

SCHEDULE 2.8 

Allocation of Purchase Price 

SCHEDULE 4.1 

Shire Disclosure Schedule 

SCHEDULE 4.1(h) 

Litigation 

1. Branson v. Shire Richwood Inc.

      Filed on October 3, 2002 in the Circuit Court, Boone County, Kentucky, plaintiff, claims that an alleged psychotic episode leading to the death of her child was caused by the her ingestion of
  Adderall. The Court filed the Judgment on April 17, 2006 and plaintiff failed to file a notice of appeal of the jury’s defense verdict by the deadline to appeal, May 17, 2006.

2. [*] 

3. UZammit v. Shire US Inc.

     Pio Peter Zammit, the plaintiff,
    claims that his ingestion of 20mg of Adderall caused him to suffer a heart
    attack on April 24, 2002.  Plaintiff
  claims negligence and failure to warn strict products liability for failing
  to adequately warn of the risks of heart attack while taking Adderall.   Plaintiff
  is currently appealing the District Court’s dismissal of the case to
  the Sixth Circuit.  Shire has filed a motion to dismiss plaintiff’s
appeal.

4. [*]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]